[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20220324860A1 - SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS - Google Patents

SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Download PDF

Info

Publication number
US20220324860A1
US20220324860A1 US17/618,066 US202017618066A US2022324860A1 US 20220324860 A1 US20220324860 A1 US 20220324860A1 US 202017618066 A US202017618066 A US 202017618066A US 2022324860 A1 US2022324860 A1 US 2022324860A1
Authority
US
United States
Prior art keywords
pyrazolo
pyridin
phenyl
methyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/618,066
Inventor
Afton Hiscox
Brice Stenne
Christine Gelin
Andrew SAMANT
Jessica WALL
Michael A. Letavic
Curt DVORAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to US17/618,066 priority Critical patent/US20220324860A1/en
Assigned to JANSSEN PHARMACEUTICA NV reassignment JANSSEN PHARMACEUTICA NV ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SAMANT, Andrew, WALL, Jessica, STENNE, BRICE, DVORAK, CURT, HISCOX, Afton, GELIN, Christine, LETAVIC, MICHAEL A.
Publication of US20220324860A1 publication Critical patent/US20220324860A1/en
Assigned to JANSSEN PHARMACEUTICA NV reassignment JANSSEN PHARMACEUTICA NV ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WALL, Jessica, LETAVIC, MICHAEL A., DVORAK, CURT, GELIN, Christine, SAMANT, Andrew, STENNE, BRICE, HISCOX, Afton
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention is related to compounds having GluN2B modulating properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with GluN2B receptor activity in animals, in particular humans.
  • Glutamate is one of the major excitatory neurotransmitters that is widely spread in the brain.
  • First indication of its role as an excitatory messenger was in the 1950's when it was observed that intravenous administration of glutamate induces convulsions.
  • the detection of the whole glutamatergic neurotransmitter system with its various receptors did not take place before the 1970's and 1980's when numerous antagonists were developed or, as in the case of PCP and ketamine, were identified as antagonists.
  • molecular biology provided the tools for the classification of the glutamatergic receptors.
  • N-methyl-D-aspartate (NMDA) receptors are a subtype of ionotropic glutamate receptors that mediate excitatory synaptic transmission in the brain. NMDA receptors are ubiquitously distributed throughout the brain and play a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning.
  • NMDA receptors are distinct from other major subtypes of ionotropic glutamate receptors (AMPA and kainate receptors) in that they are blocked by Mg 2+ at resting membrane potentials, are highly Ca 2+ permeable, and require co-activation by two distinct neurotransmitters: glutamate and glycine (or D-serine) (Traynelis S F et al., Pharmacol Rev. 2010; 62(3):405-96).
  • AMPA and kainate receptors ionotropic glutamate receptors
  • the GRIN1 gene product has 8 splice variants while there are 4 different GRIN2 genes (GRIN2A-D) encoding four distinct GluN2 subunits.
  • the glycine binding site is present on the GluN1 subunit and the glutamate binding site is present on the GluN2 subunit.
  • GluNR2 subunits play a dominant role in determining the functional and pharmacological properties of the NMDA receptor assembly and exhibit distinct distribution in different areas of the brain.
  • GluN2B subunits are expressed primarily in the forebrain in the adult mammalian brain (Paoletti P et al., Nat Rev Neurosci. 2013; 14(6):383-400; Watanabe M et al., J Comp Neurol. 1993; 338(3):377-90) and are implicated in learning, memory processing, mood, attention, emotion and pain perception (Cull-Candy S et al., Curr Opin Neurobiol. 2001; 11(3):327-35).
  • Compounds that modulate GluN2B-containing NMDA receptor function can be useful in treatment of many neurological and psychiatric disorders including but not limited to bipolar disorder (Martucci L et al., Schizophrenia Res, 2006; 84 (2-3):214-21), major depressive disorder (Miller O H et al., eLife. 2014; 3:e03581; Li N et al., Biol Psychiatry. 2011; 69(8):754-61), treatment-resistant depression (Preskorn S H et al. J Clin Psychopharmacol. 2008; 28(6):631-7) and ther mood disorders (including schizophrenia (Grimwood S et al., Neuroreport.
  • R 1 is H, halo, or CH 3 ;
  • Ar 1 is selected from the group consisting of:
  • R 2 is selected from the group consisting of:
  • R a is selected from the group consisting of: C 1-6 alkyl; C 3-6 cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
  • R b is C 1-6 alkyl
  • the compounds of Formula (I) are compounds selected from those species described or exemplified in the detailed description below.
  • the invention relates to enantiomers and diastereomers of the compounds of Formula (I), as well as the pharmaceutically acceptable salts.
  • the invention relates to pharmaceutical compositions for treating a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising an effective amount of at least one compound selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of Formula (I).
  • compositions according to the invention may further comprise one or more pharmaceutically acceptable excipients.
  • the chemical embodiments of the present invention are useful as GluN2B receptor modulators.
  • the invention is directed to a method for modulating GluN2B receptor activity, including when such receptor is in a subject, comprising exposing GluN2B receptor to an effective amount of at least one compound selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of compounds of Formula (I).
  • the invention is directed to a method of treating a subject suffering from, or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to the subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of compounds of Formula (I). Additional embodiments of methods of treatment are set forth in the detailed description.
  • the method of studying isotopically labeled compounds in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • detection or imaging techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or 11 C labeled compound may be particularly preferred for PET or SPECT studies.
  • Additional embodiments of this invention include methods of making compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of Formula (I).
  • An object of the present invention is to overcome or ameliorate at least one of the disadvantages of the conventional methodologies and/or prior art, or to provide a useful alternative thereto.
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 1 is H.
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 1 is F.
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 1 is CH 3 .
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar 1 is phenyl.
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar 1 is phenyl substituted with one member selected from the group consisting of: F, CH 3 , CF 2 H, CF 2 CH 3 , CF 3 , and OCF 3 .
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar 1 is selected from the group consisting of:
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar 1 is phenyl substituted with two members each independently selected from the group consisting of: F, Cl, CH 3 , CF 2 H, CF 3 , CF 2 CH 3 , and OCF 2 H.
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar 1 is selected from the group consisting of:
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar 1 is phenyl substituted with three members each independently selected from the group consisting of: F and CH 3 .
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar 1 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar 1 is thienyl is substituted with Cl or CH 3 .
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar 1 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) having the Formula (IA):
  • An additional embodiment of the invention is a compound of Formula (I) having the Formula (IA), wherein HAL is F; R 1 is H; R c is H; and R e is H.
  • An additional embodiment of the invention is a compound of Formula (I) having the Formula (IB):
  • a further embodiment of the current invention is a compound as shown below in Table 1.
  • An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound of Formula (IA), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IA), pharmaceutically acceptable prodrugs of compounds of Formula (IA), and pharmaceutically active metabolites of Formula (IA); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound of Formula (IB), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IB), pharmaceutically acceptable prodrugs of compounds of Formula (IB), and pharmaceutically active metabolites of Formula (IB); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising and effective amount of at least one compound in Table 1, as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Table 1, pharmaceutically acceptable prodrugs of compounds of Table 1, and pharmaceutically active metabolites of Table 1; and at least one pharmaceutically acceptable excipient.
  • enantiomers and diastereomers of the compounds of Formula (I) are enantiomers and diastereomers of the compounds of Formula (I) (as well as Formulas (IA), and (IB)).
  • pharmaceutically acceptable salts, N-oxides or solvates of the compounds of Formula (I) are also within the scope of the invention.
  • pharmaceutically acceptable prodrugs of compounds of Formula (I) are also within the scope of the invention, and pharmaceutically active metabolites of the compounds of Formula (I) (as well as Formulas (IA), and (IB)).
  • isotopic variations of compounds of Formula (I) (as well as Formulas (IA), and (IB)), such as, e.g., deuterated compounds of Formula (I).
  • pharmaceutically acceptable salts, N-oxides or solvates of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), and (IB)).
  • compositions of Formula (I) are also within the scope of the invention.
  • pharmaceutically acceptable prodrugs of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), and (IB)), and pharmaceutically active metabolites of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), and (IB)).
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I):
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I) (as well as Formulas (IA), and (IB)), enantiomers and diastereomers of the compounds of Formula (I), isotopic variations of the compounds of Formula (I), and pharmaceutically acceptable salts of all of the foregoing.
  • the disease, disorder, or medical condition is selected from: neurologic and psychiatric disorders including, but not limited to: (1) mood disorders and mood affective disorders; (2) neurotic, stress-related and somatoform disorders including anxiety disorders; (3) disorders of psychological development; (4) behavioral syndromes associated with physiological disturbances and physical factors; (5) extrapyramidal and movement disorders; (6) episodic and paroxysmal disorders, epilepsy; (7) pain; (8) forms of neurodegeneration; (9) cerebrovascular diseases, acute and chronic; and any sequelae of cerebrovascular diseases.
  • neurologic and psychiatric disorders including, but not limited to: (1) mood disorders and mood affective disorders; (2) neurotic, stress-related and somatoform disorders including anxiety disorders; (3) disorders of psychological development; (4) behavioral syndromes associated with physiological disturbances and physical factors; (5) extrapyramidal and movement disorders; (6) episodic and paroxysmal disorders, epilepsy; (7) pain; (8) forms of neurodegeneration; (9) cerebrovascular diseases, acute and chronic; and any sequelae of cere
  • mood disorders and mood affective disorders that can be treated according to the present invention include, but are not limited to, bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, depressive disorder with postpartum onset, depressive disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder.
  • disorders belonging to the neurotic, stress-related and somatoform disorders include, but are not limited to, anxiety disorders, general anxiety disorder, panic disorder with or without agoraphobia, specific phobia, social anxiety disorder, chronic anxiety disorders; obsessive compulsive disorder; reaction to sever stress and adjustment disorders, such as post-traumatic stress disorder (PTSD); other neurotic disorders such as depersonalisation-derealisation syndrome.
  • anxiety disorders general anxiety disorder, panic disorder with or without agoraphobia, specific phobia, social anxiety disorder, chronic anxiety disorders; obsessive compulsive disorder; reaction to sever stress and adjustment disorders, such as post-traumatic stress disorder (PTSD); other neurotic disorders such as depersonalisation-derealisation syndrome.
  • PTSD post-traumatic stress disorder
  • disorders of psychological development include, but are not limited to pervasive developmental disorders, including but not limited to Asperger's syndrome and Rett's syndrome, autistic disorders, childhood autism and overactive disorder associated with mental retardation and stereotyped movements, specific developmental disorder of motor function, specific developmental disorders of scholastic skills.
  • Examples of behavioral syndromes associated with physiological disturbances and physical factors include but are not limited to mental and behavioral disorders associated with childbirth, including but not limited to postnatal (postpartum) and prenatal depression; eating disorders, including but not limited to anorexia nervosa, bulimia nervosa, pica and binge eating disorder.
  • extrapyramidal and movement disorders examples include, but are not limited to Parkinson's disease; second Parkinsonism, such as post encephalitic Parkinsonism; Parkinsonism comprised in other disorders; Lewis body disease; degenerative diseases of the basal ganglia; other extrapyramidal and movement disorders including but not limited to tremor, essential tremor and drug-induced tremor, myoclonus, chorea and drug-induced chorea, drug-induced tics and tics of organic origin, drug-induced acute dystonia, drug-induced tardive dyskinesia, L-dopa-induced dyskinesia; neuroleptic-induced movement disorders including but not limited to neuroleptic malignant syndrome (NMS), neuroleptic induced parkinsonism, neuroleptic-induced early onset or acute dyskinesia, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia, neuroleptic-induced tremor;
  • NMS neuroleptic malignant
  • dystonia including but not limited to focal dystonia, multiple-focal or segmental dystonia, torsion dystonia, hemispheric, generalised and tardive dystonia (induced by psychopharmacological drugs).
  • Focal dystonia includes cervical dystonia (torticolli), blepharospasm (cramp of the eyelid), appendicular dystonia (cramp in the extremities, like the writer's cramp), oromandibular dystonia and spasmodic dysphonia (cramp of the vocal cord);
  • Examples for episodic and paroxysmal disorders include, but are not limited to epilepsy, including localization-related (focal)(partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, generalized idiopathic epilepsy and epileptic syndromes including but not limited to myoclonic epilepsy in infancy, neonatal convulsions (familial), childhood absence epilepsy (pyknolepsy), epilepsy with grand mal seizures on awakening, absence epilepsy, myoclonic epilepsy (impulsive petit mal) and nonspecific atonic, clonic, myoclonic, tonic, tonic-clonic epileptic seizures.
  • epilepsy including localization-related (focal)(partial) idi
  • epilepsy that can be treated according to the present invention include, but are not limited to epilepsy with myoclonic absences, myoclonic-astatic seizures, infantile spasms, Lennox-Gastaut syndrome, Salaam attacks, symptomatic early myoclonic encephalopathy, West's syndrome, petit and grand mal seizures; status epilepticus.
  • pain examples include, but are not limited to pain disorders related to psychological factors, such as persistent somatoform disorders; acute, chronic and chronic intractable pain, headache; acute and chronic pain related to physiological processes and physical disorders including but not limited to back pain, tooth pain, abdominal pain, low back pain, pain in joints; acute and chronic pain that is related to diseases of the musculoskeletal system and connective tissue including, but not limited to rheumatism, myalgia, neuralgia and fibromyalgia; acute and chronic pain that is related to nerve, nerve root and plexus disorders, such as trigeminal pain, postzoster neuralgia, phantom limb syndrome with pain, carpal tunnel syndrome, lesion of sciatic nerve, diabetic mononeuropathy; acute and chronic pain that is related to polyneuropathies and other disorders of the peripheral nervous system, such as hereditary and idiopathic neuropathy, inflammatory polyneuropathy, polyneuropathy induced by drugs, alcohol or toxic agents, polyneuropathy in neoplastic disease
  • diseases that include forms of neurodegeneration include, but are not limited to, acute neurodegeneration, such as intracranial brain injuries, such as stroke, diffuse and local brain injuries, epidural, subdural and subarachnoid haemorrhage, and chronic neurodegeneration, such as Alzheimer's disease, Huntington's disease, multiple sclerosis and ALS.
  • acute neurodegeneration such as intracranial brain injuries, such as stroke, diffuse and local brain injuries, epidural, subdural and subarachnoid haemorrhage
  • chronic neurodegeneration such as Alzheimer's disease, Huntington's disease, multiple sclerosis and ALS.
  • cerebrovascular diseases include, but are not limited to, subarachnoid haemorrhage, intracerebral haemorrhage and other nontraumatic intracranial haemorrhage, cerebral infarction, stroke, occlusion and stenosis or precerebral and cerebral arteries, not resulting in cerebral infarction, dissection of cerebral arteries, cerebral aneurysm, cerebral atherosclerosis, progressive vascular leukoencephalopathy, hypertensive encephalopathy, nonpyogenic thrombosis of intracranial venous system, cerebral arteritis, cerebral amyloid angiopathy and sequelae of cerebrovascular diseases.
  • administration of a compound of the invention, or pharmaceutically acceptable salt thereof is effective in preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.
  • alkyl refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain.
  • alkyl groups include methyl (Me, which also may be structurally depicted by the symbol, “/”), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.
  • C 1-4 alkyl refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain.
  • C 1-6 alkyl refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain.
  • aryl refers to a monocyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having 6 atoms per ring. (Carbon atoms in the aryl groups are sp 2 hybridized.)
  • phenyl represents the following moiety:
  • heteroaryl refers to a monocyclic or fused bicyclic heterocycle (ring structure having ring atoms selected from carbon atoms and up to four heteroatoms selected from nitrogen, oxygen, and sulfur) having from 3 to 9 ring atoms per heterocycle.
  • heteroaryl groups include the following entities, in the form of properly bonded moieties:
  • heteroaryl, cycloalkyl, aryl and heterocycloalkyl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected.
  • heterocycloalkyl refers to a monocyclic ring structure that is saturated or partially saturated and has from 4 to 7 ring atoms per ring structure selected from carbon atoms and up to two heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the ring structure may optionally contain up to two oxo groups on sulfur ring members.
  • Illustrative entities, in the form of properly bonded moieties include:
  • cycloalkyl refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle.
  • Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:
  • halo represents chloro, fluoro, bromo or iodo.
  • perhaloalkyl refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain optionally substituting hydrogens with halogens.
  • C 1-4 haloalkyl refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain, optionally substituting hydrogens with halogens.
  • C 1-6 haloalkyl refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain, optionally substituting hydrogens with halogens.
  • perhaloalkyl examples include trifluoromethyl (CF 3 ), difluoromethyl (CF 2 H), monofluoromethyl (CH 2 F), pentafluoroethyl (CF 2 CF 3 ), tetrafluoroethyl (CHFCF 3 ), monofluoroethyl (CH 2 CH 2 F), trifluoroethyl (CH 2 CF 3 ), tetrafluorotrifluoromethylethyl (—CF(CF 3 ) 2 ), and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.
  • substituted means that the specified group or moiety bears one or more substituents.
  • unsubstituted means that the specified group bears no substituents.
  • optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system. In cases where a specified moiety or group is not expressly noted as being optionally substituted or substituted with any specified substituent, it is understood that such a moiety or group is intended to be unsubstituted.
  • buffer solution or “buffer” solution are used herein interchangeably according to their standard meaning. Buffered solutions are used to control the pH of a medium, and their choice, use, and function is known to those of ordinary skill in the art. See, for example, G. D. Considine, ed., Van Nostrand's Encyclopedia of Chemistry, p. 261, 5 th ed. (2005), describing, inter alia, buffer solutions and how the concentrations of the buffer constituents relate to the pH of the buffer. For example, a buffered solution is obtained by adding MgSO 4 and NaHCO 3 to a solution in a 10:1 w/w ratio to maintain the pH of the solution at about 7.5.
  • any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms.
  • compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula.
  • any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof.
  • certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers.
  • stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers.”
  • enantiomers When a compound has an asymmetric center, for example, it is bonded to four different groups, and a pair of enantiomers is possible.
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+)- or ( ⁇ )-isomers respectively).
  • a chiral compound can exist as either an individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture.”
  • Tautomers refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of ⁇ electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro-forms of phenyl nitromethane, that are likewise formed by treatment with acid or base.
  • Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
  • the compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof.
  • Certain examples contain chemical structures that are depicted as an absolute enantiomer but are intended to indicate enantiopure material that is of unknown configuration.
  • (R*) or (S*) is used in the name to indicate that the absolute stereochemistry of the corresponding stereocenter is unknown.
  • a compound designated as (R*) refers to an enantiopure compound with an absolute configuration of either (R) or (S).
  • the structures are named using (R) and (S).
  • any formula given herein is intended to refer also to hydrates, solvates, and polymorphs of such compounds, and mixtures thereof, even if such forms are not listed explicitly.
  • Certain compounds of Formula (I) (as well as Formulas (IA), and (IB)), or pharmaceutically acceptable salts of compounds of Formula (I) (as well as Formulas (IA), and (IB)) may be obtained as solvates.
  • Solvates include those formed from the interaction or complexation of compounds of the invention with one or more solvents, either in solution or as a solid or crystalline form. In some embodiments, the solvent is water and the solvates are hydrates.
  • certain crystalline forms of compounds of Formula (I) (as well as Formulas (IA), and (IB)) or pharmaceutically acceptable salts of compounds of Formula (I) (as well as Formulas (IA), and (IB)) may be obtained as co-crystals.
  • compounds of Formula (I) were obtained in a crystalline form.
  • crystalline forms of compounds of Formula (I) were cubic in nature.
  • pharmaceutically acceptable salts of compounds of Formula (I) were obtained in a crystalline form.
  • compounds of Formula (I) were obtained in one of several polymorphic forms, as a mixture of crystalline forms, as a polymorphic form, or as an amorphous form.
  • compounds of Formula (I) convert in solution between one or more crystalline forms and/or polymorphic forms.
  • references to a compound herein stands for a reference to any one of: (a) the actually recited form of such compound, and (b) any of the forms of such compound in the medium in which the compound is being considered when named.
  • reference herein to a compound such as R—COOH encompasses reference to any one of, for example, R—COOH (s) , R—COOH (sol) , and R—COO ⁇ (sol) .
  • R—COOH (s) refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation
  • R—COOH (sol) refers to the undissociated form of the compound in a solvent
  • R—COO ⁇ (sol) refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R—COOH, from a salt thereof, or from any other entity that yields R—COO ⁇ upon dissociation in the medium being considered.
  • an expression such as “exposing an entity to compound of formula R—COOH” refers to the exposure of such entity to the form, or forms, of the compound R—COOH that exists, or exist, in the medium in which such exposure takes place.
  • an expression such as “reacting an entity with a compound of formula R—COOH” refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that exists, or exist, in the medium in which such reacting takes place, with (b) the chemically relevant form, or forms, of the compound R—COOH that exists, or exist, in the medium in which such reacting takes place.
  • a zwitterionic compound is encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form.
  • Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUPAC-endorsed names that are well known and part of standard sets of defined scientific names.
  • the name zwitterion is assigned the name identification CHEBI.27369 by the Chemical Entities of Biological Interest (ChEBI) dictionary of molecular entities.
  • a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign.
  • aminoethanoic acid (the amino acid glycine) has the formula H 2 NCH 2 COOH, and it exists in some media (in this case in neutral media) in the form of the zwitterion + H 3 NCH 2 COO ⁇ .
  • Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well established meanings of these terms are within the scope of this invention, as would in any case be so appreciated by those of ordinary skill in the art.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 125 I, respectively.
  • Such isotopically labeled compounds are useful in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example deuterium (i.e., D or 2 H); or tritium (i.e., T or 3 H)), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or 11 C labeled compound may be particularly preferred for PET or SPECT studies.
  • substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
  • Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof.
  • substituent S example is one of S 1 , S 2 , and S 3
  • this listing refers to embodiments of this invention for which S example is S 1 ; S example is S 2 ; S example is S 3 ; S example is one of S 1 and S 2 ; S example is one of S 1 and S 3 ; S example is one of S 2 and S 3 ; S example is one of S 1 , S 2 and S 3 ; and S example is any equivalent of each one of these choices.
  • C i-j when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to j including i and j, is independently realized.
  • C 1-4 refers independently to embodiments that have one carbon member (C 1 ), embodiments that have two carbon members (C 2 ), embodiments that have three carbon members (C 3 ), and embodiments that have four carbon members (C 4 ).
  • C n-m alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies n ⁇ N ⁇ m, with m>n.
  • Any disubstituent referred to herein is meant to encompass the various attachment possibilities when more than one of such possibilities are allowed.
  • the invention includes also pharmaceutically acceptable salts of the compounds of Formula (I) (as well as Formulas (IA), and (IB)), preferably of those described above and of the specific compounds exemplified herein, and methods of treatment using such salts.
  • pharmaceutically acceptable means approved or approvable by a regulatory agency of Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U. S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.
  • a “pharmaceutically acceptable salt” is intended to mean a salt of a free acid or base of compounds represented by Formula (I) (as well as Formulas (IA), and (IB)) that are non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. It should possess the desired pharmacological activity of the parent compound. See, generally, G. S. Paulekuhn, et al., “Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database”, J. Med. Chem., 2007, 50:6665-72, S. M.
  • a compound of Formula (I) (as well as Formulas (IA), and (IB)) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
  • Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phen
  • the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art.
  • an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like
  • an organic acid such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such
  • the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
  • an inorganic or organic base such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
  • suitable salts include organic salts derived from amino acids, such as N-methyl-D-glucamine, lysine, choline, glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • amino acids such as N-methyl-D-glucamine, lysine, choline, glycine and arginine
  • ammonia carbonates, bicarbonates, primary, secondary, and tertiary amines
  • cyclic amines such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine
  • inorganic salts derived
  • the invention also relates to pharmaceutically acceptable prodrugs of the compounds of Formula (I) (as well as Formulas (IA), and (IB)), and treatment methods employing such pharmaceutically acceptable prodrugs.
  • prodrug means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula (I).
  • a “pharmaceutically acceptable prodrug” is a prodrug that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “ Design of Prodrugs ”, ed. H. Bundgaard, Elsevier, 1985.
  • Exemplary prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxyl, or carboxylic acid group of a compound of Formula (I) (as well as Formulas (IA), and (IB)).
  • amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.
  • prodrugs may be produced, for instance, by derivatizing free carboxyl groups of structures of Formula (I) (as well as Formulas (IA), and (IB)) as amides or alkyl esters.
  • amides include those derived from ammonia, primary C 1-6 alkyl amines and secondary di(C 1-6 alkyl) amines. Secondary amines include 5- or 6-membered heterocycloalkyl or heteroaryl ring moieties.
  • amides include those that are derived from ammonia, C 1-3 alkyl primary amines, and di(C 1-2 alkyl)amines.
  • esters of the invention include C 1-7 alkyl, C 5-7 cycloalkyl, phenyl, and phenyl(C 1-6 alkyl) esters.
  • Preferred esters include methyl esters.
  • Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, following procedures such as those outlined in Fleisher et al., Adv. Drug Delivery Rev. 1996, 19, 115-130. Carbamate derivatives of hydroxy and amino groups may also yield prodrugs.
  • Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs.
  • Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs.
  • Prodrugs of this type may be prepared as described in Robinson et al., J Med Chem. 1996, 39 (1), 10-18. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including ether, amine, and carboxylic acid functionalities.
  • the present invention also relates to pharmaceutically active metabolites of the compounds of Formula (I) (as well as Formulas (IA), and (IB)), which may also be used in the methods of the invention.
  • a “pharmaceutically active metabolite” means a pharmacologically active product of metabolism in the body of a compound of Formula (I) (as well as Formulas (IA), and (IB)) as applicable, or salt thereof.
  • Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini, et al., J Med Chem. 1997, 40, 2011-2016; Shan, et al., J Pharm Sci.
  • the compounds of Formula (I) (as well as Formulas (IA), and (IB)) and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of the present invention are useful as modulators of the GluN2B receptor in the methods of the invention.
  • the compounds may act as antagonists, agonists, or inverse agonists.
  • modulators include both inhibitors and activators, where “inhibitors” refer to compounds that decrease, prevent, inactivate, desensitize, or down-regulate the GluN2B receptor expression or activity, and “activators” are compounds that increase, activate, facilitate, sensitize, or up-regulate GluN2B receptor expression or activity.
  • treat is intended to refer to administration of an active agent or composition of the invention to a subject for the purpose of affecting a therapeutic or prophylactic benefit through modulation of GluN2B receptor activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition mediated through modulation of GluN2B receptor activity.
  • subject refers to a mammalian patient in need of such treatment, such as a human.
  • the invention relates to methods of using the compounds described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated by GluN2B receptor activity, such as: bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, depressive disorder with postpartum onset, disruptive mood dysregulation disorder, depressive disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder; anxiety disorders, general anxiety disorder, panic disorder with or without agoraphobia, specific phobia, social anxiety disorder, chronic anxiety disorders; obsessive compulsive disorder; reaction to sever stress and adjustment disorders, such as post-traumatic stress disorder (PTSD); other neurotic disorders such as depersonalization-derealisation syndrome; pervasive developmental disorders, including but not limited to Asperger's syndrome and
  • Focal dystonia include cervical dystonia (torticolli), blepharospasm (cramp of the eyelid), appendicular dystonia (cramp in the extremities, like the writer's cramp), oromandibular dystonia and spasmodic dysphonia (cramp of the vocal cord); epilepsy, including localization-related (focal)(partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, generalized idiopathic epilepsy and epileptic syndromes including but not limited to myoclonic epilepsy in infancy, neonatal convulsions (familial), childhood absence epilepsy (pyknolepsy), epilepsy with grand mal seizures on awakening, absence epilepsy, myo
  • an effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition.
  • An “effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition.
  • Effective amounts or doses of the compounds of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician.
  • An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID).
  • a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.
  • the dose may be adjusted for preventative or maintenance treatment.
  • the dosage or the frequency of administration, or both may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained.
  • treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.
  • the active agents of the invention may be used in combination with additional active ingredients in the treatment of the above conditions.
  • the additional active ingredients may be co-administered separately with an active agent of compounds of Table 1 or included with such an agent in a pharmaceutical composition according to the invention.
  • additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by GluN2B activity, such as another GluN2B modulator or a compound active against another target associated with the particular condition, disorder, or disease.
  • the combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an active agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.
  • a pharmaceutical composition of the invention comprises: (a) an effective amount of at least one active agent in accordance with the invention; and (b) a pharmaceutically acceptable excipient.
  • a “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith.
  • excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
  • compositions containing one or more dosage units of the active agents may be prepared using suitable pharmaceutical excipients and compounding techniques known or that become available to those skilled in the art.
  • the compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
  • the preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories.
  • the compositions are formulated for intravenous infusion, topical administration, or oral administration.
  • the compounds of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension.
  • the compounds may be formulated to yield a dosage of, e.g., from about 0.05 to about 100 mg/kg daily, or from about 0.05 to about 35 mg/kg daily, or from about 0.1 to about 10 mg/kg daily.
  • a total daily dosage of about 5 mg to 5 g daily may be accomplished by dosing once, twice, three, or four times per day.
  • Oral tablets may include a compound according to the invention mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents.
  • suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
  • Exemplary liquid oral excipients include ethanol, glycerol, water, and the like.
  • Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are suitable disintegrating agents.
  • Binding agents may include starch and gelatin.
  • the lubricating agent if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract or may be coated with an enteric coating.
  • Capsules for oral administration include hard and soft gelatin capsules.
  • compounds of the invention may be mixed with a solid, semi-solid, or liquid diluent.
  • Soft gelatin capsules may be prepared by mixing the compound of the invention with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
  • Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
  • suspending agents for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose,
  • the active agents of this invention may also be administered by non-oral routes.
  • the compositions may be formulated for rectal administration as a suppository.
  • parenteral use including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the compounds of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
  • Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
  • Such forms will be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation.
  • Illustrative infusion doses may range from about 1 to 1000 ⁇ g/kg/minute of compound, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
  • the compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle.
  • a pharmaceutical carrier for topical administration, may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle.
  • Another mode of administering the compounds of the invention may utilize a patch formulation to affect transdermal delivery.
  • Compounds of the invention may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
  • 6-bromo-1H-pyrrolo[3,2-b]pyridine is fluorinated with an electrophilic halogen source under conditions known to one skilled in the art.
  • 6-bromo-1H-pyrrolo[3,2-b]pyridine is fluorinated using a reagent such as N-fluoro-N′-(chloromethyl)triethylenediamine bis(tetrafluoroborate) (Selectfluor®) and the like; in a suitable solvent such as acetonitrile (ACN), dichloromethane (DCM), and the like, at a temperature of 90° C., to provide 6-Bromo-3-fluoro-1H-pyrazolo[4,3-b]pyridine.
  • a reagent such as N-fluoro-N′-(chloromethyl)triethylenediamine bis(tetrafluoroborate) (Selectfluor®) and the like
  • ACN acetonitrile
  • DCM dichloromethane
  • a compound of formula (V), where R 1 is cyclobutyl, pyrizinyl, pyridyl, pyridyl substituted with one or two F members is brominated using a reagent such as Br 2 , HBr, pyridinium tribromide, phenyltrimehtylammonium tribromide, and the like; in a suitable solvent such as methanol (MeOH), tetrahydrofuran (THF), acetic acid (AcOH), and the like; at temperatures ranging from 0° C. to 60° C.; to provide a compound of formula (VI).
  • a reagent such as Br 2 , HBr, pyridinium tribromide, phenyltrimehtylammonium tribromide, and the like
  • a suitable solvent such as methanol (MeOH), tetrahydrofuran (THF), acetic acid (AcOH), and the like
  • a compound of formula (VII) where the hydroxymethyl group is attached at either of the carbon atoms as indicated with (*), is chlorinated using a reagent such as SOCl 2 , and the like; an amine base such as pyridine; in a solvent such as DCM, and the like; at a temperature of 90° C.; to afford a compound of formula (VIII).
  • a compound of formula (IX) where R 1 is H is alkylated with (chloromethyl)(ethyl)sulfane, a base such as Cs 2 CO 3 , and the like; in a solvent such as DMF, and the like, at room temperature, for a period of 20 hours, to provide 6-bromo-1-(ethylsulfanylmethyl)pyrazolo[4,3-b]pyridine and 6-bromo-2-(ethylsulfanylmethyl)pyrazolo[4,3-b]pyridine.
  • 6-Bromo-1-(ethylsulfanylmethyl)pyrazolo[4,3-b]pyridine is oxidized using a reagent such as meta-chloroperoxybenzoic acid (m-CPBA), and the like, in a suitable solvent such as DCM, and the like; at a temperature of 0° C.; to provide a 6-bromo-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine.
  • m-CPBA meta-chloroperoxybenzoic acid
  • a compound of formula (XII) is alkylated employing conditions previously described to provide a compound of formula (XIII).
  • a compound of formula (XIII), where Ar 1 is 3-(difluoromethoxy)-4-fluorophenyl, is oxidized using a reagent such as m-CPBA, in a solvent such as DCM, at room temperature, to provide a compound of formula (XIV).
  • a compound of formula (XIV), where Ar 1 is 3-(difluoromethoxy)-4-fluorophenyl is reduced using a reagent such as Pd/C (10%), in a solvent such as EtOH, EtOAc, or a mixture thereof, at room temperature, to provide a compound of Formula (I).
  • a compound of Formula (I) is prepared in two steps from a compound of formula (IX).
  • a compound of formula (IX) where R 1 is H, or CH 3 , is reacted in a metal mediated cross coupling reaction to provide a compound of formula (XVIII), where Ar 1 is a phenyl optionally substituted with one, two, or three members each independently selected from halo, C 1-6 alkyl, C 1-6 perhaloalkyl, and OC 1-6 perhaloalkyl.
  • a compound of formula (IX), where R 1 is H, or CH 3 is reacted with a commercially available or synthetically accessible suitably substituted aryl boronic acid, boronate ester, and the like; in the presence of a palladium catalyst such as bis(triphenylphosphine)palladium(II)chloride (PdCl 2 (PPh 3 ) 2 ), bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (PdCl 2 (dppf).DCM), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl 2 (dppf)), tetrakis(triphenylphosphine)palladium(0) (Pd(PPh 3 ) 4 ), 2-dicyclohexylphosphino-2′,6′-diisopropylphos
  • a base such
  • a compound of Formula (I) is prepared in two steps from a compound of formula (IX).
  • a compound of formula (IX) where R 1 is H, or F is alkylated employing conditions previously described with an alkyl agent of formula (XIX), where X is Br or Cl, and R 2 is as described in claim 1 , to provide a compound of formula (XX).
  • a second step coupling with a suitably substituted phenyl or thienyl boronic acid or ester, employing conditions previously described, provides a compound of Formula (I).
  • a reducing agent such as NaBH 4 , and the like
  • a suitable solvent such as MeOH, THF, or a mixture thereof
  • a compound of Formula (I), where R 2 is (C ⁇ O)C 1-6 alkyl, is reacted with a nucleophile such as hydroxylamine hydrochloride, o-methylhydroxylamine hydrochloride, and the like; using a base such as Cs 2 CO 3 , triethylamine, NaHCO 3 , and the like; in a solvent such as MeOH, EtOH, H 2 O, or a mixture thereof, to provide a compound of Formula (I), where R 2 is C( ⁇ N—OH)C 1-6 alkyl, or C( ⁇ N—OCH 3 )C 1-6 alkyl.
  • a nucleophile such as hydroxylamine hydrochloride, o-methylhydroxylamine hydrochloride, and the like
  • a base such as Cs 2 CO 3 , triethylamine, NaHCO 3 , and the like
  • a solvent such as MeOH, EtOH, H 2 O, or a mixture thereof
  • a compound of Formula (I), where R 2 is (C ⁇ O)C 1-6 alkyl, is fluorinated under conditions known to one skilled in the art, for example, reaction with a fluorinated reagent such as DAST, bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor®), and the like; in a solvent such as DCM, THF, and the like; at a temperature ranging from 0° C. to rt; to provide a compound of Formula (I), where R 2 is C(F 2 )C 1-6 alkyl.
  • a fluorinated reagent such as DAST, bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor®), and the like
  • a solvent such as DCM, THF, and the like
  • a compound of Formula (I), where R 2 is CH(OH)C 1-6 alkyl, is fluorinated under conditions known to one skilled in the art, for example, reaction with a fluorinated reagent such as DAST, Deoxo-Fluor®, and the like; in a solvent such as DCM, THF, and the like; at a temperature ranging from 0° C. to rt; to provide a compound of Formula (I), where R 2 is CH(F)C 1-6 alkyl.
  • a compound of Formula (I), where R 2 is CH(OH)C 1-6 alkyl is methylated with iodomethane; using a base such as NaH, and the like; in a suitable solvent such as DMF, and the like; to provide a compound of Formula (I), where R 2 is CH(OCH 3 )C 1-6 alkyl.
  • a compound of Formula (I), where R 2 is oxetanyl, is treated with an Agilent Bond Elut strong cation exchange (SCX) cartridge to provide a compound of Formula (I), where R 2 is CH(OH)CH 2 CH 2 OCH 3 .
  • SCX Agilent Bond Elut strong cation exchange
  • Compounds of Formula (I) may be converted to their corresponding salts using methods known to one of ordinary skill in the art.
  • an amine of Formula (I) is treated with trifluoroacetic acid, HCl, or citric acid in a solvent such as diethyl ether (Et 2 O), CH 2 Cl 2 , THF, MeOH, chloroform, or isopropanol to provide the corresponding salt form.
  • a solvent such as diethyl ether (Et 2 O), CH 2 Cl 2 , THF, MeOH, chloroform, or isopropanol
  • trifluoroacetic acid or formic acid salts are obtained as a result of reverse phase HPLC purification conditions.
  • Cyrstalline forms of pharmaceutically acceptable salts of compounds of Formula (I) may be obtained in crystalline form by recrystallization from polar solvents (including mixtures of polar solvents and aqueous mixtures of polar solvents) or from non-polar solvents (including mixtures of non-polar solvents).
  • the compounds according to this invention may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
  • Compounds prepared according to the schemes described above may be obtained as single forms, such as single enantiomers, by form-specific synthesis, or by resolution. Compounds prepared according to the schemes above may alternately be obtained as mixtures of various forms, such as racemic (1:1) or non-racemic (not 1:1) mixtures. Where racemic and non-racemic mixtures of enantiomers are obtained, single enantiomers may be isolated using conventional separation methods known to one of ordinary skill in the art, such as chiral chromatography, recrystallization, diastereomeric salt formation, derivatization into diastereomeric adducts, biotransformation, or enzymatic transformation. Where regioisomeric or diastereomeric mixtures are obtained, as applicable, single isomers may be separated using conventional methods such as chromatography or crystallization.
  • reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were “dried,” they were generally dried over a drying agent such as Na 2 SO 4 or MgSO 4 . Where mixtures, solutions, and extracts were “concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure. Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM (Microwave Reactor) Discover instrument.
  • “flowed through a LTF-VS mixer” refers to the use of a Chemyx Fusion 100 Touch Syringe Pump that is in line via 1/16′′ PTFE tubing to a LTF-VS mixer (Little Things Factory GmbH (http://www.ltf-gmbh.com), unless otherwise indicated.
  • METHOD E A Wufeng LC100 equipped with a manual Rheodyne 3725i sampler with a Gemini-NX C18 column (5 ⁇ M, 30 ⁇ 100 mm), and a mobile phase of 20-100% ACN:8 mM (NH 4 )HCO 3 (9:1) in 10 mM aqueous (NH 4 )HCO 3 over 16 min, with a flow rate of 40 mL/min. or METHOD F.
  • a Wufeng LC100 equipped with a manual Rheodyne 3725i sampler with a Gemini-NX C18 column (5 ⁇ M, 30 ⁇ 100 mm), and a mobile phase of 50-100% ACN:8 mM (NH 4 )HCO 3 (9:1) in 10 mM aqueous (NH 4 )HCO 3 over 8 min, with a flow rate of 30 mL/min.
  • SFC supercritical fluid high performance liquid chromatography
  • Mass spectra were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.
  • NMR Nuclear magnetic resonance
  • Step A 6-Bromo-1-(ethylsulfanylmethyl)pyrazolo[4,3-b]pyridine.
  • a mixture of 6-bromo-1H-pyrazolo[4,3-b]pyridine (600 mg, 3.03 mmol), (chloromethyl)(ethyl)sulfane (369 mg, 3.34 mmol) and Cs 2 CO 3 (1.48 g, 4.54 mmol) in dry DMF (12 mL) was stirred at room temperature for 20 h.
  • the reaction mixture was poured into water (15 mL) and extracted with EtOAc (3 ⁇ 10 mL). The combined organic layers were dried over Na 2 SO 4 , filtered and evaporated.
  • Step B 6-Bromo-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine.
  • Step A 4-Bromo-2-(1,1-difluoroethyl)-1-fluorobenzene.
  • a mixture of 1-(5-bromo-2-fluorophenyl)-1-ethanone (2.5 g, 11.5 mmol, 1 equiv) and DAST (1.9 mL, 14.4 mmol, 1.25 equiv) was heated at 60° C. for 16 h.
  • a sat. aq. solution of NaHCO 3 was slowly added at 0° C. and the mixture was extracted with DCM.
  • the organic layers were combined, dried over MgSO 4 , filtered, and partially concentrated (product is volatile).
  • Step B 2-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.
  • bis(pinacolato)diboron (2.87 g, 11.3 mmol, 1.5 equiv)
  • potassium acetate (2.22 g, 22.6 mmol, 3 equiv)
  • [1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (615 mg, 0.75 mmol, 0.1 equiv) were added to a solution of 4-bromo-2-(1,1-difluoroethyl)-1-fluorobenzene (3 g, 7.5 mmol, 1 equiv) in dry 1,4-dioxane (40 mL).
  • Example 7 The title compound was prepared in a manner analogous to Example 3 using 1-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one (Example 7) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one.
  • Example 9 The title compound was prepared in a manner analogous to Example 3 using 1-cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone (Example 9) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one.
  • Step A 6-(3-(Difluoromethoxy)-4-fluorophenyl)-1-((ethylsulfonyl)methyl)-1H-pyrazolo[4,3-b]pyridine 4-oxide.
  • m-CPBA (6.8 mg, 0.03 mmol) was added to a solution of (RS)-6-[3-(difluoromethoxy)-4-fluoro-phenyl]-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine (Example 12, 8.63 mg, 0.02 mmol) in DCM (2 mL) at room temperature. After 16 hours, the reaction mixture was quenched with saturated aqueous NaHCO 3 (10 mL).
  • Step B 6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(ethylsulfonylmethyl)pyrazolo[4,3-b]pyridine.
  • the title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), 2-(3-(difluoromethoxy)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane instead of 3,5-difluorophenylboronic acid, and RuPhos Pd G3 instead of Pd(dppf)Cl 2 .DCM.
  • Example 78 1-Cyclopropyl-2-[6-(4-fluoro-2,3-dimethyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Example 83 The title compound was prepared by the separation of Example 83 using chiral SFC (Stationary phase: CHIRALPAK IC 5 ⁇ m 250*30 mm, Mobile phase: 60% CO 2 , 40% MeOH). MS (ESI): mass calcd. for C 16 H 14 F 3 N 3 OS, 353.1; m/z found, 354.1 [M+H] + .
  • Example 83 The title compound was prepared by the separation of Example 83 using chiral SFC (Stationary phase: CHIRALPAK IC 5 ⁇ m 250*30 mm, Mobile phase: 60% CO 2 , 40% MeOH). MS (ESI): mass calcd. for C 16 H 14 F 3 N 3 OS, 353.1; m/z found, 354.1 [M+H] + .
  • Example 34 The title compound was prepared in a manner analogous to Example 5 using 1-(6-(3,4-difluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Example 34) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one.
  • Example 40 The title compound was prepared in a manner analogous to Example 5 using 1-(6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Example 40) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one.
  • Example 35 The title compound was prepared in a manner analogous to Example 5 using 1-[6-(3,4-difluorophenyl)-3-fluoro-pyrazolo[4,3-b]pyridin-1-yl]butan-2-one (Example 35) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one.
  • Example 31 The title compound was prepared in a manner analogous to Example 5 using 1-[6-[3-(1,1-difluoroethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one (Example 31) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one.
  • Example 62 The title compound was prepared in a manner analogous to Example 3 using 1-cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone (Example 62) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one.
  • Example 69 The title compound was prepared in a manner analogous to Example 3 using 1-cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone (Example 69) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one.
  • Example 101 The title compound was prepared by the separation of Example 101 using chiral SFC (Stationary phase: CHIRALPAK IC 5 ⁇ m 250 ⁇ 20 mm, Mobile phase: 70% CO 2 , 30% iPrOH). MS (ESI): mass calcd. for C 18 H 18 FN 3 O, 311.1; m/z found, 312.1 [M+H] + .
  • Example 101 The title compound was prepared by the separation of Example 101 using chiral SFC (Stationary phase: CHIRALPAK IC 5 ⁇ m 250 ⁇ 20 mm, Mobile phase: 70% CO 2 , 30% iPrOH). MS (ESI): mass calcd. for C 18 H 18 FN 3 O, 311.1; m/z found, 312.1 [M+H] + .
  • Example 76 The title compound was prepared in a manner analogous to Example 5 using 1-cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone (Example 76) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one.
  • Example 106 (E/Z)-1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone oxime
  • Example 62 The title compound was prepared in a manner analogous to Example 6 using 1-cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone (Example 62) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one.
  • Example 76 The title compound was prepared in a manner analogous to Example 6 using 1-cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethenone (Example 76) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one, and triethylamine instead of Cs 2 CO 3 .
  • Example 108 1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine
  • Example 76 1-cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethenone (Example 76) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one.
  • Example 109 1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine
  • Example 110 6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[(3-methyloxetan-3-yl)methyl]pyrazolo[4,3-b]pyridine
  • Example 116 The title compound was prepared by the separation of Example 116 using chiral SFC (Stationary phase: Chiralpak IC, 5 um 250 ⁇ 21 mm, Mobile phase: 30% methanol, 70% CO 2 ). MS (ESI): mass calcd. for C 19 H 17 F 3 N 4 O, 374.1; m/z found, 375.1 [M+H] + .
  • Example 116 The title compound was prepared by the separation of Example 116 using chiral SFC (Stationary phase: Chiralpak IC, 5 ⁇ M 250 ⁇ 21 mm, Mobile phase: 30% methanol, 70% CO 2 ). MS (ESI): mass calcd. for C 19 H 17 F 3 N 4 O, 374.1; m/z found, 375.1 [M+H] + .
  • Example 120 The title compound was prepared by the separation of Example 120 using chiral SFC (Stationary phase: CHIRALPAK AD-H 5 ⁇ m 250*30 mm, Mobile phase: 75% CO 2 , 25% MeOH). MS (ESI): mass calcd. for C 19 H 17 F 3 N 4 O, 374.1; m/z found, 375.0 [M+H] + .
  • Example 120 The title compound was prepared by the separation of Example 120 using chiral SFC (Stationary phase: CHIRALPAK AD-H 5 ⁇ m 250*30 mm, Mobile phase: 75% CO 2 , 25% MeOH). MS (ESI): mass calcd. for C 19 H 17 F 3 N 4 O, 374.1; m/z found, 375.0 [M+H] + .
  • Example 131 The title compound was prepared by the separation of Example 131 using chiral SFC (Stationary phase: Chiralpak IA, Sum 250 ⁇ 21 mm, Mobile phase: 35% methanol with 0.2% triethylamine, 65% CO 2 ). MS (ESI): mass calcd. for C 19 H 17 F 3 N 4 O 2 , 390.1; m/z found, 391.2 [M+H] + .
  • Example 131 The title compound was prepared by the separation of Example 131 using chiral SFC (Stationary phase: Chiralpak IA, Sum 250 ⁇ 21 mm, Mobile phase: 35% methanol with 0.2% triethylamine, 65% CO 2 ). MS (ESI): mass calcd. for C 19 H 17 F 3 N 4 O 2 , 390.1; m/z found, 391.2 [M+H] + .
  • Example 134 The title compound was prepared by the separation of Example 134 using chiral SFC (Stationary phase: Chiralpak AS, Sum 250 ⁇ 21 mm, Mobile phase: 15% methanol:isopropanol (1:1) with 0.2% isopropylamine, 85% CO 2 ).
  • Example 134 The title compound was prepared by the separation of Example 134 using chiral SFC (Stationary phase: Chiralpak AS, 5 um 250 ⁇ 21 mm, Mobile phase: 15% methanol:isopropanol (1:1) with 0.2% isopropylamine, 85% CO 2 ).
  • Example 138 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(3-thienyl)ethanone
  • Example 140 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(3-fluoropyridin-2-yl)ethan-1-one
  • Example 141 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(3,5-difluoropyridin-2-yl)ethan-1-one
  • Example 142 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(pyrazin-2-yl)ethan-1-one
  • NMDA receptors are ion channels that are highly permeable to Ca 2+ ions, rendering it possible to monitor NMDA receptor function using cell-based calcium flux assay.
  • co-agonists glutamate and glycine are added to cells heterologously expressing human GluN1/GluN2B NMDA receptors to initiate cellular Ca 2+ influx.
  • the time course of the changes in intracellular calcium is measured using a fluorescent dye and a FLIPR (Fluorometric Imaging Plate Reader) device.
  • NMDA receptors in the stable cell line is induced with Tet-On inducible system in the presence of a non-selective NMDA receptor blocker.
  • cell culture media is carefully washed and the cells are loaded with Calcium 5 Dye Kit (Molecular Devices) in dye loading buffer containing 137 mM NaCl, 4 mM KCl, 2 mM CaCl 2 ), 0.5 mM MgCl 2 (standard assay) or 1.5 mM MgCl 2 (HTS assay), 10 mM HEPES and 5 mM D-glucose; pH 7.4.
  • the dye is washed away with the assay buffer (137 mM NaCl (standard assay) or 150 mM (HTS assay), 4 mM KCl (standard assay) or 3 mM (HTS assay), 2 mM CaCl 2 ), 0.01 mM EDTA, 10 mM HEPES and 5 mM D-glucose; pH 7.4)
  • the assay buffer 137 mM NaCl (standard assay) or 150 mM (HTS assay), 4 mM KCl (standard assay) or 3 mM (HTS assay), 2 mM CaCl 2 ), 0.01 mM EDTA, 10 mM HEPES and 5 mM D-glucose; pH 7.4
  • various concentrations of the test compounds are added to the cells for 5 min while fluorescence is monitored to detect potential agonist activity.
  • co-agonists, glutamate and glycine are added for another 5 minutes.
  • the concentration of glutamate corresponding to ⁇ EC 40 (standard assay) or EC 40 (HTS assay) is used to maximize the assay's signal window and ability to detect NMDA receptor antagonists and negative allosteric modulators.
  • a saturating concentration (10 ⁇ M) of glycine is also present in the assay.
  • a non-selective NMDA receptor antagonist, (+)MK-801 is used as a positive control for antagonist activity.
  • the fluorescent signal in the presence of test compounds is quantified and normalized to the signal defined by the appropriate control wells.
  • Microsomal stability studies (Chrovian et al, “1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators”. ACS Med Chem Lett. 2019 Jan. 10; 10(3):261-266) were conducted on a Biomek® FX Robotic Liquid Handling Workstation (Beckman Coulter, Brea, Calif.), which consists of a 96-channel pipette head, a 12-position workstation deck, and a plate incubator.
  • Test compounds (1 ⁇ M) were spiked in a reaction mix consisting of 100 mM potassium phosphate buffer (pH 7.4), 3 mM MgCl 2 , and 0.5 mg/mL liver microsomes from mouse, rat, and human (BD Gentest). The reaction was brought to 37° C. and initiated by adding NADPH to a final concentration of 1 mM. After mixing on the plate deck, 50 ⁇ L aliquots were excised from the reaction plate at 0, 5, 10, 20, 40, and 60 min and quenched with four volumes of acetonitrile spiked with 500 ⁇ g/nL of the internal standard phenytoin.
  • Quenched plates were centrifuged at 5700 rpm for 10 min at 4° C., and supernatant was diluted 1:3 in water before LC/MS/MS analysis.
  • the compound half-lives were derived from plots of the ln of percent remaining compound over time to determine the intrinsic clearance.
  • the predicted hepatic clearance was derived from the intrinsic clearance value using equations from the well-stirred model (Current Drug Metabolism, 2008, 9, 940-951), where no correction was made plasma protein binding and the blood to plasma concentration ratio was assumed to be one.
  • the extraction ratio (ER) was calculated by dividing the predicted hepatic clearance by species blood flow (Q), where Q is 90, 55, and 21.7 mL/min/kg for mouse, rat and human, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the priority benefit of U.S. provisional application No. 62/861,674, filed Jun. 14, 2019, the contents of which are incorporated herein in their entireties by reference thereto.
    • FIELD OF THE INVENTION
  • The present invention is related to compounds having GluN2B modulating properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with GluN2B receptor activity in animals, in particular humans.
    • BACKGROUND OF THE INVENTION
  • Glutamate is one of the major excitatory neurotransmitters that is widely spread in the brain. First indication of its role as an excitatory messenger was in the 1950's when it was observed that intravenous administration of glutamate induces convulsions. However, the detection of the whole glutamatergic neurotransmitter system with its various receptors did not take place before the 1970's and 1980's when numerous antagonists were developed or, as in the case of PCP and ketamine, were identified as antagonists. Finally, in the 1990's molecular biology provided the tools for the classification of the glutamatergic receptors.
  • N-methyl-D-aspartate (NMDA) receptors are a subtype of ionotropic glutamate receptors that mediate excitatory synaptic transmission in the brain. NMDA receptors are ubiquitously distributed throughout the brain and play a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. NMDA receptors are distinct from other major subtypes of ionotropic glutamate receptors (AMPA and kainate receptors) in that they are blocked by Mg2+ at resting membrane potentials, are highly Ca2+ permeable, and require co-activation by two distinct neurotransmitters: glutamate and glycine (or D-serine) (Traynelis S F et al., Pharmacol Rev. 2010; 62(3):405-96). The influx of Ca2+ through NMDA receptors triggers signaling cascades and regulates gene expression that is critical for different forms of synaptic plasticity including both long-term potentiation of synapse efficacy (LTP) (Berberich S et al., Neuropharmacology 2007; 52(1):77-86) and long-term depression (LTD) (Massey, P V et al., J Neurosci. 2004 Sep. 8; 24(36):7821-8).
  • The vast majority of the mammalian NMDA receptors form a heterotetramer made of two obligatory GluN1 units and two variable GluN2 receptor subunits encoded by the GRIN1 gene and one of four GRIN2 genes, respectively. One or both GluN2 subunits can be potentially replaced by a GluN3A or a GluN3B subunit. The GRIN1 gene product has 8 splice variants while there are 4 different GRIN2 genes (GRIN2A-D) encoding four distinct GluN2 subunits. The glycine binding site is present on the GluN1 subunit and the glutamate binding site is present on the GluN2 subunit.
  • The GluNR2 subunits play a dominant role in determining the functional and pharmacological properties of the NMDA receptor assembly and exhibit distinct distribution in different areas of the brain. For instance, GluN2B subunits are expressed primarily in the forebrain in the adult mammalian brain (Paoletti P et al., Nat Rev Neurosci. 2013; 14(6):383-400; Watanabe M et al., J Comp Neurol. 1993; 338(3):377-90) and are implicated in learning, memory processing, mood, attention, emotion and pain perception (Cull-Candy S et al., Curr Opin Neurobiol. 2001; 11(3):327-35).
  • Compounds that modulate GluN2B-containing NMDA receptor function can be useful in treatment of many neurological and psychiatric disorders including but not limited to bipolar disorder (Martucci L et al., Schizophrenia Res, 2006; 84 (2-3):214-21), major depressive disorder (Miller O H et al., eLife. 2014; 3:e03581; Li N et al., Biol Psychiatry. 2011; 69(8):754-61), treatment-resistant depression (Preskorn S H et al. J Clin Psychopharmacol. 2008; 28(6):631-7) and ther mood disorders (including schizophrenia (Grimwood S et al., Neuroreport. 1999; 10(3):461-5; Weickert C S et al. Molecular Psychiatry (2013) 18, 1185-1192), ante- and postpartum depression, seasonal affective disorder and the like), Alzheimer's disease (Hanson J E et al., Neurobiol Dis. 2015; 74:254-62; Li S et al., J Neurosci. 2011; 31(18):6627-38) and other dementias (Orgogozo J M et al. Stroke 2002, 33: 1834-1839), Parkinson's disease (Duty S, CNS Drugs. 2012; 26(12):1017-32; Steece-Collier K et al., Exp Neurol. 2000; 163(1):239-43; Leaver K R et al. Clin Exp Pharmacol Physiol. 2008; 35(11):1388-94), Huntington's chorea (Tang T S et al., Proc Natl Acad Sci USA. 2005; 102(7):2602-7; Li L et al., J Neurophysiol. 2004; 92(5):2738-46), multiple sclerosis (Grasselli G et al., Br J Pharmacol. 2013; 168(2):502-17; Farjam M et al., Iran J Pharm Res. 2014; 13(2):695-705), cognitive impairment (Wang D et al. 2014, Expert Opin Ther Targets Expert Opin Ther Targets. 2014; 18(10):1121-30), head injury (Bullock M R et al., Ann NY Acad Sci. 1999; 890:51-8), spinal cord injury, stroke (Yang Y et al., J Neurosurg. 2003; 98(2):397-403), epilepsy (Naspolini A P et al., Epilepsy Res. 2012 June; 100 (1-2):12-9), movement disorders (e.g. dyskinesias) (Morissette M et al., Mov Disord. 2006; 21(1):9-17), various neurodegenerative diseases (e.g. amyotrophic lateral sclerosis (Fuller P I et al., Neurosci Lett. 2006; 399 (1-2):157-61) or neurodegeneration associated with bacterial or chronic infections), glaucoma (Naskar R et al. Semin Ophthalmol. 1999 September; 14(3):152-8), pain (e.g. chronic, cancer, post-operative and neuropathic pain (Wu L J and Zhuo M, Neurotherapeutics. 2009; 6(4):693-702), diabetic neuropathy, migraine (Peeters M et al., J Pharmacol Exp Ther. 2007; 321(2):564-72), cerebral ischemia (Yuan H et al., Neuron. 2015; 85(6):1305-18), encephalitis (Dalmau J. et al., Lancet Neurol. 2008; 7(12):1091-8), autism and autism spectrum disorders (Won H. et al., Nature. 2012; 486(7402):261-5), memory and learning disorders (Tang, Y. P. et al., Nature. 1999; 401(6748):63-9), obsessive compulsive disorder (Arnold P D et al., Psychiatry Res. 2009; 172(2):136-9), attention deficit hyperactivity disorder (ADHD) (Dorval K M et al., Genes Brain Behav. 2007; 6(5):444-52), PTSD (Haller J et al. Behav Pharmacol. 2011; 22(2):113-21; Leaderbrand K et al. Neurobiol Learn Mem. 2014; 113:35-40), tinnitus (Guitton M J, and Dudai Y, Neural Plast. 2007; 80904; Hu S S et al. 2016; 273(2): 325-332), sleep disorders (like narcolepsy or excessive daytime sleepiness, patent WO 2009058261 A1), vertigo and nystagmus (Straube A. et al., Curr Opin Neurol. 2005; 18(1):11-4; Starck M et al. J Neurol. 1997 January; 244(1):9-16), anxiety autoimmunological disorders like neuropsychiatric systemic lupus erythematosus (Kowal C et al. Proc. Natl. Acad. Sci. U.S.A. 2006; 103, 19854-19859) and addictive illnesses (e.g. alcohol addiction, drug addiction) (Nagy J, 2004, Curr Drug Targets CNS Neurol Disord 2004; 3(3):169-79; Shen H et al., Proc Natl Acad Sci USA. 2011; 108(48):19407-12).
  • In view of the clinical importance of GluN2B, the identification of compounds that modulate GluN2B receptor function represents an attractive avenue into the development of new therapeutic agents. Such compounds are provided herein.
    • SUMMARY OF THE INVENTION
  • The invention is directed to the general and preferred embodiments defined, respectively, by the independent and dependent claims appended hereto, which are incorporated by reference herein. One aspect of this invention concerns compounds of Formula (I):
  • Figure US20220324860A1-20221013-C00001
  • wherein
  • R1 is H, halo, or CH3;
  • Ar1 is selected from the group consisting of:
      • (a) phenyl;
      • (b) phenyl substituted with one member selected from the group consisting of: halo, C1-6alkyl, C1-6 perhaloalkyl, and OC1-6perhaloalkyl;
      • (c) phenyl substituted with two or three members each independently selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl; and
      • (d) thienyl substituted with one member selected from the group consisting of: halo, and C1-6alkyl;
  • R2 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00002
  • wherein Ra is selected from the group consisting of: C1-6alkyl; C3-6cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
  • Figure US20220324860A1-20221013-C00003
  • wherein Rb is C1-6alkyl;
      • (f) C1-6alkyl substituted with one, two, or three members each independently selected from the group consisting of: OH, halo, OC1-6alkyl, (═N—OH), (═N—OCH3), and cyclopropyl; and
      • (g) oxetanyl; oxetanyl substituted with C1-6alkyl; tetrahydrofuranyl; oxazolidinone; oxazolidinone substituted with C1-4alkyl, or cyclopropyl; and pyrrolidinone substituted with C1-4alkyl;
        and pharmaceutically acceptable salts, stereoisomers, isotopic variants, N-oxides, or solvates of compounds of Formula (I).
  • Further embodiments are provided by pharmaceutically acceptable salts of compounds of Formulas (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of compounds of Formula (I).
  • In certain embodiments, the compounds of Formula (I) are compounds selected from those species described or exemplified in the detailed description below.
  • In a further aspect, the invention relates to enantiomers and diastereomers of the compounds of Formula (I), as well as the pharmaceutically acceptable salts.
  • In a further aspect, the invention relates to pharmaceutical compositions for treating a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising an effective amount of at least one compound selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of Formula (I).
  • Pharmaceutical compositions according to the invention may further comprise one or more pharmaceutically acceptable excipients.
  • In another aspect, the chemical embodiments of the present invention are useful as GluN2B receptor modulators. Thus, the invention is directed to a method for modulating GluN2B receptor activity, including when such receptor is in a subject, comprising exposing GluN2B receptor to an effective amount of at least one compound selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of compounds of Formula (I).
  • In another aspect, the invention is directed to a method of treating a subject suffering from, or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to the subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of compounds of Formula (I). Additional embodiments of methods of treatment are set forth in the detailed description.
  • In another aspect, the method of studying isotopically labeled compounds in metabolic studies (preferably with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. For example, an 18F or 11C labeled compound may be particularly preferred for PET or SPECT studies.
  • Additional embodiments of this invention include methods of making compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of Formula (I).
  • An object of the present invention is to overcome or ameliorate at least one of the disadvantages of the conventional methodologies and/or prior art, or to provide a useful alternative thereto.
  • Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.
    • DETAILED DESCRIPTION OF INVENTION
  • In one aspect, provided herein are compounds of Formula (I),
  • Figure US20220324860A1-20221013-C00004
      • wherein
      • R1 is H, halo, or CH3;
      • Ar1 is selected from the group consisting of:
        • (a) phenyl;
        • (b) phenyl substituted with one member selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl;
        • (c) phenyl substituted with two or three members each independently selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl; and
        • (d) thienyl substituted with one member selected from the group consisting of: halo, and C1-6alkyl;
      • R2 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00005
      •  wherein Ra is selected from the group consisting of: C1-6alkyl; C3-6cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
  • Figure US20220324860A1-20221013-C00006
      •  wherein Rb is C1-6alkyl;
        • (f) C1-6alkyl substituted with one, two, or three members each independently selected from the group consisting of: OH, halo, OC1-6alkyl, (═N—OH), (═N—OCH3), and cyclopropyl; and
        • (g) oxetanyl; oxetanyl substituted with C1-6alkyl; tetrahydrofuranyl; oxazolidinone; oxazolidinone substituted with C1-4alkyl, or cyclopropyl; and pyrrolidinone substituted with C1-4alkyl;
  • and pharmaceutically acceptable salts, stereoisomers, isotopic variants, N-oxides, or solvates thereof.
  • An additional embodiment of the invention is a compound of Formula (I) wherein R1 is H.
  • An additional embodiment of the invention is a compound of Formula (I) wherein R1 is F.
  • An additional embodiment of the invention is a compound of Formula (I) wherein R1 is CH3.
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar1 is phenyl.
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar1 is phenyl substituted with one member selected from the group consisting of: F, CH3, CF2H, CF2CH3, CF3, and OCF3.
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar1 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00007
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar1 is phenyl substituted with two members each independently selected from the group consisting of: F, Cl, CH3, CF2H, CF3, CF2CH3, and OCF2H.
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar1 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00008
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar1 is phenyl substituted with three members each independently selected from the group consisting of: F and CH3.
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar1 is
  • Figure US20220324860A1-20221013-C00009
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar1 is thienyl is substituted with Cl or CH3.
  • An additional embodiment of the invention is a compound of Formula (I) wherein Ar1 is
  • Figure US20220324860A1-20221013-C00010
  • An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
  • Figure US20220324860A1-20221013-C00011
  • An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
  • Figure US20220324860A1-20221013-C00012
  • An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
  • Figure US20220324860A1-20221013-C00013
  • An additional embodiment of the invention is a compound of Formula (I) wherein R2 is
  • Figure US20220324860A1-20221013-C00014
  • An additional embodiment of the invention is a compound of Formula (I) having the Formula (IA):
  • Figure US20220324860A1-20221013-C00015
      • wherein
      • HAL is F or Cl;
      • R1 is H, F, or CH3;
      • R2 is selected from the group consisting of:
        • (a) (S═O)CH2CH3; (SO2)CH2CH3; or
  • Figure US20220324860A1-20221013-C00016
        •  wherein Ra is selected from the group consisting of: CH3, CH2CH3, CH(CH3)2, cyclopropyl, cyclobutyl,
  • Figure US20220324860A1-20221013-C00017
        • (b) CH2OCH3, CH(OH)(CH2CH3), CH(OH)CH(CH3)2, CF2CH2CH3, CF2(cyclopropyl), CH(OCH3)(cyclopropyl), CH(OH)(cyclopropyl), or
  • Figure US20220324860A1-20221013-C00018
        •  and
  • Figure US20220324860A1-20221013-C00019
      • Rc is H, F, or CH3;
      • Rd is selected from the group consisting of: H, F, Cl, CH3, CF2H, CF2CH3, CF3, and OCF2H; and
      • Re is H or F; wherein when Re is F, Rc is H.
  • An additional embodiment of the invention is a compound of Formula (I) having the Formula (IA), wherein HAL is F; R1 is H; Rc is H; and Re is H.
  • An additional embodiment of the invention is a compound of Formula (I) having the Formula (IB):
  • Figure US20220324860A1-20221013-C00020
      • wherein
      • Ar1 is selected from the group consisting of:
        • (a) phenyl, 3-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 3-(difluoromethyl)phenyl, 3-(1,1-difluoroethyl)phenyl, 3-(trifluoromethyl)phenyl, 3-(trifluoromethoxy)phenyl, 5-methyl-2-thienyl, or 5-chloro-2-thienyl; and
        • (b) 2-fluoro-3-methyl-phenyl, 2,3-difluorophenyl, 3,5-difluorophenyl, 3-chloro-2-fluoro-phenyl, 2-fluoro-3-(trifluoromethyl)phenyl, 4-chloro-3-(difluoromethoxy)phenyl, or 4-chloro-3-(trifluoromethyl)phenyl; and
      • R2 is selected from the group consisting of (S═O)CH2CH3, (CO)CH2CH3, (C═O)CH(CH3)2, and (C═O)cyclopropyl.
  • A further embodiment of the current invention is a compound as shown below in Table 1.
  • Ex # Compound Name
    1 1-[6-(3,5-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    2 3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-one;
    3 (RS)-3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-ol;
    4 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-one;
    5 (RS)-1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-ol;
    6 (E/Z)-3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-oneoxime;
    7 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-
    butan-2-one;
    8 (RS)-1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-
    methyl-butan-2-ol;
    9 1-Cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    10 (RS)-1-Cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-
    yl]ethanol;
    11 (RS)-1-(2-Cyclopropyl-2-methoxy-ethyl)-6-(3,4,5-
    trifluorophenyl)pyrazolol[4,3-b]pyridine;
    12 (RS)-6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-
    (ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine;
    13 6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-
    (ethylsulfonylmethyl)pyrazolo[4,3-b]pyridine;
    14 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-
    (2-pyridyl)ethanone;
    15 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-
    1-(5-fluoropyridin-2-yl)ethan-1-one;
    16 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-
    1-(pyridin-3-yl)ethan-1-one;
    17 (RS)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-
    b]pyridine;
    18 (RS)-6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-(tetrahydrofuran-2-
    ylmethyl)pyrazolo[4,3-b]pyridine;
    19 (RS)-4-[[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-
    1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    20 (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]oxazolidin-2-one;
    21 (S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]oxazolidin-2-one;
    22 (R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]oxazolidin-2-one;
    23 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]propan-2-one;
    24 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
    25 1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]propan-2-one;
    26 1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]propan-2-one;
    27 1-[6-(5-Chloro-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    28 1-[6-(4-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    29 1-[6-(3-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    30 1-[6-[3-(Difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    31 1-[6-[3-(1,1-Difluoroethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-
    one;
    32 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    33 1-[6-(2,3-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    34 1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    35 1-[6-(3,4-Difluorophenyl)-3-fluoro-pyrazolo[4,3-b]pyridin-1-yl]butan-2-
    one;
    36 1-(6-(3-(Difluoromethyl)-4-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-
    b]pyridin-1-yl)butan-2-one;
    37 1-[6-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-one;
    38 1-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-one;
    39 1-[6-[4-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-one;
    40 1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-one;
    41 1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-one;
    42 1-[6-(3,4,5-Trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    43 1-[6-(2,3,4-Trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    44 3-Methyl-1-(6-phenylpyrazolo[4,3-b]pyridin-1-yl)butan-2-one;
    45 1-[6-(4-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
    46 1-[6-(3-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
    47 1-[6-[3-(Difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-
    butan-2-one;
    48 1-[6-(2,3-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-
    one;
    49 1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-
    one;
    50 1-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-
    methyl-butan-2-one;
    51 1-[6-[4-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-
    methyl-butan-2-one;
    52 1-[6-(4-Fluoro-2-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-
    butan-2-one;
    53 3-Methyl-1-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-
    one;
    54 3-Methyl-1-[6-(2,3,4-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-
    one;
    55 2-[6-(5-Chloro-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-
    ethanone;
    56 1-Cyclopropyl-2-[6-(5-methyl-2-thienyl)pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    57 1-Cyclopropyl-2-[6-(3-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    58 1-Cyclopropyl-2-[6-(2-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    59 1-Cyclopropyl-2-[6-(4-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    60 1-Cyclopropyl-2-[6-(m-tolyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    61 1-Cyclopropyl-2-[6-[3-(difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    62 1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    63 1-Cyclopropyl-2-[6-[3-(trifluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    64 1-Cyclopropyl-2-[6-(2,3-difluorophenyl)pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    65 1-Cyclopropyl-2-[6-(3,4-difluorophenyl)pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    66 1-Cyclopropyl-2-[6-(3,5-difluorophenyl)pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    67 2-[6-(3-Chloro-2-fluoro-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-1-
    cyclopropyl-ethanone;
    68 2-[6-(3-Chloro-4-fluoro-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-1-
    cyclopropyl-ethanone;
    69 1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    70 1-Cyclobutyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    71 1-Cyclopropyl-2-[6-(2-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    72 1-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    73 1-Cyclopropyl-2-[6-[2-fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-
    b]pyridin-1-yl]ethanone;
    74 1-Cyclopropyl-2-[6-[4-fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-
    b]pyridin-1-yl]ethanone;
    75 2-[6-[4-Chloro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-
    cyclopropyl-ethanone;
    76 1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-
    b]pyridin-1-yl]ethanone;
    77 1-Cyclopropyl-2-[6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-
    b]pyridin-1-yl]ethanone;
    78 1-Cyclopropyl-2-[6-(4-fluoro-2,3-dimethyl-phenyl)pyrazolo[4,3-b]pyridin-
    1-yl]ethanone;
    79 1-Cyclopropyl-2-[6-(2,3,4-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    80 (RS)-1-(Ethylsulfinylmethyl)-6-(3-fluorophenyl)pyrazolo[4,3-b]pyridine;
    81 (RS)-1-(Ethylsulfinylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-
    b]pyridine;
    82 (RS)6-(3,4-Difluorophenyl)-1-(ethylsulfinylmethyl)pyrazolo[4,3-
    b]pyridine;
    83 (RS)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-
    pyrazolo[4,3-b]pyridine;
    84 (S*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-
    pyrazolo[4,3-b]pyridine;
    85 (R*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-
    pyrazolo[4,3-b]pyridine;
    86 (RS)-1-(Ethylsulfinylmethyl)-6-[2-fluoro-3-
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
    87 (RS)-6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-
    (ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine;
    88 (RS)-1-(Ethylsulfinylmethyl)-6-(3,4,5-trifluorophenyl)pyrazolo[4,3-
    b]pyridine;
    89 6-(4-Fluoro-3-methyl-phenyl)-1-(2-methoxyethyl)pyrazolo[4,3-b]pyridine;
    90 (RS)-4-Methoxy-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-ol;
    91 (RS)-1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    92 (RS)-1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-ol;
    93 (RS)-1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-ol;
    94 (RS)-1-[6-(3,4-Difluorophenyl)-3-fluoro-pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-ol;
    95 (RS)-1-[6-[3-(1,1-Difluoroethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-
    2-ol;
    96 (RS)-3-Methyl-1-(6-phenylpyrazolo[4,3-b]pyridin-1-yl)butan-2-ol;
    97 (RS)-3-Methyl-1-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-
    yl]butan-2-ol;
    98 1-(2,2-Difluorobutyl)-6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-
    b]pyridine;
    99 1-(2,2-Difluorobutyl)-6-[3-(difluoromethoxy)-4-fluoro-
    phenyl]pyrazolo[4,3-b]pyridine;
    100 (RS)-1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-
    b]pyridin-1-yl]ethanol;
    101 (RS)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-
    b]pyridin-1-yl]ethanol;
    102 (R)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-
    1-yl]ethanol;
    103 (S)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-
    1-yl]ethanol;
    104 (RS)-1-Cyclopropyl-2-(6-(3-(difluoromethyl)-4-fluorophenyl)-1H-
    pyrazolo[4,3-b]pyridin-1-yl)ethan-1-ol;
    105 (E/Z)-N-Methoxy-3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-
    b]pyridin-1-yl]butan-2-imine;
    106 (E/Z)-1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-
    b]pyridin-1-yl]ethanone oxime;
    107 (E/Z)-1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-
    phenyl[pyrazolo[4,3-b]pyridin-1-yl]ethanone oxime;
    108 1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3-(difluoromethyl)-4-fluoro-
    phenyl]pyrazolo[4,3-b]pyridine;
    109 1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3-(difluoromethoxy)-4-fluoro-
    phenyl]pyrazolo[4,3-b]pyridine;
    110 6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[(3-methyloxetan-3-
    yl)methyl]pyrazolo[4,3-b]pyridine;
    111 (RS)-1-(Tetrahydrofuran-2-ylmethyl)-6-[3-
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
    112 (RS)-6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(tetrahydrofuran-2-
    ylmethyl)pyrazolo[4,3-b]pyridine;
    113 (RS)-6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-(tetrahydrofuran-3-
    ylmethyl)pyrazolo[4,3-b]pyridine;
    114 (RS)-5-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-
    b]pyridin-1-yl)methyl)-1-methylpyrrolidin-2-one;
    115 (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-1-methyl-pyrrolidin-2-one;
    116 (RS)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-1-methyl-pyrrolidin-2-one;
    117 (S)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-1-methyl-pyrrolidin-2-one;
    118 (R)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-1-methyl-pyrrolidin-2-one;
    119 (RS)-3-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-
    b]pyridin-1-yl)methyl)-1-methylpyrrolidin-2-one;
    120 (RS)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-1-methyl-pyrrolidin-2-one;
    121 (S)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-1-methyl-pyrrolidin-2-one;
    122 (R)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-1-methyl-pyrrolidin-2-one;
    123 (RS)-4-((6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-
    b]pyridin-1-yl)methyl)-3-methyloxazolidin-2-one;
    124 (RS)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-3-methyl-oxazolidin-2-one;
    125 (RS)-5-[[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-
    1-yl]methyl]oxazolidin-2-one;
    126 (RS)-5-[[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-
    1-yl]methyl]oxazolidin-2-one;
    127 (RS)-5-[[6-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-
    1-yl]methyl]oxazolidin-2-one;
    128 (RS)-5-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-
    b]pyridin-1-yl)methyl)-3-methyloxazolidin-2-one;
    129 (5R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-3-methyl-oxazolidin-2-one;
    130 (5S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-3-methyl-oxazolidin-2-one;
    131 (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-3-ethyl-oxazolidin-2-one;
    132 (S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-3-ethyl-oxazolidin-2-one;
    133 (R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]-3-ethyl-oxazolidin-2-one;
    134 (RS)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
    135 (S)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-
    b]pyridin-1-yl]methyl]oxazolidin-2-one;
    136 (R)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
    137 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-
    (2-thienyl)ethanone;
    138 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-
    (3-thienyl)ethanone;
    139 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-
    (4-pyridyl)ethanone;
    140 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-
    1-(3-fluoropyridin-2-yl)ethan-1-one;
    141 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-
    1-(3,5-difluoropyridin-2-yl)ethan-1-one; and
    142 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-
    1-(pyrazin-2-yl)ethan-1-one;

    and pharmaceutically acceptable salts, N-oxides, or solvates thereof.
  • A further embodiment of the current invention is a compound selected from the group consisting of:
    • 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
    • 1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1H-yl]butan-2-one;
    • 1-(6-(3-(Difluoromethyl)-4-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one;
    • 1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-Cyclopropyl-2-[6-(4-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • (RS)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
    • (S*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine; and
    • (5R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one;
    • and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides thereof.
  • An additional embodiment of the invention is a pharmaceutical composition comprising:
      • (A) an effective amount of at least one compound selected from compounds of Formula (I):
  • Figure US20220324860A1-20221013-C00021
      • wherein
      • R1 is H, halo, or CH3;
      • Ar1 is selected from the group consisting of:
        • (a) phenyl;
        • (b) phenyl substituted with one member selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl;
        • (c) phenyl substituted with two or three members each independently selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl; and
        • (d) thienyl substituted with one member selected from the group consisting of: halo, and C1-6alkyl;
      • R2 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00022
      •  wherein Ra is selected from the group consisting of: C1-6alkyl; C3-6cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
  • Figure US20220324860A1-20221013-C00023
      •  wherein Rb is C1-6alkyl;
        • (f) C1-6alkyl substituted with one, two, or three members each independently selected from the group consisting of: OH, halo, OC1-6alkyl, (═N—OH), (═N—OCH3), and cyclopropyl; and
        • (g) oxetanyl; oxetanyl substituted with C1-6alkyl; tetrahydrofuranyl; oxazolidinone; oxazolidinone substituted with C1-4alkyl, or cyclopropyl; and pyrrolidinone substituted with C1-4alkyl;
          and pharmaceutically acceptable salts, stereoisomers, isotopic variants, N-oxides or solvates of compounds of Formula (I);
  • and (B) at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound of Formula (IA), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IA), pharmaceutically acceptable prodrugs of compounds of Formula (IA), and pharmaceutically active metabolites of Formula (IA); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound of Formula (IB), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IB), pharmaceutically acceptable prodrugs of compounds of Formula (IB), and pharmaceutically active metabolites of Formula (IB); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition comprising and effective amount of at least one compound in Table 1, as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Table 1, pharmaceutically acceptable prodrugs of compounds of Table 1, and pharmaceutically active metabolites of Table 1; and at least one pharmaceutically acceptable excipient.
  • Also within the scope of the invention are enantiomers and diastereomers of the compounds of Formula (I) (as well as Formulas (IA), and (IB)). Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the compounds of Formula (I) (as well as Formulas (IA), and (IB)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of compounds of Formula (I) (as well as Formulas (IA), and (IB)), and pharmaceutically active metabolites of the compounds of Formula (I) (as well as Formulas (IA), and (IB)).
  • Also within the scope of the invention are isotopic variations of compounds of Formula (I) (as well as Formulas (IA), and (IB)), such as, e.g., deuterated compounds of Formula (I). Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), and (IB)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), and (IB)), and pharmaceutically active metabolites of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), and (IB)).
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I):
  • Figure US20220324860A1-20221013-C00024
      • wherein
      • R1 is H, halo, or CH3;
      • Ar1 is selected from the group consisting of:
        • (a) phenyl;
        • (b) phenyl substituted with one member selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl;
        • (c) phenyl substituted with two or three members each independently selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl; and
        • (d) thienyl substituted with one member selected from the group consisting of: halo, and C1-6alkyl;
      • R2 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00025
      •  wherein Ra is selected from the group consisting of: C1-6alkyl; C3-6cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
  • Figure US20220324860A1-20221013-C00026
      •  wherein Rb is C1-6alkyl;
        • (f) C1-6alkyl substituted with one, two, or three members each independently selected from the group consisting of: OH, halo, OC1-6alkyl, (═N—OH), (═N—OCH3), and cyclopropyl; and
        • (g) oxetanyl; oxetanyl substituted with C1-6alkyl; tetrahydrofuranyl; oxazolidinone; oxazolidinone substituted with C1-4alkyl, or cyclopropyl; and pyrrolidinone substituted with C1-4alkyl;
          and pharmaceutically acceptable salts, stereoisomers, isotopic variants, N-oxides, or solvates thereof, to a subject in need thereof.
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I) (as well as Formulas (IA), and (IB)), enantiomers and diastereomers of the compounds of Formula (I), isotopic variations of the compounds of Formula (I), and pharmaceutically acceptable salts of all of the foregoing.
  • In preferred embodiments of the inventive method, the disease, disorder, or medical condition is selected from: neurologic and psychiatric disorders including, but not limited to: (1) mood disorders and mood affective disorders; (2) neurotic, stress-related and somatoform disorders including anxiety disorders; (3) disorders of psychological development; (4) behavioral syndromes associated with physiological disturbances and physical factors; (5) extrapyramidal and movement disorders; (6) episodic and paroxysmal disorders, epilepsy; (7) pain; (8) forms of neurodegeneration; (9) cerebrovascular diseases, acute and chronic; and any sequelae of cerebrovascular diseases.
  • Examples of mood disorders and mood affective disorders that can be treated according to the present invention include, but are not limited to, bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, depressive disorder with postpartum onset, depressive disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder.
  • Examples of disorders belonging to the neurotic, stress-related and somatoform disorders that can be treated according to the present invention include, but are not limited to, anxiety disorders, general anxiety disorder, panic disorder with or without agoraphobia, specific phobia, social anxiety disorder, chronic anxiety disorders; obsessive compulsive disorder; reaction to sever stress and adjustment disorders, such as post-traumatic stress disorder (PTSD); other neurotic disorders such as depersonalisation-derealisation syndrome.
  • Examples of disorders of psychological development that can be treated according to the present invention include, but are not limited to pervasive developmental disorders, including but not limited to Asperger's syndrome and Rett's syndrome, autistic disorders, childhood autism and overactive disorder associated with mental retardation and stereotyped movements, specific developmental disorder of motor function, specific developmental disorders of scholastic skills.
  • Examples of behavioral syndromes associated with physiological disturbances and physical factors according to the present invention include but are not limited to mental and behavioral disorders associated with childbirth, including but not limited to postnatal (postpartum) and prenatal depression; eating disorders, including but not limited to anorexia nervosa, bulimia nervosa, pica and binge eating disorder.
  • Examples of extrapyramidal and movement disorders that can be treated according to the present invention include, but are not limited to Parkinson's disease; second Parkinsonism, such as post encephalitic Parkinsonism; Parkinsonism comprised in other disorders; Lewis body disease; degenerative diseases of the basal ganglia; other extrapyramidal and movement disorders including but not limited to tremor, essential tremor and drug-induced tremor, myoclonus, chorea and drug-induced chorea, drug-induced tics and tics of organic origin, drug-induced acute dystonia, drug-induced tardive dyskinesia, L-dopa-induced dyskinesia; neuroleptic-induced movement disorders including but not limited to neuroleptic malignant syndrome (NMS), neuroleptic induced parkinsonism, neuroleptic-induced early onset or acute dyskinesia, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia, neuroleptic-induced tremor; restless leg syndrome, Stiff-man syndrome.
  • Further examples of movement disorders with malfunction and/or degeneration of basal ganglia that can be treated according to the present invention include but are not limited to dystonia including but not limited to focal dystonia, multiple-focal or segmental dystonia, torsion dystonia, hemispheric, generalised and tardive dystonia (induced by psychopharmacological drugs). Focal dystonia includes cervical dystonia (torticolli), blepharospasm (cramp of the eyelid), appendicular dystonia (cramp in the extremities, like the writer's cramp), oromandibular dystonia and spasmodic dysphonia (cramp of the vocal cord);
  • Examples for episodic and paroxysmal disorders that can be treated according to the present invention include, but are not limited to epilepsy, including localization-related (focal)(partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, generalized idiopathic epilepsy and epileptic syndromes including but not limited to myoclonic epilepsy in infancy, neonatal convulsions (familial), childhood absence epilepsy (pyknolepsy), epilepsy with grand mal seizures on awakening, absence epilepsy, myoclonic epilepsy (impulsive petit mal) and nonspecific atonic, clonic, myoclonic, tonic, tonic-clonic epileptic seizures.
  • Further examples of epilepsy that can be treated according to the present invention include, but are not limited to epilepsy with myoclonic absences, myoclonic-astatic seizures, infantile spasms, Lennox-Gastaut syndrome, Salaam attacks, symptomatic early myoclonic encephalopathy, West's syndrome, petit and grand mal seizures; status epilepticus.
  • Examples of pain include, but are not limited to pain disorders related to psychological factors, such as persistent somatoform disorders; acute, chronic and chronic intractable pain, headache; acute and chronic pain related to physiological processes and physical disorders including but not limited to back pain, tooth pain, abdominal pain, low back pain, pain in joints; acute and chronic pain that is related to diseases of the musculoskeletal system and connective tissue including, but not limited to rheumatism, myalgia, neuralgia and fibromyalgia; acute and chronic pain that is related to nerve, nerve root and plexus disorders, such as trigeminal pain, postzoster neuralgia, phantom limb syndrome with pain, carpal tunnel syndrome, lesion of sciatic nerve, diabetic mononeuropathy; acute and chronic pain that is related to polyneuropathies and other disorders of the peripheral nervous system, such as hereditary and idiopathic neuropathy, inflammatory polyneuropathy, polyneuropathy induced by drugs, alcohol or toxic agents, polyneuropathy in neoplastic disease, diabetic polyneuropathy.
  • Examples of diseases that include forms of neurodegeneration include, but are not limited to, acute neurodegeneration, such as intracranial brain injuries, such as stroke, diffuse and local brain injuries, epidural, subdural and subarachnoid haemorrhage, and chronic neurodegeneration, such as Alzheimer's disease, Huntington's disease, multiple sclerosis and ALS.
  • Examples of cerebrovascular diseases include, but are not limited to, subarachnoid haemorrhage, intracerebral haemorrhage and other nontraumatic intracranial haemorrhage, cerebral infarction, stroke, occlusion and stenosis or precerebral and cerebral arteries, not resulting in cerebral infarction, dissection of cerebral arteries, cerebral aneurysm, cerebral atherosclerosis, progressive vascular leukoencephalopathy, hypertensive encephalopathy, nonpyogenic thrombosis of intracranial venous system, cerebral arteritis, cerebral amyloid angiopathy and sequelae of cerebrovascular diseases.
  • In some embodiments, administration of a compound of the invention, or pharmaceutically acceptable salt thereof, is effective in preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.
  • Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.
  • The invention may be more fully appreciated by reference to the following description, including the following glossary of terms and the concluding examples. For the sake of brevity, the disclosures of the publications, including patents, cited in this specification are herein incorporated by reference.
  • As used herein, the terms “including”, “containing” and “comprising” are used herein in their open, non-limiting sense.
  • The term “alkyl” refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain. Examples of alkyl groups include methyl (Me, which also may be structurally depicted by the symbol, “/”), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples. The term C1-4alkyl as used here refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain. The term C1-6alkyl as used here refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain.
  • The term “aryl” refers to a monocyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having 6 atoms per ring. (Carbon atoms in the aryl groups are sp2 hybridized.)
  • The term “phenyl” represents the following moiety:
  • Figure US20220324860A1-20221013-C00027
  • The term “thienyl” represents the following moiety:
  • Figure US20220324860A1-20221013-C00028
  • The term “heteroaryl” refers to a monocyclic or fused bicyclic heterocycle (ring structure having ring atoms selected from carbon atoms and up to four heteroatoms selected from nitrogen, oxygen, and sulfur) having from 3 to 9 ring atoms per heterocycle. Illustrative examples of heteroaryl groups include the following entities, in the form of properly bonded moieties:
  • Figure US20220324860A1-20221013-C00029
  • Those skilled in the art will recognize that the species of heteroaryl, cycloalkyl, aryl and heterocycloalkyl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected.
  • A “heterocycloalkyl” refers to a monocyclic ring structure that is saturated or partially saturated and has from 4 to 7 ring atoms per ring structure selected from carbon atoms and up to two heteroatoms selected from nitrogen, oxygen, and sulfur. The ring structure may optionally contain up to two oxo groups on sulfur ring members. Illustrative entities, in the form of properly bonded moieties, include:
  • Figure US20220324860A1-20221013-C00030
  • The term “cycloalkyl” refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle. Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:
  • Figure US20220324860A1-20221013-C00031
  • The term “halo” represents chloro, fluoro, bromo or iodo.
  • The term “perhaloalkyl” or “haloalkyl” refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain optionally substituting hydrogens with halogens. The term “C1-4haloalkyl” as used here refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain, optionally substituting hydrogens with halogens. The term “C1-6haloalkyl” as used here refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain, optionally substituting hydrogens with halogens. Examples of “perhaloalkyl”, “haloalkyl” groups include trifluoromethyl (CF3), difluoromethyl (CF2H), monofluoromethyl (CH2F), pentafluoroethyl (CF2CF3), tetrafluoroethyl (CHFCF3), monofluoroethyl (CH2CH2F), trifluoroethyl (CH2CF3), tetrafluorotrifluoromethylethyl (—CF(CF3)2), and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.
  • The term “substituted” means that the specified group or moiety bears one or more substituents. The term “unsubstituted” means that the specified group bears no substituents. The term “optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system. In cases where a specified moiety or group is not expressly noted as being optionally substituted or substituted with any specified substituent, it is understood that such a moiety or group is intended to be unsubstituted.
  • The terms “para”, “meta”, and “ortho” have the meanings as understood in the art. Thus, for example, a fully substituted phenyl group has substituents at both “ortho” (o) positions adjacent to the point of attachment of the phenyl ring, both “meta” (m) positions, and the one “para” (p) position across from the point of attachment. To further clarify the position of substituents on the phenyl ring, the 2 different ortho positions will be designated as ortho and ortho′ and the 2 different meta positions as meta and meta′ as illustrated below.
  • Figure US20220324860A1-20221013-C00032
  • When referring to substituents on a pyridyl group, the terms “para”, “meta”, and “ortho” refer to the placement of a substituent relative to the point of attachment of the pyridyl ring. For example the structure below is described as 3-pyridyl with the X1 substituent in the ortho position, the X2 substituent in the meta position, and X3 substituent in the para position:
  • Figure US20220324860A1-20221013-C00033
  • To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term “about”. It is understood that, whether the term “about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and/or measurement conditions for such given value. Whenever a yield is given as a percentage, such yield refers to a mass of the entity for which the yield is given with respect to the maximum amount of the same entity that could be obtained under the particular stoichiometric conditions. Concentrations that are given as percentages refer to mass ratios, unless indicated differently.
  • The terms “buffered” solution or “buffer” solution are used herein interchangeably according to their standard meaning. Buffered solutions are used to control the pH of a medium, and their choice, use, and function is known to those of ordinary skill in the art. See, for example, G. D. Considine, ed., Van Nostrand's Encyclopedia of Chemistry, p. 261, 5th ed. (2005), describing, inter alia, buffer solutions and how the concentrations of the buffer constituents relate to the pH of the buffer. For example, a buffered solution is obtained by adding MgSO4 and NaHCO3 to a solution in a 10:1 w/w ratio to maintain the pH of the solution at about 7.5.
  • Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula. Thus, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof. Furthermore, certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers.
  • It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “.”
  • Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers.” When a compound has an asymmetric center, for example, it is bonded to four different groups, and a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+)- or (−)-isomers respectively). A chiral compound can exist as either an individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture.”
  • “Tautomers” refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of π electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro-forms of phenyl nitromethane, that are likewise formed by treatment with acid or base.
  • Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
  • The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof.
  • Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.
  • Certain examples contain chemical structures that are depicted as an absolute enantiomer but are intended to indicate enantiopure material that is of unknown configuration. In these cases (R*) or (S*) is used in the name to indicate that the absolute stereochemistry of the corresponding stereocenter is unknown. Thus, a compound designated as (R*) refers to an enantiopure compound with an absolute configuration of either (R) or (S). In cases where the absolute stereochemistry has been confirmed, the structures are named using (R) and (S).
  • The symbols
    Figure US20220324860A1-20221013-P00001
    and
    Figure US20220324860A1-20221013-P00002
    are used as meaning the same spatial arrangement in chemical structures shown herein. Analogously, the symbols
    Figure US20220324860A1-20221013-P00003
    and
    Figure US20220324860A1-20221013-P00004
    are used as meaning the same spatial arrangement in chemical structures shown herein.
  • Additionally, any formula given herein is intended to refer also to hydrates, solvates, and polymorphs of such compounds, and mixtures thereof, even if such forms are not listed explicitly. Certain compounds of Formula (I) (as well as Formulas (IA), and (IB)), or pharmaceutically acceptable salts of compounds of Formula (I) (as well as Formulas (IA), and (IB)) may be obtained as solvates. Solvates include those formed from the interaction or complexation of compounds of the invention with one or more solvents, either in solution or as a solid or crystalline form. In some embodiments, the solvent is water and the solvates are hydrates. In addition, certain crystalline forms of compounds of Formula (I) (as well as Formulas (IA), and (IB)) or pharmaceutically acceptable salts of compounds of Formula (I) (as well as Formulas (IA), and (IB)) may be obtained as co-crystals. In certain embodiments of the invention, compounds of Formula (I) were obtained in a crystalline form. In other embodiments, crystalline forms of compounds of Formula (I) were cubic in nature. In other embodiments, pharmaceutically acceptable salts of compounds of Formula (I) were obtained in a crystalline form. In still other embodiments, compounds of Formula (I) were obtained in one of several polymorphic forms, as a mixture of crystalline forms, as a polymorphic form, or as an amorphous form. In other embodiments, compounds of Formula (I) convert in solution between one or more crystalline forms and/or polymorphic forms.
  • Reference to a compound herein stands for a reference to any one of: (a) the actually recited form of such compound, and (b) any of the forms of such compound in the medium in which the compound is being considered when named. For example, reference herein to a compound such as R—COOH, encompasses reference to any one of, for example, R—COOH(s), R—COOH(sol), and R—COO− (sol). In this example, R—COOH(s) refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation; R—COOH(sol) refers to the undissociated form of the compound in a solvent; and R—COO− (sol) refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R—COOH, from a salt thereof, or from any other entity that yields R—COO− upon dissociation in the medium being considered. In another example, an expression such as “exposing an entity to compound of formula R—COOH” refers to the exposure of such entity to the form, or forms, of the compound R—COOH that exists, or exist, in the medium in which such exposure takes place. In still another example, an expression such as “reacting an entity with a compound of formula R—COOH” refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that exists, or exist, in the medium in which such reacting takes place, with (b) the chemically relevant form, or forms, of the compound R—COOH that exists, or exist, in the medium in which such reacting takes place. In this regard, if such entity is for example in an aqueous environment, it is understood that the compound R—COOH is in such same medium, and therefore the entity is being exposed to species such as R—COOH(aq) and/or R—COO− (aq), where the subscript “(aq)” stands for “aqueous” according to its conventional meaning in chemistry and biochemistry. A carboxylic acid functional group has been chosen in these nomenclature examples; this choice is not intended, however, as a limitation but it is merely an illustration. It is understood that analogous examples can be provided in terms of other functional groups, including but not limited to hydroxyl, basic nitrogen members, such as those in amines, and any other group that interacts or transforms according to known manners in the medium that contains the compound. Such interactions and transformations include, but are not limited to, dissociation, association, tautomerism, solvolysis, including hydrolysis, solvation, including hydration, protonation, and deprotonation. No further examples in this regard are provided herein because these interactions and transformations in a given medium are known by any one of ordinary skill in the art.
  • In another example, a zwitterionic compound is encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form. Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUPAC-endorsed names that are well known and part of standard sets of defined scientific names. In this regard, the name zwitterion is assigned the name identification CHEBI.27369 by the Chemical Entities of Biological Interest (ChEBI) dictionary of molecular entities. As generally well known, a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign. Sometimes these compounds are referred to by the term “inner salts”. Other sources refer to these compounds as “dipolar ions”, although the latter term is regarded by still other sources as a misnomer. As a specific example, aminoethanoic acid (the amino acid glycine) has the formula H2NCH2COOH, and it exists in some media (in this case in neutral media) in the form of the zwitterion +H3NCH2COO−. Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well established meanings of these terms are within the scope of this invention, as would in any case be so appreciated by those of ordinary skill in the art. Because there is no need to name each and every embodiment that would be recognized by those of ordinary skill in the art, no structures of the zwitterionic compounds that are associated with the compounds of this invention are given explicitly herein. They are, however, part of the embodiments of this invention. No further examples in this regard are provided herein because the interactions and transformations in a given medium that lead to the various forms of a given compound are known by any one of ordinary skill in the art.
  • Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine such as 2H, 3H, 11C, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, 36Cl, 125I, respectively. Such isotopically labeled compounds are useful in metabolic studies (preferably with 14C), reaction kinetic studies (with, for example deuterium (i.e., D or 2H); or tritium (i.e., T or 3H)), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or 11C labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the same choice of the species for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula, unless stated otherwise.
  • According to the foregoing interpretive considerations on assignments and nomenclature, it is understood that explicit reference herein to a set implies, where chemically meaningful and unless indicated otherwise, independent reference to embodiments of such set, and reference to each and every one of the possible embodiments of subsets of the set referred to explicitly.
  • By way of a first example on substituent terminology, if substituent S1 example is one of Si and S2, and substituent S2 example is one of S3 and S4, then these assignments refer to embodiments of this invention given according to the choices S1 example is S1 and S2 example is S3; S1 example is S1 and S2 example is S4; S1 example is S2 and S2 example is S3; S1 example is S2 and S2 example is S4; and equivalents of each one of such choices. The shorter terminology “S1 example is one of S1 and S2, and S2 example is one of S3 and S4” is accordingly used herein for the sake of brevity, but not by way of limitation.
  • The foregoing first example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein. The foregoing convention given herein for substituents extends, when applicable, to members such as R1, Ar1, R2, Ra, Rb, Rc, Rd, Re, HAL, and X, and any other generic substituent symbol used herein.
  • Furthermore, when more than one assignment is given for any member or substituent, embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof. By way of a second example on substituent terminology, if it is herein described that substituent Sexample is one of S1, S2, and S3, this listing refers to embodiments of this invention for which Sexample is S1; Sexample is S2; Sexample is S3; Sexample is one of S1 and S2; Sexample is one of S1 and S3; Sexample is one of S2 and S3; Sexample is one of S1, S2 and S3; and Sexample is any equivalent of each one of these choices. The shorter terminology “Sexample is one of S1, S2, and S3” is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing second example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein. The foregoing convention given herein for substituents extends, when applicable, to members such as R1, Ar1, R2, Ra, Rb, Rc, Rd, Re, HAL, and X, and any other generic substituent symbol used herein.
  • The nomenclature “Ci-j” with j>i, when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to j including i and j, is independently realized. By way of example, the term C1-4 refers independently to embodiments that have one carbon member (C1), embodiments that have two carbon members (C2), embodiments that have three carbon members (C3), and embodiments that have four carbon members (C4).
  • The term Cn-malkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies n≤N≤m, with m>n. Any disubstituent referred to herein is meant to encompass the various attachment possibilities when more than one of such possibilities are allowed. For example, reference to disubstituent-A-B—, where A≠B, refers herein to such disubstituent with A attached to a first substituted member and B attached to a second substituted member, and it also refers to such disubstituent with A attached to the second substituted member and B attached to the first substituted member.
  • The invention includes also pharmaceutically acceptable salts of the compounds of Formula (I) (as well as Formulas (IA), and (IB)), preferably of those described above and of the specific compounds exemplified herein, and methods of treatment using such salts.
  • The term “pharmaceutically acceptable” means approved or approvable by a regulatory agency of Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U. S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.
  • A “pharmaceutically acceptable salt” is intended to mean a salt of a free acid or base of compounds represented by Formula (I) (as well as Formulas (IA), and (IB)) that are non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. It should possess the desired pharmacological activity of the parent compound. See, generally, G. S. Paulekuhn, et al., “Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database”, J. Med. Chem., 2007, 50:6665-72, S. M. Berge, et al., “Pharmaceutical Salts”, J Pharm Sci., 1977, 66:1-19, and Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002. Examples of pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. A compound of Formula (I) (as well as Formulas (IA), and (IB)) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
  • Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.
  • When the compounds of Formula (I) (as well as Formulas (IA), and (IB)) contain a basic nitrogen, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art. For example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid, glutaric acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a sulfonic acid, such as laurylsulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, any compatible mixture of acids such as those given as examples herein, and any other acid and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
  • When the compound of Formula (I) (as well as Formulas (IA), and (IB)) is an acid, such as a carboxylic acid or sulfonic acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology. Illustrative examples of suitable salts include organic salts derived from amino acids, such as N-methyl-D-glucamine, lysine, choline, glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • The invention also relates to pharmaceutically acceptable prodrugs of the compounds of Formula (I) (as well as Formulas (IA), and (IB)), and treatment methods employing such pharmaceutically acceptable prodrugs. The term “prodrug” means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula (I). A “pharmaceutically acceptable prodrug” is a prodrug that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
  • Exemplary prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxyl, or carboxylic acid group of a compound of Formula (I) (as well as Formulas (IA), and (IB)). Examples of amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.
  • Additional types of prodrugs may be produced, for instance, by derivatizing free carboxyl groups of structures of Formula (I) (as well as Formulas (IA), and (IB)) as amides or alkyl esters. Examples of amides include those derived from ammonia, primary C1-6alkyl amines and secondary di(C1-6alkyl) amines. Secondary amines include 5- or 6-membered heterocycloalkyl or heteroaryl ring moieties. Examples of amides include those that are derived from ammonia, C1-3alkyl primary amines, and di(C1-2alkyl)amines. Examples of esters of the invention include C1-7alkyl, C5-7cycloalkyl, phenyl, and phenyl(C1-6alkyl) esters. Preferred esters include methyl esters. Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, following procedures such as those outlined in Fleisher et al., Adv. Drug Delivery Rev. 1996, 19, 115-130. Carbamate derivatives of hydroxy and amino groups may also yield prodrugs. Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs. Prodrugs of this type may be prepared as described in Robinson et al., J Med Chem. 1996, 39 (1), 10-18. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including ether, amine, and carboxylic acid functionalities.
  • The present invention also relates to pharmaceutically active metabolites of the compounds of Formula (I) (as well as Formulas (IA), and (IB)), which may also be used in the methods of the invention. A “pharmaceutically active metabolite” means a pharmacologically active product of metabolism in the body of a compound of Formula (I) (as well as Formulas (IA), and (IB)) as applicable, or salt thereof. Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini, et al., J Med Chem. 1997, 40, 2011-2016; Shan, et al., J Pharm Sci. 1997, 86 (7), 765-767; Bagshawe, Drug Dev Res. 1995, 34, 220-230; Bodor, Adv Drug Res. 1984, 13, 224-331; Bundgaard, Design of Prodrugs (Elsevier Press, 1985); and Larsen, Design and Application of Prodrugs, Drug Design and Development (Krogsgaard-Larsen, et al., eds., Harwood Academic Publishers, 1991).
  • The compounds of Formula (I) (as well as Formulas (IA), and (IB)) and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of the present invention are useful as modulators of the GluN2B receptor in the methods of the invention. As such modulators, the compounds may act as antagonists, agonists, or inverse agonists. The term “modulators” include both inhibitors and activators, where “inhibitors” refer to compounds that decrease, prevent, inactivate, desensitize, or down-regulate the GluN2B receptor expression or activity, and “activators” are compounds that increase, activate, facilitate, sensitize, or up-regulate GluN2B receptor expression or activity.
  • The term “treat”, “treatment” or “treating”, as used herein, is intended to refer to administration of an active agent or composition of the invention to a subject for the purpose of affecting a therapeutic or prophylactic benefit through modulation of GluN2B receptor activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition mediated through modulation of GluN2B receptor activity. The term “subject” refers to a mammalian patient in need of such treatment, such as a human.
  • Accordingly, the invention relates to methods of using the compounds described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated by GluN2B receptor activity, such as: bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, depressive disorder with postpartum onset, disruptive mood dysregulation disorder, depressive disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder; anxiety disorders, general anxiety disorder, panic disorder with or without agoraphobia, specific phobia, social anxiety disorder, chronic anxiety disorders; obsessive compulsive disorder; reaction to sever stress and adjustment disorders, such as post-traumatic stress disorder (PTSD); other neurotic disorders such as depersonalization-derealisation syndrome; pervasive developmental disorders, including but not limited to Asperger's syndrome and Rett's syndrome, autistic disorders, childhood autism and overactive disorder associated with mental retardation and stereotyped movements, specific developmental disorder of motor function, specific developmental disorders of scholastic skills; postnatal (postpartum) and prenatal depression; eating disorders, including but not limited to anorexia nervosa, bulimia nervosa, pica and binge eating disorder; Parkinson's disease; second Parkinsonism, such as post encephalitic Parkinsonism; Parkinsonism comprised in other disorders; Lewis body disease; degenerative diseases of the basal ganglia; other extrapyramidal and movement disorders including but not limited to tremor, essential tremor and drug-induced tremor, myoclonus, chorea and drug-induced chorea, drug-induced tics and tics of organic origin, drug-induced acute dystonia, drug-induced tardive dyskinesia, L-dopa-induced dyskinesia; neuroleptic-induced movement disorders including but not limited to neuroleptic malignant syndrome (NMS), neuroleptic induced parkinsonism, neuroleptic-induced early onset or acute dyskinesia, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia, neuroleptic-induced tremor; restless leg syndrome, Stiff-man syndrome; dystonia including but not limited to focal dystonia, multiple-focal or segmental dystonia, torsion dystonia, hemispheric, generalized and tardive dystonia (induced by psychopharmacological drugs). Focal dystonia include cervical dystonia (torticolli), blepharospasm (cramp of the eyelid), appendicular dystonia (cramp in the extremities, like the writer's cramp), oromandibular dystonia and spasmodic dysphonia (cramp of the vocal cord); epilepsy, including localization-related (focal)(partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, generalized idiopathic epilepsy and epileptic syndromes including but not limited to myoclonic epilepsy in infancy, neonatal convulsions (familial), childhood absence epilepsy (pyknolepsy), epilepsy with grand mal seizures on awakening, absence epilepsy, myoclonic epilepsy (impulsive petit mal) and nonspecific atonic, clonic, myoclonic, tonic, tonic-clonic epileptic seizures; epilepsy with myoclonic absences, myoclonic-astatic seizures, infantile spasms, Lennox-Gastaut syndrome, Salaam attacks, symptomatic early myoclonic encephalopathy, West's syndrome, petit and grand mal seizures; status epilepticus; persistent somatoform disorders; acute, chronic and chronic intractable pain, headache; acute and chronic pain related to physiological processes and physical disorders including but not limited to back pain, tooth pain, abdominal pain, low back pain, pain in joints; acute and chronic pain that is related to diseases of the musculoskeletal system and connective tissue including, but not limited to rheumatism, myalgia, neuralgia and fibromyalgia; acute and chronic pain that is related to nerve, nerve root and plexus disorders, such as trigeminal pain, postzoster neuralgia, phantom limb syndrome with pain, carpal tunnel syndrome, lesion of sciatic nerve, diabetic mononeuropathy; acute and chronic pain that is related to polyneuropathies and other disorders of the peripheral nervous system, such as hereditary and idiopathic neuropathy, inflammatory polyneuropathy, polyneuropathy induced by drugs, alcohol or toxic agents, polyneuropathy in neoplastic disease, diabetic polyneuropathy; and acute neurodegeneration, such as intracranial brain injuries, such as stroke, diffuse and local brain injuries, epidural, subdural and subarachnoid haemorrhage, and chronic neurodegeneration, such as Alzheimer's disease, Huntington's disease, multiple sclerosis, and ALS; subarachnoid haemorrhage, intracerebral haemorrhage and other nontraumatic intracranial haemorrhage, cerebral infarction, stroke, occlusion and stenosis or precerebral and cerebral arteries, not resulting in cerebral infarction, dissection of cerebral arteries, cerebral aneurysm, cerebral atherosclerosis, progressive vascular leukoencephalopathy, hypertensive encephalopathy, nonpyogenic thrombosis of intracranial venous system, cerebral arteritis, cerebral amyloid angiopathy and sequelae of cerebrovascular diseases; glaucoma and other neuropathies; dementias, vascular dementia, Lewy body dementia, frontotemporal dementia, and HIV-dementia; vertigo and nystagmus; tinnitus; neuropsychiatric systemic lupus erythematosus; disruptive mood dysregulation disorder; schizophrenia spectrum disorder; and sleep/wake disorders.
  • In treatment methods according to the invention, an effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition. An “effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the compounds of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.
  • Once improvement of the patient's disease, disorder, or condition has occurred, the dose may be adjusted for preventative or maintenance treatment. For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.
  • In addition, the active agents of the invention may be used in combination with additional active ingredients in the treatment of the above conditions. The additional active ingredients may be co-administered separately with an active agent of compounds of Table 1 or included with such an agent in a pharmaceutical composition according to the invention. In an exemplary embodiment, additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by GluN2B activity, such as another GluN2B modulator or a compound active against another target associated with the particular condition, disorder, or disease. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an active agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.
  • The active agents of the invention are used, alone or in combination with one or more additional active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises: (a) an effective amount of at least one active agent in accordance with the invention; and (b) a pharmaceutically acceptable excipient.
  • A “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
  • Delivery forms of the pharmaceutical compositions containing one or more dosage units of the active agents may be prepared using suitable pharmaceutical excipients and compounding techniques known or that become available to those skilled in the art. The compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
  • The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories. Preferably, the compositions are formulated for intravenous infusion, topical administration, or oral administration.
  • For oral administration, the compounds of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the compounds may be formulated to yield a dosage of, e.g., from about 0.05 to about 100 mg/kg daily, or from about 0.05 to about 35 mg/kg daily, or from about 0.1 to about 10 mg/kg daily. For example, a total daily dosage of about 5 mg to 5 g daily may be accomplished by dosing once, twice, three, or four times per day.
  • Oral tablets may include a compound according to the invention mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like. Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract or may be coated with an enteric coating.
  • Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, compounds of the invention may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the compound of the invention with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
  • Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
  • The active agents of this invention may also be administered by non-oral routes. For example, the compositions may be formulated for rectal administration as a suppository. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the compounds of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms will be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses may range from about 1 to 1000 μg/kg/minute of compound, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
  • For topical administration, the compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle. Another mode of administering the compounds of the invention may utilize a patch formulation to affect transdermal delivery. Compounds of the invention may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
  • Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Unless otherwise specified, the variables are as defined above in reference to Formula (I). Reactions may be performed between the melting point and the reflux temperature of the solvent, and preferably between 0° C. and the reflux temperature of the solvent. Reactions may be heated employing conventional heating or microwave heating. Reactions may also be conducted in sealed pressure vessels above the normal reflux temperature of the solvent.
  • Abbreviations and acronyms used herein include the following:
  • TABLE 2
    Term Acronym
    Aqueous aq
    Atmosphere atm
    tert-Butylcarbamoyl Boc
    Broad br
    Diatomaceous Earth Celite ®
    Electrospray ionization ESI
    Normal-phase silica gel chromatography FCC
    GluNR2B * GluN2B, NMDA-
    R2B, NR2B,
    hNR3
    Grams g
    Hours h
    High-pressure liquid chromatography HPLC
    Hertz Hz
    Isopropyl alcohol iPrOH, IPA
    Liquid chromatography and mass spectrometry LCMS
    Molar M
    Mass to charge ratio m/z
    Milligrams mg
    Minute min
    Milliliter mL
    Microliter μL
    Millimoles mmol
    Mass spectrometry MS
    Normal N
    Nuclear magnetic resonance NMR
    Parts per million ppm
    Precipitate ppt
    Polytetrafluoroethylene PTFE
    Retention time Rt
    Room temperature rt
    Saturated sat
    Supercritical Fluid Chromatography SFC
    Temperature T
    Thin layer chromatography TLC
    Volume in milliliters of solvent per gram of substrate V, or volumes
    * (Collingridge, G. L, et al, Neuropharmacology, 2009, 56, 2-5)
    • PREPARATIVE EXAMPLES
  • Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples to follow.
  • Figure US20220324860A1-20221013-C00034
  • According to SCHEME 1, commercially available or synthetically accessible 6-bromo-1H-pyrrolo[3,2-b]pyridine is fluorinated with an electrophilic halogen source under conditions known to one skilled in the art. For example, 6-bromo-1H-pyrrolo[3,2-b]pyridine is fluorinated using a reagent such as N-fluoro-N′-(chloromethyl)triethylenediamine bis(tetrafluoroborate) (Selectfluor®) and the like; in a suitable solvent such as acetonitrile (ACN), dichloromethane (DCM), and the like, at a temperature of 90° C., to provide 6-Bromo-3-fluoro-1H-pyrazolo[4,3-b]pyridine.
  • Figure US20220324860A1-20221013-C00035
  • According to SCHEME 2, a compound of formula (V), where R1 is cyclobutyl, pyrizinyl, pyridyl, pyridyl substituted with one or two F members is brominated using a reagent such as Br2, HBr, pyridinium tribromide, phenyltrimehtylammonium tribromide, and the like; in a suitable solvent such as methanol (MeOH), tetrahydrofuran (THF), acetic acid (AcOH), and the like; at temperatures ranging from 0° C. to 60° C.; to provide a compound of formula (VI).
  • Figure US20220324860A1-20221013-C00036
  • According to SCHEME 3, a compound of formula (VII) where the hydroxymethyl group is attached at either of the carbon atoms as indicated with (*), is chlorinated using a reagent such as SOCl2, and the like; an amine base such as pyridine; in a solvent such as DCM, and the like; at a temperature of 90° C.; to afford a compound of formula (VIII).
  • Figure US20220324860A1-20221013-C00037
  • According to SCHEME 4, a compound of formula (IX) where R1 is H, is alkylated with (chloromethyl)(ethyl)sulfane, a base such as Cs2CO3, and the like; in a solvent such as DMF, and the like, at room temperature, for a period of 20 hours, to provide 6-bromo-1-(ethylsulfanylmethyl)pyrazolo[4,3-b]pyridine and 6-bromo-2-(ethylsulfanylmethyl)pyrazolo[4,3-b]pyridine. 6-Bromo-1-(ethylsulfanylmethyl)pyrazolo[4,3-b]pyridine is oxidized using a reagent such as meta-chloroperoxybenzoic acid (m-CPBA), and the like, in a suitable solvent such as DCM, and the like; at a temperature of 0° C.; to provide a 6-bromo-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine.
  • Figure US20220324860A1-20221013-C00038
  • According to SCHEME 5, a compound of formula (XII) is alkylated employing conditions previously described to provide a compound of formula (XIII). A compound of formula (XIII), where Ar1 is 3-(difluoromethoxy)-4-fluorophenyl, is oxidized using a reagent such as m-CPBA, in a solvent such as DCM, at room temperature, to provide a compound of formula (XIV). A compound of formula (XIV), where Ar1 is 3-(difluoromethoxy)-4-fluorophenyl, is reduced using a reagent such as Pd/C (10%), in a solvent such as EtOH, EtOAc, or a mixture thereof, at room temperature, to provide a compound of Formula (I).
  • Figure US20220324860A1-20221013-C00039
  • According to SCHEME 6, a compound of formula (XVI), where Ar1 is 4-fluoro-3-methyl-phenyl and R3 is ethyl for example, is reacted with diethylaminosulfur trifluoride (DAST), in a suitable solvent such as DCM, and the like, at a temperature of about 0° C. to room temperature, to provide a compound of formula (XVII)
  • Figure US20220324860A1-20221013-C00040
  • According to SCHEME 7, a compound of Formula (I) is prepared in two steps from a compound of formula (IX). In a first step, a compound of formula (IX), where R1 is H, or CH3, is reacted in a metal mediated cross coupling reaction to provide a compound of formula (XVIII), where Ar1 is a phenyl optionally substituted with one, two, or three members each independently selected from halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl. For example, a compound of formula (IX), where R1 is H, or CH3, is reacted with a commercially available or synthetically accessible suitably substituted aryl boronic acid, boronate ester, and the like; in the presence of a palladium catalyst such as bis(triphenylphosphine)palladium(II)chloride (PdCl2(PPh3)2), bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (PdCl2(dppf).DCM), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl2(dppf)), tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4), 2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate (RuPhos-Pd-G3), and the like; a base such as Na2CO3, Cs2CO3, and the like; in a suitable solvent such as ACN, water, 1,4-dioxane, or a mixture thereof; at a temperature ranging from 70° C.-120° C.; for a period ranging from 2 h to 48 h, using conventional or microwave heating, to provide a compound of formula (XVIII).
  • In a second step, a compound of formula (XVIII), where R1 is H or CH3, and Ari is a phenyl optionally substituted with one, two, or three members each independently selected from halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl, is alkylated with a compound of formula (XIX), where X is Br or Cl, and R2 is as described in claim 1; using a base such as N-ethyldiisopropylamine (DIEA, DIPEA), Cs2CO3, NaHCO3, NaH, and the like; an additive such as KI; in a solvent such as dimethylformamide (DMF), tetrahydrofuran (THF), acetonitrile (ACN), and the like; at a temperature ranging from 0° C. to 80° C.; for a period of up to 76 h; to provide a compound of Formula (I).
  • In an alternate method, a compound of Formula (I) is prepared in two steps from a compound of formula (IX). In a first step, a compound of formula (IX) where R1 is H, or F, is alkylated employing conditions previously described with an alkyl agent of formula (XIX), where X is Br or Cl, and R2 is as described in claim 1, to provide a compound of formula (XX). In a second step, coupling with a suitably substituted phenyl or thienyl boronic acid or ester, employing conditions previously described, provides a compound of Formula (I).
  • A compound of Formula (I), where R2 is (C═O)C1-6alkyl, is reduced with a reducing agent such as NaBH4, and the like; in a suitable solvent such as MeOH, THF, or a mixture thereof, at a temperature ranging from 0° C. to rt; to provide a compound of Formula (I), where R2 is CH(OH)C1-6alkyl.
  • A compound of Formula (I), where R2 is (C═O)C1-6alkyl, is reacted with a nucleophile such as hydroxylamine hydrochloride, o-methylhydroxylamine hydrochloride, and the like; using a base such as Cs2CO3, triethylamine, NaHCO3, and the like; in a solvent such as MeOH, EtOH, H2O, or a mixture thereof, to provide a compound of Formula (I), where R2 is C(═N—OH)C1-6alkyl, or C(═N—OCH3)C1-6alkyl.
  • A compound of Formula (I), where R2 is (C═O)C1-6alkyl, is fluorinated under conditions known to one skilled in the art, for example, reaction with a fluorinated reagent such as DAST, bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor®), and the like; in a solvent such as DCM, THF, and the like; at a temperature ranging from 0° C. to rt; to provide a compound of Formula (I), where R2 is C(F2)C1-6alkyl.
  • A compound of Formula (I), where R2 is CH(OH)C1-6alkyl, is fluorinated under conditions known to one skilled in the art, for example, reaction with a fluorinated reagent such as DAST, Deoxo-Fluor®, and the like; in a solvent such as DCM, THF, and the like; at a temperature ranging from 0° C. to rt; to provide a compound of Formula (I), where R2 is CH(F)C1-6alkyl.
  • A compound of Formula (I), where R2 is CH(OH)C1-6alkyl is methylated with iodomethane; using a base such as NaH, and the like; in a suitable solvent such as DMF, and the like; to provide a compound of Formula (I), where R2 is CH(OCH3)C1-6alkyl.
  • A compound of Formula (I), where R2 is oxetanyl, is treated with an Agilent Bond Elut strong cation exchange (SCX) cartridge to provide a compound of Formula (I), where R2 is CH(OH)CH2CH2OCH3.
  • Compounds of Formula (I) may be converted to their corresponding salts using methods known to one of ordinary skill in the art. For example, an amine of Formula (I) is treated with trifluoroacetic acid, HCl, or citric acid in a solvent such as diethyl ether (Et2O), CH2Cl2, THF, MeOH, chloroform, or isopropanol to provide the corresponding salt form. Alternately, trifluoroacetic acid or formic acid salts are obtained as a result of reverse phase HPLC purification conditions. Cyrstalline forms of pharmaceutically acceptable salts of compounds of Formula (I) may be obtained in crystalline form by recrystallization from polar solvents (including mixtures of polar solvents and aqueous mixtures of polar solvents) or from non-polar solvents (including mixtures of non-polar solvents).
  • Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
  • Compounds prepared according to the schemes described above may be obtained as single forms, such as single enantiomers, by form-specific synthesis, or by resolution. Compounds prepared according to the schemes above may alternately be obtained as mixtures of various forms, such as racemic (1:1) or non-racemic (not 1:1) mixtures. Where racemic and non-racemic mixtures of enantiomers are obtained, single enantiomers may be isolated using conventional separation methods known to one of ordinary skill in the art, such as chiral chromatography, recrystallization, diastereomeric salt formation, derivatization into diastereomeric adducts, biotransformation, or enzymatic transformation. Where regioisomeric or diastereomeric mixtures are obtained, as applicable, single isomers may be separated using conventional methods such as chromatography or crystallization.
  • The following specific examples are provided to further illustrate the invention and various preferred embodiments.
    • EXAMPLES
  • In obtaining the compounds described in the examples below and the corresponding analytical data, the following experimental and analytical protocols were followed unless otherwise indicated.
  • Unless otherwise stated, reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were “dried,” they were generally dried over a drying agent such as Na2SO4 or MgSO4. Where mixtures, solutions, and extracts were “concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure. Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM (Microwave Reactor) Discover instrument.
  • For the reactions conducted under continuous flow conditions, “flowed through a LTF-VS mixer” refers to the use of a Chemyx Fusion 100 Touch Syringe Pump that is in line via 1/16″ PTFE tubing to a LTF-VS mixer (Little Things Factory GmbH (http://www.ltf-gmbh.com), unless otherwise indicated.
  • Normal-phase silica gel chromatography (FCC) was performed on silica gel (SiO2) using prepacked cartridges.
  • Preparative reverse-phase high performance liquid chromatography (RP HPLC) was performed on either:
  • METHOD A. An Agilent HPLC with an Xterra Prep RP18 column (5 μM, 30×100 or 50×150 mm) or an XBridge C18 OBD column (5 μM, 30×100 or 50×150 mm), and a mobile phase of 5% ACN in 20 mM NH4OH was held for 2 min, then a gradient of 5-99% ACN over 15 min, then held at 99% ACN for 5 min, with a flow rate of 40 or 80 mL/min. or
  • METHOD B. A Shimadzu LC-8A Series HPLC with an Inertsil ODS-3 column (3 m, 30×100 mm, T=45° C.), mobile phase of 5% ACN in H2O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 6 min, then held at 99% ACN for 3 min, with a flow rate of 80 mL/min.
  • or
  • METHOD C. A Shimadzu LC-8A Series HPLC with an XBridge C18 OBD column (5 m, 50×100 mm), mobile phase of 5% ACN in H2O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 14 min, then held at 99% ACN for 10 min, with a flow rate of 80 mL/min.
  • or
  • METHOD D. A Gilson HPLC with an XBridge C18 column (5 μm, 100×50 mm), mobile phase of 5-99% ACN in 20 mM NH4OH over 10 min and then hold at 99 ACN for 2 min, at a flow rate of 80 mL/min.
  • or
  • METHOD E. A Wufeng LC100 equipped with a manual Rheodyne 3725i sampler with a Gemini-NX C18 column (5 μM, 30×100 mm), and a mobile phase of 20-100% ACN:8 mM (NH4)HCO3 (9:1) in 10 mM aqueous (NH4)HCO3 over 16 min, with a flow rate of 40 mL/min. or METHOD F. A Wufeng LC100 equipped with a manual Rheodyne 3725i sampler with a Gemini-NX C18 column (5 μM, 30×100 mm), and a mobile phase of 50-100% ACN:8 mM (NH4)HCO3 (9:1) in 10 mM aqueous (NH4)HCO3 over 8 min, with a flow rate of 30 mL/min.
  • or
  • METHOD G. A Wufeng LC100 equipped with a manual Rheodyne 3725i sampler with a Gemini-NX C18 column (5 μM, 30×100 mm), and a mobile phase of 30-100% ACN:8 mM (NH4)HCO3 (9:1) in 10 mM aqueous (NH4)HCO3 over 5 min, with a flow rate of 30 mL/min.
  • or
  • METHOD H. An HPLC equipped with an XBridge C18 OBD column (5 μM, 30×100 or 50×150 mm), and a mobile phase of 46-64% ACN:8 mM (NH4)HCO3 (9:1) in 10 mM aqueous (NH4)HCO3.
  • Preparative supercritical fluid high performance liquid chromatography (SFC) was performed either on a Jasco preparative SFC system, an APS 1010 system from Berger instruments, or a SFC-PICLAB-PREP 200 (PIC SOLUTION, Avignon, France). The separations were conducted at 100 to 150 bar with a flow rate ranging from 40 to 60 mL/min. The column was heated to 35 to 40° C.
  • Mass spectra (MS) were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.
  • Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. Definitions for multiplicity are as follows: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad. It will be understood that for compounds comprising an exchangeable proton, said proton may or may not be visible on an NMR spectrum depending on the choice of solvent used for running the NMR spectrum and the concentration of the compound in the solution.
  • Chemical names were generated using ChemDraw Ultra 17.1 (CambridgeSoft Corp., Cambridge, Mass.) or OEMetaChem V1.4.0.4 (Open Eye).
  • Compounds designated as R* or S* are enantiopure compounds where the absolute configuration was not determined.
    • Intermediate 1: 6-Bromo-3-fluoro-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00041
  • To a solution of 6-bromo-1H-pyrazolo[4,3-b]pyridine (2.5 g, 12.6 mmol) in acetonitrile (62.5 mL) was added N-fluoro-N-(chloromethyl)triethylenediamine bis(tetrafluoroborate) (6.7 g, 18.9 mmol) and the reaction mixture was stirred at 90° C. for 22 h. The reaction mixture was poured into water (120 mL) and was diluted with ethyl acetate (EA or EtOAc) (80 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (2×60 mL). The combined organic layers were dried over MgSO4, filtered and evaporated. Purification (METHOD E) afforded the title compound (641 mg, 2.97 mmol, 23%) as a brown powder. MS (ESI): mass calcd. for C6H3BrFN3; 214.9 m/z found, 216.0 [M+H]+.
    • Intermediate 2: 6-(4-Fluoro-3-methylphenyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00042
  • 6-Bromo-1H-pyrazolo[4,3-B]pyridine (1 g, 5.05 mmol), 4-fluoro-3-methylphenylboronic acid (1.17 g, 7.58 mmol), Cs2CO3 (3.29 g, 10.1 mmol), PdCl2(dppf) DCM (258.66 mg, 0.353 mmol), and 1,4-dioxane (46.6 mL), were combined and heated, with stirring, to 70° C. After two hours the reaction was removed from the heat and allowed to cool to rt. It was then loaded on to a column for purification (FCC, SiO2, 0-70% EtOAc in hexanes) to afford the title compound (210 mg, 18.3%). MS (ESI): mass calcd for C13H10FN3, 227.1; m/z found, 228.1 [M+H]+.
    • Intermediate 3: 6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00043
  • A mixture of 6-bromo-1H-pyrazolo[4,3-b]pyridine (1.40 g, 7.07 mmol), 2-[3-(difluoromethyl)-4-fluoro-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.31 g, 8.49 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.673 g, 0.92 mmol) and Na2CO3 (2.25 g, 21.2 mmol) in degassed acetonitrile (24.4 mL) and water (3.76 mL) was stirred at 120° C. for 4 h under microwave irradiation. The reaction mixture was poured into water (30 mL) and the mixture was extracted with EtOAc (3×30 mL). The combined organic layers were dried over Na2SO4, filtered and evaporated. Purification (FCC, SiO2, 10 to 50% n-heptane/EtOAc) afforded a solid that was triturated with Et2O (4 mL) to afford the title compound (1.41 g, 5.36 mmol, 76%) as an off-white powder. MS (ESI): mass calcd. for C13H8F3N3, 263.1; m/z found, 264.2 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 13.48 (br s, 1H), 8.84 (d, J=2.0 Hz, 1H), 8.41-8.30 (m, 1H), 8.30-8.20 (m, 1H), 8.13-7.99 (m, 2H), 7.60-7.49 (m, 1H), 7.27 (t, J=54.1 Hz, 1H).
    • Intermediate 4: 6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00044
  • The title compound was prepared in a manner analogous to Intermediate 3 using 2-(3-(difluoromethoxy)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane instead of 2-[3-(difluoromethyl)-4-fluoro-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C13H8F3N3O, 279.0; m/z found, 280.2 [M+H]+.
    • Intermediate 5: 6-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00045
  • The title compound was prepared in a manner analogous to Intermediate 3 using 2-(3-(difluoromethoxy)-4-chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane instead of 2-[3-(difluoromethyl)-4-fluoro-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C13H8ClF2N3O, 295.0; m/z found, 296.0 [M+H]+.
    • Intermediate 6: 6-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00046
  • The title compound was prepared in a manner analogous to Intermediate 3 using 2-(3-(1,1-difluoroethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane instead of 2-[3-(difluoromethyl)-4-fluoro-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C14H10F3N3, 277.1; m/z found, 278.1 [M+H]+.
    • Intermediate 7: 6-(3-(1,1-Difluoroethyl)phenyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00047
  • The title compound was prepared in a manner analogous to Intermediate 3 using 2-(3-(1,1-difluoroethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane instead of 2-[3-(difluoromethyl)-4-fluoro-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C14H11F2N3, 259.1; m/z found, 260.1 [M+H]+.
    • Intermediate 8: 6-(3-(Trifluoromethyl)phenyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00048
  • A suspension of 6-bromo-1H-pyrazolo[4,3-B]pyridine (5.0 g, 25.25 mmol), 3-trifluoromethylphenylboronic acid (5.755 g, 30.3 mmol), Pd(PPh3)4 (1.459 g, 1.262 mmol) and Na2CO3 (2 M in H2O, 32.468 mL, 64.935 mmol) in 1,4-dioxane (96.9 mL) was stirred at 120° C. for 48 h. The mixture was cooled to rt, diluted with EtOAc, and washed with H2O (×2). The organic layer was dried over Na2SO4 and concentrated under reduced pressure. Purification (FCC, SiO2, 0-50% EtOAc in heptane), followed by trituration with Et2O, afforded the title compound (2.1 g, 32%). MS (ESI): mass calcd. for C13H8F3N3, 263.1; m/z found, 264.1 [M+H]+.
    • Intermediate 9: 6-(4-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00049
  • The title compound was prepared in a manner analogous to Intermediate 2 using 4-fluorophenylboronic acid instead of 4-fluoro-3-methylphenylboronic acid. MS (ESI): mass calcd. for C13H8F3N3, 213.1; m/z found, 214.0 [M+H]+.
    • Intermediate 10: 6-(3-(Difluoromethyl)-4-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00050
  • The title compound was prepared in a manner analogous to Intermediate 3, using 6-bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine. MS (ESI): mass calcd. for C14H10F3N3, 277.1; m/z found, 278.1 [M+H]+.
    • Intermediate 11: 1-(6-Bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one
  • Figure US20220324860A1-20221013-C00051
  • Under an atmosphere of nitrogen was added 6-bromo-1H-pyrazolo[4,3-B]pyridine (500 mg, 2.53 mmol) to a suspension of NaH (60% dispersion in mineral oil, 141.39 mg, 3.54 mmol) in DMF (21.7 mL) at rt. After 10 min, 1-bromo-2-butanone (0.373 mL, 3.54 mmol) was added, and the reaction mixture was left to stir at rt overnight. The reaction was quenched with a small amount of H2O, then adsorbed onto silica gel and purified (FCC, SiO2, 0-100% EtOAc in hexanes) to afford the title compound (265 mg, 39%). MS (ESI): mass calcd. for C10H10BrN3O, 267.0; m/z found, 268.0 [M+H]+.
    • Intermediate 12: 1-(6-Bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)propan-2-one
  • Figure US20220324860A1-20221013-C00052
  • The title compound was prepared in a manner analogous to Intermediate 11 using chloroacetone instead of 1-bromo-2-butanone. MS (ESI): mass calcd. for C9H8BrN3O, 253.0; m/z found, 254.0 [M+H]+.
    • Intermediate 13: 1-(6-Bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one
  • Figure US20220324860A1-20221013-C00053
  • The title compound was prepared in a manner analogous to Intermediate 11 using 1-bromo-3-methyl-2-butanone instead of 1-bromo-2-butanone. MS (ESI): mass calcd. for C11H12BrN3O, 282.1; m/z found 283 [M+H]+.
    • Intermediate 14: 2-(6-Bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one
  • Figure US20220324860A1-20221013-C00054
  • The title compound was prepared in a manner analogous to Intermediate 11 using 2-bromo-1-cyclopropylethanone instead of 1-bromo-2-butanone. MS (ESI): mass calcd. for C11H10BrN3O, 280.1; m/z found 282 [M+H]+.
    • Intermediate 15: 1-(6-Bromo-3-fluoro-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one
  • Figure US20220324860A1-20221013-C00055
  • The title compound was prepared in a manner analogous to Intermediate 11 using 6-bromo-3-fluoro-1H-pyrazolo[4,3-b]pyridine (Intermediate 1) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine. MS (ESI): mass calcd. for C10H9BrFN3O, 284.9; m/z found, 286.1 [M+H]+.
    • Intermediate 16: 6-Bromo-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00056
  • Step A. 6-Bromo-1-(ethylsulfanylmethyl)pyrazolo[4,3-b]pyridine. A mixture of 6-bromo-1H-pyrazolo[4,3-b]pyridine (600 mg, 3.03 mmol), (chloromethyl)(ethyl)sulfane (369 mg, 3.34 mmol) and Cs2CO3 (1.48 g, 4.54 mmol) in dry DMF (12 mL) was stirred at room temperature for 20 h. The reaction mixture was poured into water (15 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were dried over Na2SO4, filtered and evaporated. Purification (FCC, SiO2, 0 to 10% hexanes/EtOAc) afforded the title compound (431 mg, 1.584 mmol, 52%) as a pale yellow oil. MS (ESI): mass calcd. for C9H10BrN5S, 270.9; m/z found, 272.0 [M+H]+. The reaction also provided 6-bromo-2-(ethylsulfanylmethyl)pyrazolo[4,3-b]pyridine (240 mg, 0.882 mmol, 29%) as a pale yellow powder. MS (ESI): mass calcd. for C9H10BrN3S, 270.9; m/z found, 272.0 [M+H]+.
  • Step B. 6-Bromo-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine. To a solution of 6-bromo-1-(ethylsulfanylmethyl)pyrazolo[4,3-b]pyridine (421 mg, 1.55 mmol) from Step A in DCM (12.9 mL) was added 3-chloroperbenzoic acid (248 mg, 1.11 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 1 h, then at room temperature for 46 h. The reaction mixture was diluted with DCM (12 mL) and washed with 10% Na2CO3 (1×15 mL). The aqueous layer was extracted with DCM (2×15 mL) and the combined organic layers were dried over Na2SO4, filtered and evaporated. Purification (FCC, SiO2, 0 to 5% MeOH in DCM) afforded the title compound (290 mg, 1.01 mmol, 91%) as a white powder. MS (ESI): mass calcd. for C9H10BrN3OS, 286.9; m/z found, 288.0 [M+H]+.
    • Intermediate 17: 2-Bromo-1-cyclobutylethan-1-one
  • Figure US20220324860A1-20221013-C00057
  • To cyclobutyl methyl ketone (1.0 g, 10.189 mmol) stirring in MeOH (10 mL) at 0° C. was added bromine (1.6 g, 10.012 mmol). The reaction mixture was allowed to stir and slowly warm to rt as the ice bath melted. After 2 hours, water was added to the reaction mixture and it was stirred for an additional 30 min. Water (50 mL) was added, and the aqueous layer was extracted with ether (2×50 mL). The organic layer was dried, filtered, and concentrated under reduced pressure to afford the title compound (376 mg, 21%). 1H NMR (300 MHz, CDCl3) δ 3.89 (s, 2H), 3.70-3.53 (m, 1H), 2.37-2.16 (m, 4H), 2.12-1.97 (m, 1H), 1.95-1.80 (m, 1H).
    • Intermediate 18: (R)-5-(Chloromethyl)-3-methyloxazolidin-2-one
  • Figure US20220324860A1-20221013-C00058
  • To (R)-5-(hydroxymethyl)-3-methyloxazolidin-2-one (518.2 mg, 3.952 mmol) stirring in DCE (20 mL) in a round bottom flask at rt was added SOCl2 (1.5 mL, 20.677 mmol) followed by pyridine (1.6 mL, 19.863 mmol). The reaction was connected to a reflux apparatus and stirred at 90° C. for 1 h. The reaction mixture was then cooled to rt, then cooled to 0° C. and quenched by the dropwise addition of a saturated aqueous solution of NaHCO3 until pH 7 was reached. The layers were separated and the organic layer was washed with saturated aqueous solutions of NaHCO3(×3), NH4Cl (×3), then CuSO4 (×2). The organic layer was then dried (Na2SO4) and concentrated under reduced pressure to afford the title compound as a yellow oil (172.2 mg, 29%). 1H NMR (500 MHz, CDCl3) δ 4.70 (dddd, J=8.7, 7.0, 5.7, 4.1 Hz, 1H), 3.78-3.59 (m, 3H), 3.46 (dd, J=9.0, 5.7 Hz, 1H), 2.90 (s, 3H).
    • Intermediate 19: (S)-5-(Chloromethyl)-3-methyloxazolidin-2-one
  • Figure US20220324860A1-20221013-C00059
  • The title compound was prepared in a manner analogous to Intermediate 18 using (S)-5-(hydroxymethyl)-3-methyloxazolidin-2-one instead of (R)-5-(hydroxymethyl)-3-methyloxazolidin-2-one. 1H NMR (500 MHz, CDCl3) δ 4.70 (dddd, J=8.7, 7.0, 5.7, 4.1 Hz, 1H), 3.78-3.59 (m, 3H), 3.46 (dd, J=9.0, 5.7 Hz, 1H), 2.90 (s, 3H).
    • Intermediate 20: (RS)-4-(Chloromethyl)-3-methyloxazolidin-2-one
  • Figure US20220324860A1-20221013-C00060
  • The title compound was prepared in a manner analogous to Intermediate 18 using (RS)-4-(hydroxymethyl)-3-methyl-1,3-oxazolidin-2-one instead of (R)-5-(hydroxymethyl)-3-methyloxazolidin-2-one. 1H NMR (500 MHz, CDCl3) δ 4.48-4.33 (m, 1H), 4.20 (dd, J=9.1, 5.4 Hz, 1H), 4.05-3.89 (m, 1H), 3.70-3.56 (m, 2H), 2.91 (s, 3H).
    • Intermediate 21: 2-Bromo-1-(pyridin-2-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00061
  • To a solution of 2-acetylpyridine (500 mg, 4.13 mmol) in acetic acid (AcOH) (6.25 mL, 109 mmol) was added pyridinium tribromide (1.32 g, 4.13 mmol) and the reaction mixture was stirred at 50° C. for 17 h. The precipitate was collected and was washed with Et2O (4×5 mL) to give the title compound (941 mg, 3.35 mmol, 81%) as an off-white powder. MS (ESI): mass calcd. for C7H6BrNO; 198.9 m/z found, 200.1 [M+H]+.
    • Intermediate 22: 2-Bromo-1-(pyridin-4-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00062
  • The title compound was prepared in a manner analogous to Intermediate 21 using 1-(pyridin-4-yl)ethan-1-one instead of 2-acetylpyridine. MS (ESI): mass calcd. for C7H6BrNO; 198.9 m/z found, 200.1 [M+H]+.
    • Intermediate 23: 2-Bromo-1-(3,5-difluoropyridin-2-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00063
  • To a solution of phenyltrimethylammonium tribromide (420 mg, 1.12 mmol) in THE (3.5 mL) was added a solution of 1-(3,5-difluoropyridin-2-yl)ethanone (160 mg, 1.02 mmol) in THE (1.5 mL) and the reaction mixture was stirred at 60° C. for 1 h. The mixture was filtered and the solids washed with THE (5×5 mL). The combined filtrates were concentrated. Purification (FCC, SiO2, 0 to 100% n-heptane/DCM) afforded the title compound (142 mg, 0.651 mmol, 64%) as a pale yellow oil. No mass found in MS.
    • Intermediate 24: 2-Bromo-1-(3-fluoropyridin-2-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00064
  • The title compound was prepared in a manner analogous to Intermediate 23 using 1-(3-fluoropyridin-2-yl)ethan-1-one instead of 1-(3,5-difluoropyridin-2-yl)ethanone. Material used without further purification. No mass found in MS.
    • Intermediate 25: 2-Bromo-1-(pyrazin-2-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00065
  • The title compound was prepared in a manner analogous to Intermediate 23 using 1-(pyrazin-2-yl)ethan-1-one instead of 1-(3,5-difluoropyridin-2-yl)ethanone. Material used without further purification. No mass found in MS.
    • Intermediate 26: 2-Bromo-1-(pyrimidin-2-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00066
  • The title compound was prepared in a manner analogous to Intermediate 23 using 1-(pyrimidin-2-yl)ethan-1-one instead of 1-(3,5-difluoropyridin-2-yl)ethanone. Material used without further purification. No mass found in MS.
    • Intermediate 27: 2-Bromo-1-(pyridin-3-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00067
  • To a solution of 3-acetylpyridine (500 mg, 4.128 mmol) and HBr (33 wt % in acetic acid, 1.25 mL, 7.238 mmol) in acetic acid (1.25 mL) was added pyridinium tribromide (1.45 g, 4.534 mmol) and the reaction mixture was stirred at rt for 30 min. Diethyl ether (8 mL) was added to the reaction, and the mixture was cooled to 0° C. The precipitate was collected and washed with diethyl ether (5×5 mL) to afford the title compound as an off-white powder (1.921 g, 165%). MS (ESI): mass calcd. for C7H6BrNO; 198.9 m/z found, 200.1 [M+H]+.
    • Intermediate 28: 2-Bromo-1-(5-fluoropyridin-2-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00068
  • The title compound was prepared in a manner analogous to Intermediate 23 using 1-(5-fluoropyridin-2-yl)ethanone instead of 1-(3,5-difluoropyridin-2-yl)ethanone. No mass found in MS.
    • Intermediate 29: 2-(3-(Difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
  • Figure US20220324860A1-20221013-C00069
  • A solution of 4-bromo-2-(difluoromethyl)-1-fluorobenzene (20 g, 88.9 mmol), bis(pinacolato)diboron (24.8 g, 97.8 mmol), potassium acetate (26.2 g, 267 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (3.12 g, 4.44 mmol) in 1,4-dioxane (400 mL) was purged with N2, and the reaction mixture was stirred at 90° C. overnight. Upon completion, the reaction mixture was cooled to room temperature, filtered through Celite®, and rinsed with EtOAc. The filtrate was washed with water and brine. The combined organics were dried with Na2SO4, filtered and concentrated to yield a clear oil (22.1 g, 81.0 mmol, 91%), which solidified upon standing. 1H NMR (400 MHz, Chloroform-d) δ 8.12-8.00 (m, 1H), 7.96-7.85 (m, 1H), 7.17-7.06 (m, 1H), 6.88 (t, J=54.9 Hz, 1H), 1.35 (s, 12H). MS (ESI): mass calcd. for C13H16BF3O2, 272.1; m/z found, 273.0 [M+H]+.
    • Intermediate 30: 2-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
  • Figure US20220324860A1-20221013-C00070
  • Step A: 4-Bromo-2-(1,1-difluoroethyl)-1-fluorobenzene. In a round bottom flask, a mixture of 1-(5-bromo-2-fluorophenyl)-1-ethanone (2.5 g, 11.5 mmol, 1 equiv) and DAST (1.9 mL, 14.4 mmol, 1.25 equiv) was heated at 60° C. for 16 h. Then a sat. aq. solution of NaHCO3 was slowly added at 0° C. and the mixture was extracted with DCM. The organic layers were combined, dried over MgSO4, filtered, and partially concentrated (product is volatile). Purification (FCC, SiO2, 100% DCM) afforded the title compound (3 g, 7.5 mmol, purity 60%, 65%) as a brown oil. 1H NMR (300 MHz, CDCl3) δ 7.73-7.61 (m, 1H), 7.60-7.48 (m, 1H), 7.02 (t, J=9.4 Hz, 1H), 1.98 (t, J=18.6 Hz, 3H).
  • Step B: 2-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. In a round bottom flask, bis(pinacolato)diboron (2.87 g, 11.3 mmol, 1.5 equiv), potassium acetate (2.22 g, 22.6 mmol, 3 equiv), and [1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (615 mg, 0.75 mmol, 0.1 equiv) were added to a solution of 4-bromo-2-(1,1-difluoroethyl)-1-fluorobenzene (3 g, 7.5 mmol, 1 equiv) in dry 1,4-dioxane (40 mL). The reaction mixture was purged with nitrogen and stirred at 90° C. for 16 h. Then, a sat. aq. solution of NaHCO3 was added and the mixture was extracted with EtOAc. The combined organics were dried with MgSO4, filtered and concentrated to afford the title compound as a brown oil (2.15 g, 7.53 mmol), which was used in the next step without further purification. MS (ESI): mass calcd. for C14H15BF3O2, 286.1; m/z found, 287.1 [M+H]+.
    • Intermediate 31: 2-(3-(Difluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
  • Figure US20220324860A1-20221013-C00071
  • The title compound was prepared in a manner analogous to Intermediate 29 using 1-bromo-3-(difluoromethyl)benzene instead of 4-bromo-2-(difluoromethyl)-1-fluorobenzene. No mass observed.
    • Intermediate 32: 2-(3-(1,1-Difluoroethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
  • Figure US20220324860A1-20221013-C00072
  • The title compound was prepared in a manner analogous to Intermediate 29 using 1-bromo-3-(1,1-difluoroethyl)benzene instead of 4-bromo-2-(difluoromethyl)-1-fluorobenzene. No mass observed.
    • Intermediate 33: 2-(3-(Difluoromethoxy)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
  • Figure US20220324860A1-20221013-C00073
  • The title compound was prepared in a manner analogous to Intermediate 29 using 4-bromo-2-(difluoromethoxy)-1-fluorobenzene instead of 4-bromo-2-(difluoromethyl)-1-fluorobenzene. MS (ESI): mass calcd. for C13H16BF3O3, 288.1; m/z found, 289.0 [M+H]+.
    • Intermediate 34: 2-(4-Chloro-3-(difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
  • Figure US20220324860A1-20221013-C00074
  • The title compound was prepared in a manner analogous to Intermediate 29 using 4-bromo-1-chloro-2-(difluoromethoxy)benzene instead of 4-bromo-2-(difluoromethyl)-1-fluorobenzene. 1H NMR (500 MHz, CDCl3) δ 7.62-7.56 (m, 2H), 7.44 (d, J=7.9 Hz, 1H), 6.56 (t, J=73.6 Hz, 1H), 1.34 (s, 12H).
    • Example 1: 1-[6-(3,5-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00075
  • 1-(6-Bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11, 30 mg, 0.112 mmol), 3,5-difluorophenylboronic acid (21.2 mg, 0.134 mmol), Cs2CO3 (109 mg, 0.336 mmol), Pd(dppf)Cl2.DCM (8.2 mg, 0.0112 mmol), and 1,4-dioxane (1 mL) were combined and heated, with stirring, to 90° C. overnight. After cooling to rt, the crude material was loaded directly onto a column and purified (FCC, SiO2, 0-100% EtOAc in hexanes) to afford the title compound (37.4 mg, 111%). MS (ESI): mass calcd. for C16H13F2N3O, 301.1; m/z found, 302.0 [M+H]+.
    • Example 2: 3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00076
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 3-trifluoromethyl-phenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H16F3N3O, 347.1; m/z found, 348.0 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.94 (d, J=2.0 Hz, 1H), 8.47-8.43 (m, 1H), 8.40-8.38 (m, 1H), 8.16-8.10 (m, 2H), 7.85-7.75 (m, 2H), 5.67 (s, 2H), 2.89-2.77 (m, 1H), 1.13 (m, 6H).
    • Example 3: (RS)-3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol
  • Figure US20220324860A1-20221013-C00077
  • To 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one (Example 2, 50 mg, 0.144 mmol) stirring in THE (1.885 mL) and MeOH (1.885 mL) at 0° C. was added NaBH4 (10.89 mg, 0.288 mmol). The reaction mixture was stirred at this temperature for 30 min, then warmed to rt. The reaction mixture was concentrated under reduced pressure and taken up in EtOAc. The organic layer was washed with water, dried, and concentrated under reduced pressure to afford the title compound (34.6 mg, 69%). MS (ESI): mass calcd. for C18H18F3N3O, 349.1; m/z found, 350.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J=1.9 Hz, 1H), 8.52-8.50 (m, 1H), 8.34-8.33 (m, 1H), 8.17-8.13 (m, 2H), 7.84-7.77 (m, 2H), 4.79 (d, J=6.0 Hz, 1H), 4.50-4.46 (m, 2H), 3.69 (p, J=5.8 Hz, 1H), 1.68-1.59 (m, 1H), 0.97 (d, J=6.9 Hz, 3H), 0.94 (d, J=6.7 Hz, 3H).
    • Example 4: 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00078
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine, and 1-bromo-2-butanone instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C17H14F3N3O, 333.1; m/z found, 334.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J=2.0 Hz, 1H), 8.44-8.41 (m, 1H), 8.38-8.36 (m, 1H), 8.08-8.01 (m, 2H), 7.61-7.53 (m, 1H), 7.29 (t, J=54.2 Hz, 1H), 5.54 (s, 2H), 2.57 (q, J=7.3 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H).
    • Example 5: (RS)-1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol
  • Figure US20220324860A1-20221013-C00079
  • To a solution of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one (Example 4, 45 mg, 0.135 mmol) in methanol (1.5 mL) was added sodium borohydride (13 mg, 0.344 mmol) at 0° C. The reaction mixture was warmed to room temperature and stirred for 1 h. Water (5 mL) was added and the mixture was extracted with EtOAc (2×5 mL). The combined organics were dried over Na2SO4, filtered and evaporated. Purification (FCC, SiO2, 0 to 5% MeOH in DCM) afforded the title compound (35 mg, 0.104 mmol, 77%) as a white powder. MS (ESI): mass calcd. for C17H16F3N3O, 335.1; m/z found, 336.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.84 (d, J=1.9 Hz, 1H), 8.51-8.40 (m, 1H), 8.38-8.26 (m, 1H), 8.16-8.00 (m, 2H), 7.64-7.52 (m, 1H), 7.30 (t, J=54.1 Hz, 1H), 4.85 (d, J=5.6 Hz, 1H), 4.44 (d, J=5.7 Hz, 2H), 3.92-3.76 (m, 1H), 1.57-1.26 (m, 2H), 0.93 (t, J=7.4 Hz, 3H).
    • Example 6: (E/Z)-3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one oxime
  • Figure US20220324860A1-20221013-C00080
  • To 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one (Example 2, 20 mg, 0.0576 mmol) stirring in MeOH (2 mL) was added an aqueous solution of hydroxylamine hydrochloride (8.0 mg, 0.115 mmol) and NaHCO3 (9.8 mg, 0.115 mmol) in 0.5 mL H2O. The reaction was stirred at rt overnight. The reaction was then diluted with H2O and extracted with EtOAc. The organic layer was dried and concentrated under reduced pressure to afford the title compound (20.1 mg, 96%). MS (ESI): mass calcd. for C18H17F3N4O, 362.1; m/z found, 363.0 [M+H]+.
    • Example 7: 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one
  • Figure US20220324860A1-20221013-C00081
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 4-fluoro-3-methylphenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H18FN3O, 311.1; m/z found, 312.1 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.85 (d, J=1.9 Hz, 1H), 8.35-8.33 (m, 1H), 8.32-8.30 (m, 1H), 7.76-7.71 (m, 1H), 7.67-7.62 (m, 1H), 7.35-7.27 (m, 1H), 5.65 (s, 2H), 2.89-2.77 (m, 1H), 2.36-2.32 (m, 3H), 1.12 (d, J=6.9 Hz, 6H).
    • Example 8: (RS)-1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-ol
  • Figure US20220324860A1-20221013-C00082
  • The title compound was prepared in a manner analogous to Example 3 using 1-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one (Example 7) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C18H20FN3O, 313.2; m/z found, 314.1 [M+H]+. 1H NMR (500 MHz, DMSO) δ 8.80 (d, J=1.9 Hz, 1H), 8.36-8.34 (m, 1H), 8.30-8.28 (m, 1H), 7.78-7.75 (m, 1H), 7.69-7.64 (m, 1H), 7.34-7.29 (m, 1H), 4.79 (d, J=5.9 Hz, 1H), 4.48-4.42 (m, 2H), 3.71-3.65 (m, 1H), 2.36-2.33 (m, 3H), 1.68-1.58 (m, 1H), 0.97 (d, J=6.8 Hz, 3H), 0.94 (d, J=6.8 Hz, 3H).
    • Example 9: 1-Cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00083
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 3,4,5-trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H12F3N3O, 331.1; m/z found, 332.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.94 (d, J=2.0 Hz, 1H), 8.54-8.51 (m, 1H), 8.39-8.37 (m, 1H), 7.92-7.85 (m, 2H), 5.69 (s, 2H), 2.16-2.09 (m, 1H), 1.04-0.92 (m, 4H).
    • Example 10: (R/S)-1-Cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol
  • Figure US20220324860A1-20221013-C00084
  • The title compound was prepared in a manner analogous to Example 3 using 1-cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone (Example 9) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C17H14F3N3O, 333.1; m/z found, 334.0 [M+H]+.
    • Example 11: (R/S)-1-(2-Cyclopropyl-2-methoxy-ethyl)-6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00085
  • To (RS)-1-cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol (Example 10, 15 mg, 0.045 mmol) stirring in DMF (0.86 mL) at rt was added NaH (60% dispersion in mineral oil, 3.6 mg, 0.09 mmol). The mixture was stirred at rt for 10 min, then iodomethane (0.00336 mL) was added, and the reaction mixture was stirred at rt for 3 h. The reaction was quenched with H2O, then evaporated under reduced pressure. The residue was dissolved in MeOH and purified by prep HPLC (METHOD A) to afford the title compound (2.4 mg, 15%). MS (ESI): mass calcd. for C18H16F3N3O, 347.1; m/z found, 347.9 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.90 (d, J=2.0 Hz, 1H), 8.58-8.53 (m, 1H), 8.36-8.32 (m, 1H), 7.96-7.87 (m, 2H), 4.70-4.55 (m, 2H), 3.19 (s, 3H), 3.10-3.03 (m, 1H), 0.86-0.74 (m, 1H), 0.57-0.46 (m, 1H), 0.43-0.34 (m, 1H), 0.27-0.18 (m, 1H), −0.08-0.16 (m, 1H).
    • Example 12: (RS)-6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00086
  • The title compound was prepared in a manner analogous to Intermediate 3, using 6-bromo-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 16) instead of 6-bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine, and 2-(3-(difluoromethoxy)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane instead of 2-(3-(difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C16H14F3N3O2S, 369.1; m/z found, 370.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.92 (d, J=2.0 Hz, 1H), 8.58 (dd, J=2.0, 1.0 Hz, 1H), 8.50 (d, J=0.9 Hz, 1H), 7.82 (dd, J=7.5, 2.3 Hz, 1H), 7.78-7.72 (m, 1H), 7.62 (dd, J=10.5, 8.6 Hz, 1H), 7.38 (t, J=73.2 Hz, 1H), 5.92 (d, J=13.7 Hz, 1H), 5.76 (d, J=13.7 Hz, 1H), 2.98-2.89 (m, 1H), 2.84-2.76 (m, 1H), 1.25 (t, J=7.5 Hz, 3H).
    • Example 13: 6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(ethylsulfonylmethyl)pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00087
  • Step A: 6-(3-(Difluoromethoxy)-4-fluorophenyl)-1-((ethylsulfonyl)methyl)-1H-pyrazolo[4,3-b]pyridine 4-oxide. m-CPBA (6.8 mg, 0.03 mmol) was added to a solution of (RS)-6-[3-(difluoromethoxy)-4-fluoro-phenyl]-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine (Example 12, 8.63 mg, 0.02 mmol) in DCM (2 mL) at room temperature. After 16 hours, the reaction mixture was quenched with saturated aqueous NaHCO3 (10 mL). The mixture was extracted with DCM (3×150 mL). The combined organic layers were dried (MgSO4), filtered and concentrated under vacuum to provide the title compound. MS (ESI): mass calcd. for C16H14F3N3O4S, 401.1; m/z found, 402.1 [M+H]+.
  • Step B: 6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(ethylsulfonylmethyl)pyrazolo[4,3-b]pyridine. A mixture of 6-(3-(difluoromethoxy)-4-fluorophenyl)-1-((ethylsulfonyl)methyl)-1H-pyrazolo[4,3-b]pyridine 4-oxide (9.4 mg, 0.02 mmol) from Step A and Pd/C (10 wt. %, 1.2 mg, 0.001 mmol) in EtOH (2.0 mL) and EtOAc (2.0 mL) was stirred at room temperature under a nitrogen atmosphere. After 16 hours, the reaction mixture was filtered. The filtrate was purified (HPLC, METHOD D) to provide the title compound (3.7 mg, 41%). MS (ESI): mass calcd. for C16H14F3N3O3S, 385.1; m/z found, 386.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.97 (d, J=2.0 Hz, 1H), 8.69-8.67 (m, 1H), 8.57-8.55 (m, 1H), 7.85-7.82 (m, 1H), 7.79-7.75 (m, 1H), 7.63 (dd, J=10.5, 8.6 Hz, 1H), 7.39 (t, J=73.1 Hz, 1H), 6.20 (s, 2H), 3.16 (q, J=7.4 Hz, 2H), 1.26 (t, J=7.5 Hz, 3H).
    • Example 14: 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(2-pyridyl)ethanone
  • Figure US20220324860A1-20221013-C00088
  • To a solution of 6-[3-(difluoromethyl)-4-fluoro-phenyl]-1H-pyrazolo[4,3-b]pyridine (Intermediate 3, 100 mg, 0.380 mmol) in acetonitrile (2 mL) was added Cs2CO3 (371 mg, 1.14 mmol) and the reaction mixture was stirred at room temperature for 30 min. To the reaction mixture was added 2-bromo-1-(2-pyridyl)ethanone hydrobromide (Intermediate 21, 140 mg, 0.498 mmol) and the reaction mixture was stirred at room temperature for 22 h. The mixture was then diluted with water (8 mL) and extracted with EtOAc (3×8 mL). The combined organics were dried over Na2SO4, filtered and evaporated. Purification (FCC, SiO2, 0 to 5% DCM/MeOH) afforded a solid that was recrystallized from ethanol (3 mL) to give the title compound (44 mg, 0.115 mmol, 30%) as an off-white powder. MS (ESI): mass calcd. for C20H13F3N4O, 382.1; m/z found, 383.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.92 (d, J=1.9 Hz, 1H), 8.88-8.85 (m, 1H), 8.60-8.56 (m, 1H), 8.43-8.40 (m, 1H), 8.09 (td, J=7.7, 1.8 Hz, 1H), 8.07-8.03 (m, 2H), 8.02-7.97 (m, 1H), 7.81-7.76 (m, 1H), 7.57-7.51 (m, 1H), 7.27 (t, J=54.1 Hz, 1H), 6.33 (s, 2H).
    • Example 15: 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(5-fluoropyridin-2-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00089
  • A mixture of 6-[3-(difluoromethyl)-4-fluoro-phenyl]-1H-pyrazolo[4,3-b]pyridine (Intermediate 3, 150 mg, 0.57 mmol) and NaHCO3 (105 mg, 1.25 mmol) in DMF (2.9 mL) was stirred at rt for 30 min. To the reaction mixture was added 2-bromo-1-(5-fluoropyridin-2-yl)ethan-1-one (Intermediate 28, 149 mg, 0.683 mmol) in DMF (1 mL) and the reaction mixture was stirred at rt for 3 h. Additional NaHCO3 (105 mg, 1.25 mmol) and a solution of 2-bromo-1-(5-fluoropyridin-2-yl)ethan-1-one (Intermediate 28, 149 mg, 0.683 mmol) in DMF (1 mL) was added and the reaction mixture was stirred at rt for 17 h. The reaction was evaporated under reduced pressure, and the residue was purified (FCC, SiO2, dichloromethane:methanol (100/0 to 98/2), then re-purified by n-hexane/ethyl acetate (4/1 to 1/2)). The product was re-purified by prep HPLC (METHOD E) and triturated with diethyl ether (4 mL) to afford the title compound. MS (ESI): mass calcd. for C20H12F4N4O, 400.1; m/z found, 401.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.95-8.90 (m, 1H), 8.90-8.85 (m, 1H), 8.59-8.55 (m, 1H), 8.44-8.39 (m, 1H), 8.11 (dd, J=8.8, 4.6 Hz, 1H), 8.08-8.03 (m, 2H), 8.00 (td, J=8.7, 2.6 Hz, 1H), 7.58-7.51 (m, 1H), 7.27 (t, J=54.1 Hz, 1H), 6.30 (s, 2H).
    • Example 16: 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(pyridin-3-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00090
  • To a solution of 6-[3-(difluoromethyl)-4-fluoro-phenyl]-1H-pyrazolo[4,3-b]pyridine (Intermediate 3, 150 mg, 0.57 mmol) and DIPEA (300 μL, 1.722 mmol) in DMF (3.9 mL) was added 2-bromo-1-(pyridin-3-yl)ethan-1-one HBr salt (Intermediate 27, 192 mg, 0.683 mmol) and the reaction mixture was stirred at rt for 1 h. Over the next 75 h, 6 additional portions of DIPEA (300 μL, 1.722 mmol) for a total of 2.1 mL (12.06 mmol) and 2-bromo-1-(pyridine-3-yl)ethan-1-one HBr salt (192 mg, 0.683 mmol) for a total of 1.34 g (4.78 mmol) were added. The reaction mixture was poured into water (20 mL), then extracted with ethyl acetate (3×20 mL). The combined organic layers were dried (Na2SO4), filtered, and evaporated. The residue was purified (FCC, SiO2, n-hexane/ethyl acetate/methanol (2:1:0 to 0:1:0 to 0:20:1) to afford the title compound. MS (ESI): mass calcd. for C20H13F3N4O, 382.1; m/z found, 383.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 9.33-9.26 (m, 1H), 8.92 (d, J=2.0 Hz, 1H), 8.89 (dd, J=4.9, 1.7 Hz, 1H), 8.56-8.51 (m, 1H), 8.46-8.39 (m, 2H), 8.09-7.98 (m, 2H), 7.66 (dd, J=7.9, 4.8 Hz, 1H), 7.59-7.50 (m, 1H), 7.27 (t, J=54.1 Hz, 1H), 6.34 (s, 2H).
    • Example 17: (RS)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00091
  • To a suspension of NaH (60% dispersion in mineral oil, 28.9 mg, 0.723 mmol) in DMF (5.4 mL) at rt under an atmosphere of N2 was added 6-(3-(trifluoromethyl)phenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 8, 136 mg, 0.517 mmol). After 10 minutes, 2-(bromomethyl)oxetane (0.0697 mL, 0.723 mmol) was added and the reaction mixture was heated to 75° C. Upon completion the reaction mixture was cooled to rt and water (20 mL) was added. The mixture was extracted using EtOAc (3×30 mL) and the combined organic layers were dried over MgSO4, filtered and concentrated under vacuum. Purification by prep HPLC (METHOD A) afforded the title compound and (RS)-4-methoxy-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol. MS (ESI): mass calcd. for C17H14F3N3O, 333.1; m/z found, 334.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.82 (d, J=1.9 Hz, 1H), 8.33-8.31 (m, 1H), 8.12-8.09 (m, 1H), 7.91-7.88 (m, 1H), 7.86-7.82 (m, 1H), 7.72-7.61 (m, 2H), 5.31-5.24 (m, 1H), 4.71-4.67 (m, 2H), 4.61-4.54 (m, 1H), 4.19-4.13 (m, 1H), 2.80-2.70 (m, 1H), 2.60-2.50 (m, 1H).
    • Example 18: (RS)-6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-(tetrahydrofuran-2-ylmethyl)pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00092
  • A mixture of 6-[3-(difluoromethyl)-4-fluoro-phenyl]-1H-pyrazolo[4,3-b]pyridine (Intermediate 3, 150 mg, 0.570 mmol), 2-(chloromethyl)oxolane (76 mg, 0.63 mmol), Cs2CO3 (279 mg, 0.856 mmol) and potassium iodide (19 mg, 0.114 mmol) in dry DMF (3 mL) was stirred at 80° C. for 20 h. The reaction mixture was poured into water (5 mL) and extracted with EtOAc (3×5 mL). The combined organics were dried over Na2SO4, filtered and evaporated. The residue was purified by preparative HPLC (METHOD F) to afford the title compound (42 mg, 0.121 mmol, 21%) as a brown oil. MS (ESI): mass calcd. for C18H16F3N3O, 347.1; m/z found, 348.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.85 (d, J=1.9 Hz, 1H), 8.54-8.46 (m, 1H), 8.33 (s, 1H), 8.13-7.99 (m, 2H), 7.63-7.52 (m, 1H), 7.30 (t, J=54.1 Hz, 1H), 4.57 (d, J=5.6 Hz, 2H), 4.36-4.24 (m, 1H), 3.73-3.62 (m, 1H), 3.63-3.52 (m, 1H), 2.02-1.87 (m, 1H), 1.84-1.59 (m, 3H).
    • Example 19: (RS)-4-[[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one
  • Figure US20220324860A1-20221013-C00093
  • A mixture of 6-[3-(difluoromethoxy)-4-fluoro-phenyl]-1H-pyrazolo[4,3-b]pyridine (Intermediate 4, 60 mg, 0.215 mmol), 4-(chloromethyl)-1-methyl-pyrrolidin-2-one (35 mg, 0.237 mmol) and Cs2CO3 (420 mg, 1.29 mmol) in dry DMF (1.2 mL) was stirred at room temperature for 2 h, then at 60° C. for 11 h. The reaction mixture was then cooled, and diluted with water (5 mL), and extracted with EtOAc (2×). The combined organics were dried over Na2SO4, filtered and evaporated. Purification (FCC, SiO2, 5 to 10% DCM/MeOH) afforded the title compound (17 mg, 0.044 mmol, 20%) as an off-white powder after triturating the solid with diethyl ether. MS (ESI): mass calcd. for C19H17F3N4O2, 390.1; m/z found, 391.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J=1.9 Hz, 1H), 8.61-8.54 (m, 1H), 8.39-8.32 (m, 1H), 7.87 (dd, J=7.6, 2.3 Hz, 1H), 7.83-7.77 (m, 1H), 7.60 (dd, J=10.5, 8.6 Hz, 1H), 7.38 (t, J=73.2 Hz, 1H), 4.57 (d, J=7.4 Hz, 2H), 3.35 (dd, J=9.9, 8.0 Hz, 1H), 3.20 (dd, J=9.9, 5.6 Hz, 1H), 3.06-2.96 (m, 1H), 2.68 (s, 3H), 2.34 (dd, J=16.7, 8.8 Hz, 1H), 2.14 (dd, J=16.7, 6.6 Hz, 1H).
    • Example 20: (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00094
  • To a suspension of sodium hydride (60% in mineral oil, 18 mg, 0.45 mmol) in dry DMF (1 mL) was added a solution of 6-[3-(difluoromethyl)-4-fluoro-phenyl]-1H-pyrazolo[4,3-b]pyridine (Intermediate 3, 100 mg, 0.38 mmol) in dry DMF (500 μL) at 0° C. and the reaction was stirred at 0° C. for 30 min. To the reaction mixture was added a solution of 5-chloromethyl-2-oxazolidinone (77 mg, 0.568 mmol) in dry DMF (500 μL) and the reaction mixture was stirred at 80° C. for 18 h under argon. The reaction mixture was poured into water (10 mL) and extracted with EtOAc (3×5 mL). The combined organics were dried over MgSO4, filtered and evaporated. Purification (FCC, SiO2, 0 to 5% CHCl3/MeOH) afforded the title compound (46 mg, 0.127 mmol, 33%) as a white powder. MS (ESI): mass calcd. for C17H13F3N4O2, 362.1; m/z found, 363.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J=1.9 Hz, 1H), 8.55-8.52 (m, 1H), 8.39 (d, J=0.9 Hz, 1H), 8.12-8.04 (m, 2H), 7.61-7.55 (m, 1H), 7.52-7.47 (m, 1H), 7.29 (t, J=54.2 Hz, 1H), 5.09-5.00 (m, 1H), 4.84 (dd, J=15.0, 6.4 Hz, 1H), 4.79 (dd, J=15.1, 4.5 Hz, 1H), 3.66-3.60 (m, 1H), 3.38-3.33 (m, 1H).
    • Example 21: (S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00095
  • The title compound was prepared by the separation of (RS)-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one (Example 20) using chiral SFC (Stationary phase: Chiralpak IA, 5 um 250×21 mm, Mobile phase: 20% methanol, 80% CO2). MS (ESI): mass calcd. for C17H13F3N4O2, 362.1; m/z found, 363.1 [M+H]+.
    • Example 22: (R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00096
  • The title compound was prepared by the separation of (RS)-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one (Example 20) using chiral SFC (Stationary phase: Chiralpak IA, Sum 250×21 mm, Mobile phase: 20% methanol, 80% CO2). MS (ESI): mass calcd. for C17H13F3N4O2, 362.1; m/z found, 363.1 [M+H]+.
    • Example 23: 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one
  • Figure US20220324860A1-20221013-C00097
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and chloropropane-2-one instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C16H12F3N3O, 319.1; m/z found, 320.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J=1.9 Hz, 1H), 8.44-8.43 (m, 1H), 8.37 (d, J=1.0 Hz, 1H), 8.08-8.00 (m, 2H), 7.62-7.53 (m, 1H), 7.30 (t, J=54.1 Hz, 1H), 5.55 (s, 2H), 2.21 (s, 3H).
    • Example 24: 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]propan-2-one
  • Figure US20220324860A1-20221013-C00098
  • The title compound was prepared in a manner analogous to Intermediate 3, using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)propan-2-one (Intermediate 12) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine, and 4-fluoro-3-methylphenylboronic acid instead of 2-[3-(difluoromethyl)-4-fluoro-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C16H14FN3O, 283.1; m/z found, 284.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.86-8.78 (m, 1H), 8.37-8.28 (m, 2H), 7.77-7.67 (m, 1H), 7.67-7.59 (m, 1H), 7.28 (t, J=9.1 Hz, 1H), 5.51 (s, 2H), 2.38-2.25 (m, 3H), 2.18 (s, 3H).
    • Example 25: 1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one
  • Figure US20220324860A1-20221013-C00099
  • The title compound was prepared in a manner analogous to Intermediate 3, using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)propan-2-one (Intermediate 12) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine, and 2-(3-(difluoromethoxy)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane instead of 2-[3-(difluoromethyl)-4-fluoro-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C16H12F3N3O2, 335.1; m/z found, 336.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.94-8.83 (m, 1H), 8.43-8.38 (m, 1H), 8.39-8.35 (m, 1H), 7.87-7.79 (m, 1H), 7.78-7.70 (m, 1H), 7.63-7.56 (m, 1H), 7.37 (t, J=73.2 Hz, 1H), 5.55 (s, 2H), 2.21 (s, 3H).
    • Example 26: 1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one
  • Figure US20220324860A1-20221013-C00100
  • The title compound was prepared in a manner analogous to Intermediate 3, using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)propan-2-one (Intermediate 12) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine, and 2-(3-(difluoromethoxy)-4-chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane instead of 2-[3-(difluoromethyl)-4-fluoro-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C16H12ClF2N3O2, 351.1; m/z found, 352.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.92 (d, J=1.9 Hz, 1H), 8.46-8.41 (m, 1H), 8.41-8.35 (m, 1H), 7.83-7.79 (m, 1H), 7.77 (d, J=8.6 Hz, 1H), 7.72 (dd, J=8.4, 2.0 Hz, 1H), 7.43 (t, J=73.2 Hz, 1H), 5.56 (s, 2H), 2.21 (s, 3H).
    • Example 27: 1-[6-(5-Chloro-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00101
  • The title compound was prepared in a manner analogous to Example 1 using 5-chlorothiophene-2-boronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C14H12ClN3OS, 305.0; m/z found, 306.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.86 (d, J=1.8 Hz, 1H), 8.35-8.33 (m, 1H), 8.30-8.28 (m, 1H), 7.59 (d, J=4.0 Hz, 1H), 7.25 (d, J=4.0 Hz, 1H), 5.52 (s, 2H), 2.58 (q, J=7.3 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H).
    • Example 28: 1-[6-(4-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00102
  • The title compound was prepared in a manner analogous to Example 1 using 4-fluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C16H14FN3O, 283.1; m/z found, 284.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.85 (d, J=1.9 Hz, 1H), 8.36-8.34 (m, 2H), 7.88-7.81 (m, 2H), 7.42-7.34 (m, 2H), 5.53 (s, 2H), 2.57 (q, J=7.3 Hz, 2H), 0.97 (t, J=7.2 Hz, 3H).
    • Example 29: 1-[6-(3-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00103
  • The title compound was prepared in a manner analogous to Example 1 using 3-fluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C16H14FN3O, 283.1; m/z found, 284.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.91 (d, J=1.9 Hz, 1H), 8.44-8.42 (m, 1H), 8.38-8.35 (m, 1H), 7.72-7.65 (m, 2H), 7.62-7.55 (m, 1H), 7.32-7.25 (m, 1H), 5.54 (s, 2H), 2.57 (q, J=7.3 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H).
    • Example 30: 1-[6-[3-(Difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00104
  • The title compound was prepared in a manner analogous to Example 1 using 3-difluoromethyl-phenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H15F2N3O, 315.1; m/z found, 316.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J=1.9 Hz, 1H), 8.44-8.42 (m, 1H), 8.38-8.36 (m, 1H), 8.01-7.97 (m, 2H), 7.73-7.64 (m, 2H), 7.13 (t, J=55.8 Hz, 1H), 5.55 (s, 2H), 2.57 (q, J=7.3 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H).
    • Example 31: 1-[6-[3-(1,1-Difluoroethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00105
  • The title compound was prepared in a manner analogous to Intermediate 11, using 6-(3-(1,1-difluoroethyl)phenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 7) instead of bromo-1H-pyrazolo[4,3-B]pyridine. MS (ESI): mass calcd. for C18H17F2N3O, 329.1; m/z found, 330.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.91 (d, J=2.0 Hz, 1H), 8.44-8.40 (m, 1H), 8.39-8.36 (m, 1H), 7.96-7.91 (m, 2H), 7.69-7.62 (m, 2H), 5.55 (s, 2H), 2.57 (q, J=7.3 Hz, 2H), 2.06 (t, J=18.9 Hz, 3H), 0.98 (t, J=7.3 Hz, 3H).
    • Example 32: 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one trifluoroacetate salt
  • Figure US20220324860A1-20221013-C00106
  • The title compound was prepared in a manner analogous to Intermediate 11, using 6-(4-fluoro-3-methylphenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 2) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine. MS (ESI): mass calcd. for C17H16FN3O, 297.1; m/z found, 299.1 [M+H]+. 1H NMR (500 MHz, MeOD) δ 8.87-8.84 (m, 1H), 8.34-8.32 (m, 1H), 8.31-8.29 (m, 1H), 7.68-7.63 (m, 1H), 7.61-7.55 (m, 1H), 7.22-7.16 (m, 1H), 5.50 (s, 2H), 2.63 (q, J=7.4 Hz, 2H), 2.38-2.36 (m, 3H), 1.09 (t, J=7.3 Hz, 3H).
    • Example 33: 1-[6-(2,3-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00107
  • The title compound was prepared in a manner analogous to Example 1 using 2,3-difluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C16H13F2N3O, 301.1; m/z found, 302.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.73 (t, J=1.9 Hz, 1H), 8.40 (d, J=1.0 Hz, 1H), 8.34-8.33 (m, 1H), 7.58-7.51 (m, 1H), 7.50-7.45 (m, 1H), 7.41-7.36 (m, 1H), 5.55 (s, 2H), 2.57 (q, J=7.3 Hz, 2H), 0.97 (t, J=7.3 Hz, 3H).
    • Example 34: 1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00108
  • The title compound was prepared in a manner analogous to Example 1 using 3,4-difluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C16H13F2N3O, 301.1; m/z found, 302.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J=2.0 Hz, 1H), 8.43-8.41 (m, 1H), 8.36 (d, J=1.0 Hz, 1H), 7.98-7.92 (m, 1H), 7.72-7.67 (m, 1H), 7.66-7.58 (m, 1H), 5.53 (s, 2H), 2.57 (q, J=7.3 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H).
    • Example 35: 1-[6-(3,4-Difluorophenyl)-3-fluoro-pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00109
  • The title compound was prepared in a manner analogous to Intermediate 3, using 1-(6-bromo-3-fluoro-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 15) instead of 6-bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine, and 3,4-difluorophenylboronic acid instead of 2-(3-(difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C16H12F3N3O, 319.1; m/z found, 320.3 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.94 (d, J=1.8 Hz, 1H), 8.47-8.41 (m, 1H), 8.00-7.92 (m, 1H), 7.73-7.68 (m, 1H), 7.64 (dt, J=10.5, 8.5 Hz, 1H), 5.42 (s, 2H), 2.57 (q, J=7.3 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H).
    • Example 36: 1-(6-(3-(Difluoromethyl)-4-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one
  • Figure US20220324860A1-20221013-C00110
  • The title compound was prepared in a manner analogous to Intermediate 11, using 6-(3-(difluoromethyl)-4-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-b]pyridine (Intermediate 10) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine. MS (ESI): mass calcd. for C18H16F3N3O, 347.1; m/z found, 348.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.75 (d, J=1.9 Hz, 1H), 7.83 (d, J=6.5 Hz, 1H), 7.76-7.68 (m, 1H), 7.64 (d, J=1.9 Hz, 1H), 7.26 (s, 1H), 6.98 (t, J=54.9 Hz, 1H), 5.14 (s, 2H), 2.71 (s, 3H), 2.47 (q, J=7.3 Hz, 2H), 1.09 (t, J=7.3 Hz, 3H).
    • Example 37: 1-[6-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00111
  • The title compound was prepared in a manner analogous to Intermediate 11, using 6-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 6) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine. MS (ESI): mass calcd. for C18H16F3N3O, 347.1; m/z found, 348.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J=1.9 Hz, 1H), 8.43-8.39 (m, 1H), 8.38-8.36 (m, 1H), 8.02-7.96 (m, 1H), 7.92 (dd, J=7.1, 2.4 Hz, 1H), 7.55 (dd, J=11.0, 8.6 Hz, 1H), 5.55 (s, 2H), 2.57 (q, J=7.3 Hz, 2H), 2.09 (t, J=19.1 Hz, 3H), 0.97 (t, J=7.3 Hz, 3H).
    • Example 38: 1-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00112
  • The title compound was prepared in a manner analogous to Example 1 using (2-fluoro-3-(trifluoromethyl)phenyl)boronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H13F4N3O, 351.1; m/z found, 352.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.73 (t, J=1.8 Hz, 1H), 8.42-8.40 (m, 1H), 8.38-8.36 (m, 1H), 8.03-7.97 (m, 1H), 7.93-7.86 (m, 1H), 7.59 (t, J=7.8 Hz, 1H), 5.56 (s, 2H), 2.57 (q, J=7.3 Hz, 2H), 0.97 (t, J=7.3 Hz, 3H).
    • Example 39: 1-[6-[4-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00113
  • The title compound was prepared in a manner analogous to Example 1 using (4-fluoro-3-(trifluoromethyl)phenyl)boronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H13F4N3O, 351.1; m/z found, 352.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.92 (d, J=2.0 Hz, 1H), 8.48-8.45 (m, 1H), 8.40-8.38 (m, 1H), 8.23-8.13 (m, 2H), 7.75-7.67 (m, 1H), 5.54 (s, 2H), 2.57 (q, J=7.3 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H).
    • Example 40: 1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00114
  • The title compound was prepared in a manner analogous to Intermediate 11, using 6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 4) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine. MS (ESI): mass calcd. for C17H14F3N3O2, 349.1; m/z found, 350.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J=2.0 Hz, 1H), 8.41-8.38 (m, 1H), 8.38-8.35 (m, 1H), 7.82 (dd, J=7.7, 2.2 Hz, 1H), 7.77-7.71 (m, 1H), 7.59 (dd, J=10.5, 8.6 Hz, 1H), 7.36 (t, J=73.2 Hz, 1H), 5.53 (s, 2H), 2.56 (q, J=7.3 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H).
    • Example 41: 1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00115
  • The title compound was prepared in a manner analogous to Intermediate 11, using 6-(4-chloro-3-(difluoromethoxy)phenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 5) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine. MS (ESI): mass calcd. for C17H14ClF2N3O2, 365.1; m/z found, 366.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.92 (d, J=1.9 Hz, 1H), 8.46-8.41 (m, 1H), 8.41-8.36 (m, 1H), 7.84-7.76 (m, 2H), 7.72 (dd, J=8.4, 1.9 Hz, 1H), 7.44 (t, J=73.2 Hz, 1H), 5.55 (s, 2H), 2.57 (q, J=7.5 Hz, 2H), 0.98 (t, J=7.2 Hz, 3H).
    • Example 42: 1-[6-(3,4,5-Trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00116
  • The title compound was prepared in a manner analogous to Example 1 using 3,4,5-trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C16H12F3N3O, 319.1; m/z found, 320.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.94 (d, J=2.0 Hz, 1H), 8.48-8.46 (m, 1H), 8.38 (d, J=1.0 Hz, 1H), 7.91-7.84 (m, 2H), 5.53 (s, 2H), 2.58 (q, J=7.3 Hz, 2H), 0.98 (t, J=7.3 Hz, 3H).
    • Example 43: 1-[6-(2,3,4-Trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00117
  • The title compound was prepared in a manner analogous to Example 1 using 2,3,4-trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C16H12F3N3O, 319.1; m/z found, 320.0 [M+H]+.
    • Example 44: 3-Methyl-1-(6-phenylpyrazolo[4,3-b]pyridin-1-yl)butan-2-one
  • Figure US20220324860A1-20221013-C00118
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and phenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H17N3O, 279.1; m/z found, 280.1 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.87 (d, J=1.9 Hz, 1H), 8.35-8.32 (m, 2H), 7.83-7.77 (m, 2H), 7.58-7.52 (m, 2H), 7.49-7.43 (m, 1H), 5.65 (s, 2H), 2.89-2.78 (m, 1H), 1.13 (d, J=6.9 Hz, 6H).
    • Example 45: 1-[6-(4-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one
  • Figure US20220324860A1-20221013-C00119
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 4-fluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H16FN3O, 297.1; m/z found, 298.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.86 (d, J=1.9 Hz, 1H), 8.36-8.31 (m, 2H), 7.88-7.81 (m, 2H), 7.43-7.35 (m, 2H), 5.65 (s, 2H), 2.89-2.77 (m, 1H), 1.13 (d, J=6.9 Hz, 6H).
    • Example 46: 1-[6-(3-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one
  • Figure US20220324860A1-20221013-C00120
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 3-fluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H16FN3O, 297.1; m/z found, 298.1 [M+H]+.
    • Example 47: 1-[6-[3-(Difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one
  • Figure US20220324860A1-20221013-C00121
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and (3-(difluoromethyl)phenyl)boronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H17F2N3O, 329.1; m/z found, 330.1 [M+H]+.
    • Example 48: 1-[6-(2,3-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one
  • Figure US20220324860A1-20221013-C00122
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 2,3-difluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H15F2N3O, 315.1; m/z found, 316.0 [M+H]+.
    • Example 49: 1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one
  • Figure US20220324860A1-20221013-C00123
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 3,4-difluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H15F2N3O, 315.1; m/z found, 316.0 [M+H]+.
    • Example 50: 1-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one
  • Figure US20220324860A1-20221013-C00124
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and (2-fluoro-3-(trifluoromethyl)phenyl)boronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H15F4N3O, 365.1; m/z found, 366.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.73 (t, J=1.8 Hz, 1H), 8.43-8.39 (m, 1H), 8.37-8.33 (m, 1H), 8.03-7.97 (m, 1H), 7.93-7.87 (m, 1H), 7.63-7.56 (m, 1H), 5.67 (s, 2H), 2.87-2.77 (m, 1H), 1.12 (d, J=6.9 Hz, 6H).
    • Example 51: 1-[6-[4-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one
  • Figure US20220324860A1-20221013-C00125
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and (4-fluoro-3-(trifluoromethyl)phenyl)boronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H15F4N3O, 365.1; m/z found, 366.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.92 (d, J=2.0 Hz, 1H), 8.45-8.41 (m, 1H), 8.40-8.37 (m, 1H), 8.21-8.12 (m, 2H), 7.76-7.67 (m, 1H), 5.65 (s, 2H), 2.88-2.78 (m, 1H), 1.13 (d, J=6.9 Hz, 6H).
    • Example 52: 1-[6-(4-Fluoro-2-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one
  • Figure US20220324860A1-20221013-C00126
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 4-fluoro-2-methylphenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H18FN3O, 311.1; m/z found, 312.1 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.51 (d, J=1.8 Hz, 1H), 8.39-8.33 (m, 1H), 8.08-8.02 (m, 1H), 7.39-7.32 (m, 1H), 7.29-7.21 (m, 1H), 7.20-7.12 (m, 1H), 5.62 (s, 2H), 2.86-2.74 (m, 1H), 2.26 (s, 3H), 1.10 (d, J=7.0 Hz, 6H).
    • Example 53: 3-Methyl-1-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00127
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 3,4,5-trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H14F3N3O, 333.1; m/z found, 334.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.93 (d, J=2.0 Hz, 1H), 8.46-8.44 (m, 1H), 8.39-8.37 (m, 1H), 7.92-7.82 (m, 2H), 5.64 (s, 2H), 2.90-2.79 (m, 1H), 1.13 (d, J=6.9 Hz, 6H).
    • Example 54: 3-Methyl-1-[6-(2,3,4-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one
  • Figure US20220324860A1-20221013-C00128
  • The title compound was prepared in a manner analogous to Example 1 using 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-3-methylbutan-2-one (Intermediate 13) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 2,3,4-trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H14F3N3O, 333.1; m/z found, 334.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.71 (t, J=1.9 Hz, 1H), 8.40 (d, J=1.0 Hz, 1H), 8.31-8.28 (m, 1H), 7.57-7.48 (m, 2H), 5.66 (s, 2H), 2.88-2.77 (m, 1H), 1.12 (d, J=7.0 Hz, 6H).
    • Example 55: 2-[6-(5-Chloro-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone
  • Figure US20220324860A1-20221013-C00129
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 2-(5-chlorothiophen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C15H12ClN3OS, 317.0; m/z found, 317.9 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J=1.9 Hz, 1H), 8.36-8.31 (m, 2H), 7.61 (d, J=4.0 Hz, 1H), 7.26 (d, J=3.9 Hz, 1H), 5.69 (s, 2H), 2.15-2.07 (m, 1H), 1.05-0.91 (m, 4H).
    • Example 56: 1-Cyclopropyl-2-[6-(5-methyl-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00130
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 4,4,5,5-tetramethyl-2-(5-methylthiophen-2-yl)-1,3,2-dioxaborolane instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C16H15N3OS, 297.1; m/z found, 298.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.83 (d, J=1.9 Hz, 1H), 8.30 (d, J=1.0 Hz, 1H), 8.24-8.22 (m, 1H), 7.51 (d, J=3.5 Hz, 1H), 6.92-6.89 (m, 1H), 5.68 (s, 2H), 2.14-2.07 (m, 1H), 1.04-0.90 (m, 4H).
    • Example 57: 1-Cyclopropyl-2-[6-(3-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00131
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 3-fluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H14FN3O, 295.1; m/z found, 296.0 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.92 (d, J=2.0 Hz, 1H), 8.50-8.47 (m, 1H), 8.38-8.36 (m, 1H), 7.73-7.66 (m, 2H), 7.62-7.55 (m, 1H), 7.32-7.26 (m, 1H), 5.71 (s, 2H), 2.15-2.07 (m, 1H), 1.04-0.91 (m, 4H).
    • Example 58: 1-Cyclopropyl-2-[6-(2-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00132
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 2-fluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H14FN3O, 295.1; m/z found, 296.0 [M+H]+. 1H NMR (500 MHz, DMSO) δ 8.71 (t, J=2.0 Hz, 1H), 8.38 (d, J=1.0 Hz, 1H), 8.31-8.29 (m, 1H), 7.68-7.63 (m, 1H), 7.54-7.49 (m, 1H), 7.43-7.36 (m, 2H), 5.72 (s, 2H), 2.13-2.07 (m, 1H), 1.02-0.90 (m, 4H).
    • Example 59: 1-Cyclopropyl-2-[6-(4-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00133
  • The title compound was prepared in a manner analogous to Intermediate 11, using 6-(4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 9) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine, and 2-bromo-1-cyclopropylethanone instead of 1-bromo-2-butanone. MS (ESI): mass calcd. for C17H14FN3O, 295.1; m/z found, 296.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.85 (d, J=1.9 Hz, 1H), 8.39-8.37 (m, 1H), 8.35-8.34 (m, 1H), 7.88-7.83 (m, 2H), 7.41-7.35 (m, 2H), 5.70 (s, 2H), 2.14-2.07 (m, 1H), 1.02-0.91 (m, 4H).
    • Example 60: 1-Cyclopropyl-2-[6-(m-tolyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00134
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 3-methylphenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H17N3O, 291.1; m/z found, 292.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J=1.9 Hz, 1H), 8.39-8.36 (m, 1H), 8.36-8.33 (m, 1H), 7.64-7.61 (m, 1H), 7.61-7.57 (m, 1H), 7.42 (t, J=7.6 Hz, 1H), 7.29-7.24 (m, 1H), 5.71 (s, 2H), 2.41 (s, 3H), 2.14-2.06 (m, 1H), 1.04-0.90 (m, 4H).
    • Example 61: 1-Cyclopropyl-2-[6-[3-(difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00135
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and (3-(difluoromethyl)phenyl)boronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H15F2N3O, 327.1; m/z found, 328.0 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.90 (d, J=2.0 Hz, 1H), 8.49-8.46 (m, 1H), 8.39-8.36 (m, 1H), 8.03-7.96 (m, 2H), 7.73-7.63 (m, 2H), 7.13 (t, J=55.7 Hz, 1H), 5.73 (s, 2H), 2.15-2.07 (m, 1H), 1.04-0.91 (m, 4H).
    • Example 62: 1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00136
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 3-(trifluoromethyl)phenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H14F3N3O, 345.1; m/z found, 346.0 [M+H]+. 1H NMR (500 MHz, DMSO) δ 9.05-8.86 (d, J=2.1 Hz, 1H), 8.60-8.47 (t, J=1.6 Hz, 1H), 8.44-8.32 (d, J=1.1 Hz, 1H), 8.21-8.07 (d, J=6.5 Hz, 2H), 7.91-7.69 (m, 2H), 5.84-5.57 (s, 2H), 2.19-1.99 (d, J=4.5 Hz, 1H), 1.13-0.78 (m, 6H).
    • Example 63: 1-Cyclopropyl-2-[6-[3-(trifluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00137
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), 3-(trifluoromethoxy)phenylboronic acid instead of 3,5-difluorophenylboronic acid, and RuPhos Pd G3 instead of Pd(dppf)C12.DCM. MS (ESI): mass calcd. for C18H14F3N3O2, 361.1; m/z found, 362.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.82 (d, J=1.9 Hz, 1H), 8.35 (d, J=1.0 Hz, 1H), 7.73 (dd, J=1.8, 1.0 Hz, 1H), 7.59-7.51 (m, 2H), 7.47 (d, J=2.7 Hz, 1H), 7.32-7.29 (m, 1H), 5.37 (s, 2H), 1.90 (tt, J=7.8, 4.5 Hz, 1H), 1.20-1.13 (m, 2H), 1.02-0.95 (m, 2H).
    • Example 64: 1-Cyclopropyl-2-[6-(2,3-difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00138
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 2,3-difluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H13F2N3O, 313.1; m/z found, 313.9 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.73 (t, J=1.9 Hz, 1H), 8.40 (d, J=1.0 Hz, 1H), 8.37-8.35 (m, 1H), 7.59-7.45 (m, 2H), 7.43-7.35 (m, 1H), 5.73 (s, 2H), 2.15-2.06 (m, 1H), 1.03-0.90 (m, 4H).
    • Example 65: 1-Cyclopropyl-2-[6-(3,4-difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00139
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 3,4-difluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H13F2N3O, 313.1; m/z found, 314.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J=1.9 Hz, 1H), 8.47-8.46 (m, 1H), 8.37 (d, J=0.9 Hz, 1H), 7.96 (ddd, J=12.2, 7.8, 2.3 Hz, 1H), 7.72-7.67 (m, 1H), 7.65-7.58 (m, 1H), 5.70 (s, 2H), 2.15-2.08 (m, 1H), 1.03-0.92 (m, 4H).
    • Example 66: 1-Cyclopropyl-2-[6-(3,5-difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00140
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11). MS (ESI): mass calcd. for C17H13F2N3O, 313.1; m/z found, 314.0 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.95 (d, J=1.9 Hz, 1H), 8.56-8.54 (m, 1H), 8.39-8.37 (m, 1H), 7.69-7.60 (m, 2H), 7.38-7.29 (m, 1H), 5.70 (s, 2H), 2.17-2.08 (m, 1H), 1.04-0.91 (m, 4H).
    • Example 67: 2-[6-(3-Chloro-2-fluoro-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone
  • Figure US20220324860A1-20221013-C00141
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 3-chloro-2-fluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H13ClFN3O, 329.1; m/z found, 330.0 [M+H]+.
    • Example 68: 2-[6-(3-Chloro-4-fluoro-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone
  • Figure US20220324860A1-20221013-C00142
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 3-chloro-4-fluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H13ClFN3O, 329.1; m/z found, 330.0 [M+H]+.
    • Example 69: 1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00143
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 4-fluoro-3-methylphenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H16FN3O, 309.1; m/z found, 310.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.85 (d, J=2.0 Hz, 1H), 8.39-8.36 (m, 1H), 8.35-8.33 (m, 1H), 7.78-7.73 (m, 1H), 7.69-7.63 (m, 1H), 7.34-7.27 (m, 1H), 5.70 (s, 2H), 2.37-2.31 (m, 3H), 2.14-2.06 (m, 1H), 1.03-0.90 (m, 4H).
    • Example 70: 1-Cyclobutyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00144
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(4-fluoro-3-methylphenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 2) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine, and 2-bromo-1-cyclobutylethan-1-one (Intermediate 17) instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C19H18FN3O, 323.1; m/z found, 324.0 [M+H]+. 1H NMR (400 MHz, Methanol-d4) δ 8.80 (br.s, 1H), 8.28-8.24 (m, 1H), 8.20-8.17 (m, 1H), 7.65-7.60 (m, 1H), 7.59-7.53 (m, 1H), 7.22-7.14 (m, 1H), 5.41 (s, 2H), 3.55-3.45 (m, 1H), 2.40-2.26 (m, 5H), 2.22-2.12 (m, 2H), 2.09-1.96 (m, 1H), 1.91-1.79 (m, 1H).
    • Example 71: 1-Cyclopropyl-2-[6-(2-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00145
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 2-fluoro-3-methylphenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H16FN3O, 309.1; m/z found, 310.1 [M+H]+.
    • Example 72: 1-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00146
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 4-fluoro-2-methylphenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H16FN3O, 309.1; m/z found, 310.0 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.51 (d, J=1.8 Hz, 1H), 8.37-8.36 (m, 1H), 8.11-8.08 (m, 1H), 7.38-7.33 (m, 1H), 7.27-7.22 (m, 1H), 7.19-7.13 (m, 1H), 5.68 (s, 2H), 2.27 (s, 3H), 2.12-2.03 (m, 1H), 1.04-0.87 (m, 4H).
    • Example 73: 1-Cyclopropyl-2-[6-[2-fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00147
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and (2-fluoro-3-(trifluoromethyl)phenyl)boronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C18H13F4N3O, 363.1; m/z found, 363.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.75-8.71 (m, 1H), 8.43-8.38 (m, 2H), 8.03-7.97 (m, 1H), 7.93-7.86 (m, 1H), 7.63-7.56 (m, 1H), 5.74 (s, 2H), 2.15-2.06 (m, 1H), 1.04-0.89 (m, 4H).
    • Example 74: 1-Cyclopropyl-2-[6-[4-fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00148
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), 4-fluoro-3-(trifluoromethyl)phenylboronic acid instead of 3,5-difluorophenylboronic acid, and RuPhos Pd G3 instead of Pd(dppf)Cl2.DCM. MS (ESI): mass calcd. for C18H13F4N3O, 363.1; m/z found, 364.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.79 (d, J=1.9 Hz, 1H), 8.35 (d, J=1.0 Hz, 1H), 7.86-7.82 (m, 1H), 7.82-7.77 (m, 1H), 7.70 (dd, J=1.9, 1.0 Hz, 1H), 7.40-7.35 (m, 1H), 5.39 (s, 2H), 1.92 (tt, J=7.7, 4.5 Hz, 1H), 1.19-1.14 (m, 2H), 1.02-0.97 (m, 2H).
    • Example 75: 2-[6-[4-Chloro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone
  • Figure US20220324860A1-20221013-C00149
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), 4-chloro-3-(trifluoromethyl)phenylboronic acid instead of 3,5-difluorophenylboronic acid, and RuPhos Pd G3 instead of Pd(dppf)Cl2.DCM. MS (ESI): mass calcd. for C18H13ClF3N3O, 379.1; m/z found, 380.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.80 (d, J=1.9 Hz, 1H), 8.36 (d, J=1.0 Hz, 1H), 7.93 (d, J=2.2 Hz, 1H), 7.77-7.72 (m, 2H), 7.66 (d, J=8.4 Hz, 1H), 5.39 (s, 2H), 1.96-1.88 (m, 1H), 1.19-1.14 (m, 2H), 1.03-0.97 (m, 2H).
    • Example 76: 1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00150
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and 2-bromo-1-cyclopropylethanone instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C18H14F3N3O, 345.1; m/z found, 346.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.80 (d, J=1.9 Hz, 1H), 8.35 (d, J=1.0 Hz, 1H), 7.86-7.82 (m, 1H), 7.75-7.70 (m, 2H), 7.31-7.27 (m, 1H), 6.98 (t, J=54.9 Hz, 1H), 5.38 (s, 2H), 1.91 (tt, J=7.8, 4.5 Hz, 1H), 1.19-1.14 (m, 2H), 1.02-0.97 (m, 2H).
    • Example 77: 1-Cyclopropyl-2-[6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00151
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), 2-(3-(difluoromethoxy)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane instead of 3,5-difluorophenylboronic acid, and RuPhos Pd G3 instead of Pd(dppf)Cl2.DCM. MS (ESI): mass calcd. for C18H14F3N3O2, 361.1; m/z found, 362.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.78 (d, J=1.9 Hz, 1H), 8.34 (d, J=1.0 Hz, 1H), 7.68 (dd, J=1.9, 1.0 Hz, 1H), 7.53-7.43 (m, 2H), 7.34-7.30 (m, 1H), 6.64 (t, J=73.2 Hz, 1H), 5.37 (s, 2H), 1.90 (tt, J=7.8, 4.5 Hz, 1H), 1.19-1.12 (m, 2H), 1.03-0.95 (m, 2H).
    • Example 78: 1-Cyclopropyl-2-[6-(4-fluoro-2,3-dimethyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00152
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11), and 4-fluoro-2,3-dimethylphenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C19H18FN3O, 323.1; m/z found, 324.0 [M+H]+.
    • Example 79: 1-Cyclopropyl-2-[6-(2,3,4-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone
  • Figure US20220324860A1-20221013-C00153
  • The title compound was prepared in a manner analogous to Example 1 using 2-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-cyclopropylethan-1-one (Intermediate 14) instead of 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Intermediate 11) and 2,3,4-trifluorophenylboronic acid instead of 3,5-difluorophenylboronic acid. MS (ESI): mass calcd. for C17H12F3N3O, 331.1; m/z found, 331.9 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.73-8.69 (m, 1H), 8.42-8.40 (m, 1H), 8.35 (s, 1H), 7.58-7.47 (m, 2H), 5.72 (s, 2H), 2.15-2.06 (m, 1H), 1.05-0.89 (m, 4H).
    • Example 80: (RS)-1-(Ethylsulfinylmethyl)-6-(3-fluorophenyl)pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00154
  • The title compound was prepared in a manner analogous to Intermediate 3, using 6-bromo-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 16) instead of 6-bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine, and 3-fluorophenylboronic acid instead of 2-(3-(difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C15H14FN3OS, 303.1; m/z found, 304.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.95 (d, J=1.9 Hz, 1H), 8.68-8.57 (m, 1H), 8.51 (s, 1H), 7.77-7.65 (m, 2H), 7.66-7.54 (m, 1H), 7.38-7.24 (m, 1H), 5.93 (d, J=13.7 Hz, 1H), 5.77 (d, J=13.6 Hz, 1H), 3.07-2.66 (m, 2H), 1.25 (t, J=7.5 Hz, 3H).
    • Example 81: (RS)-1-(Ethylsulfinylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00155
  • The title compound was prepared in a manner analogous to Intermediate 3, using 6-bromo-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 16) instead of 6-bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine, and 3-trifluoromethylphenylboronic acid instead of 2-(3-(difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C16H14F3N3OS, 353.1; m/z found, 354.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.98 (d, J=1.9 Hz, 1H), 8.72-8.63 (m, 1H), 8.52 (s, 1H), 8.21-8.08 (m, 2H), 7.89-7.76 (m, 2H), 5.95 (d, J=13.7 Hz, 1H), 5.79 (d, J=13.7 Hz, 1H), 3.03-2.70 (m, 2H), 1.25 (t, J=7.5 Hz, 3H).
    • Example 82: (RS) 6-(3,4-Difluorophenyl)-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00156
  • The title compound was prepared in a manner analogous to Intermediate 3, using 6-bromo-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 16) instead of 6-bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine, and 3,4-difluorophenylboronic acid instead of 2-(3-(difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C15H13F2N3OS, 321.1; m/z found, 322.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.94 (d, J=2.0 Hz, 1H), 8.61 (dd, J=2.0, 1.0 Hz, 1H), 8.50 (d, J=1.0 Hz, 1H), 7.99-7.91 (m, 1H), 7.73-7.61 (m, 2H), 5.91 (d, J=13.7 Hz, 1H), 5.75 (d, J=13.7 Hz, 1H), 2.99-2.89 (m, 1H), 2.85-2.76 (m, 1H), 1.25 (t, J=7.5 Hz, 3H).
    • Example 83: (RS)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00157
  • The title compound was prepared in a manner analogous to Intermediate 16, Steps A and B, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine in Step A. MS (ESI): mass calcd. for C16H14F3N3OS, 353.1; m/z found, 354.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.92 (d, J=2.0 Hz, 1H), 8.61 (dd, J=2.0, 1.0 Hz, 1H), 8.51 (d, J=1.0 Hz, 1H), 8.10-8.01 (m, 2H), 7.64-7.56 (m, 1H), 7.31 (t, J=54.1 Hz, 1H), 5.93 (d, J=13.7 Hz, 1H), 5.77 (d, J=13.7 Hz, 1H), 2.99-2.89 (m, 1H), 2.85-2.76 (m, 1H), 1.25 (t, J=7.5 Hz, 3H).
    • Example 84: (S*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00158
  • The title compound was prepared by the separation of Example 83 using chiral SFC (Stationary phase: CHIRALPAK IC 5 μm 250*30 mm, Mobile phase: 60% CO2, 40% MeOH). MS (ESI): mass calcd. for C16H14F3N3OS, 353.1; m/z found, 354.1 [M+H]+.
    • Example 85: (R*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00159
  • The title compound was prepared by the separation of Example 83 using chiral SFC (Stationary phase: CHIRALPAK IC 5 μm 250*30 mm, Mobile phase: 60% CO2, 40% MeOH). MS (ESI): mass calcd. for C16H14F3N3OS, 353.1; m/z found, 354.1 [M+H]+.
    • Example 86: (RS)-1-(Ethylsulfinylmethyl)-6-[2-fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00160
  • The title compound was prepared in a manner analogous to Intermediate 3, using 6-bromo-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 16) instead of 6-bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine, and 2-fluoro-3-trifluoromethylphenylphenylboronic acid instead of 2-(3-(difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C16H13F4N3OS, 371.1; m/z found, 372.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.84-8.71 (m, 1H), 8.64-8.46 (m, 2H), 8.06-7.96 (m, 1H), 7.96-7.87 (m, 1H), 7.61 (t, J=7.8 Hz, 1H), 5.95 (d, J=13.7 Hz, 1H), 5.78 (d, J=13.7 Hz, 1H), 3.02-2.86 (m, 1H), 2.87-2.72 (m, 1H), 1.24 (t, J=7.5 Hz, 3H).
    • Example 87: (RS)-6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00161
  • The title compound was prepared in a manner analogous to Intermediate 3, using 6-bromo-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 16) instead of 6-bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine, and 2-(3-(difluoromethoxy)-4-chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane instead of 2-(3-(difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C16H14ClF2N3O2S, 385.1; m/z found, 386.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.95 (d, J=1.9 Hz, 1H), 8.66-8.57 (m, 1H), 8.57-8.48 (m, 1H), 7.86-7.77 (m, 2H), 7.73 (dd, J=8.4, 2.0 Hz, 1H), 7.45 (t, J=73.2 Hz, 1H), 5.94 (d, J=13.7 Hz, 1H), 5.77 (d, J=13.7 Hz, 1H), 3.04-2.72 (m, 2H), 1.25 (t, J=7.5 Hz, 3H).
    • Example 88: (RS)-1-(Ethylsulfinylmethyl)-6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00162
  • The title compound was prepared in a manner analogous to Intermediate 3, using 6-bromo-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 16) instead of 6-bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine, and 3,4,5-trifluorophenylboronic acid instead of 2-(3-(difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. MS (ESI): mass calcd. for C15H12F3N3OS, 339.1; m/z found, 340.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.97 (d, J=2.0 Hz, 1H), 8.67 (dd, J=2.0, 1.0 Hz, 1H), 8.52 (d, J=1.0 Hz, 1H), 7.91-7.83 (m, 2H), 5.89 (d, J=13.6 Hz, 1H), 5.74 (d, J=13.7 Hz, 1H), 2.99-2.89 (m, 1H), 2.86-2.76 (m, 1H), 1.25 (t, J=7.5 Hz, 3H).
    • Example 89: 6-(4-Fluoro-3-methyl-phenyl)-1-(2-methoxyethyl)pyrazolo[4,3-b]pyridine trifluoroacetate salt
  • Figure US20220324860A1-20221013-C00163
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(4-fluoro-3-methylphenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 2) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine, and 2-bromoethyl methyl ether instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C16H16FN3O, 285.1; m/z found, 286.0 [M+H]+.
    • Example 90: (RS)-4-Methoxy-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol
  • Figure US20220324860A1-20221013-C00164
  • The title compound was obtained from the treatment of Example 17 ((RS)-1-(oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine) with Agilent Bond Elut SCX cartridge. MS (ESI): mass calcd. for C18H18F3N3O2, 365.1; m/z found, 366.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.90 (d, J=2.0 Hz, 1H), 8.54-8.51 (m, 1H), 8.34 (d, J=0.9 Hz, 1H), 8.18-8.13 (m, 2H), 7.85-7.76 (m, 2H), 4.92 (d, J=5.8 Hz, 1H), 4.50-4.46 (m, 2H), 4.08-3.98 (m, 1H), 3.47-3.40 (m, 2H), 3.20 (s, 3H), 1.74-1.64 (m, 1H), 1.62-1.52 (m, 1H).
    • Example 91: (RS)-1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol
  • Figure US20220324860A1-20221013-C00165
  • The title compound was prepared in a manner analogous to Example 5 using 1-(6-(3,4-difluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Example 34) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C16H15F2N3O, 303.1; m/z found, 304.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.67 (d, J=1.9 Hz, 1H), 8.17 (d, J=1.0 Hz, 1H), 7.91 (dd, J=1.9, 1.0 Hz, 1H), 7.50-7.42 (m, 1H), 7.41-7.35 (m, 1H), 7.35-7.29 (m, 1H), 4.52-4.45 (m, 1H), 4.34 (dd, J=14.2, 8.1 Hz, 1H), 4.17-4.10 (m, 1H), 3.23 (br s, 1H), 1.70-1.57 (m, 2H), 1.10 (t, J=7.4 Hz, 3H).
    • Example 92: (RS)-1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol
  • Figure US20220324860A1-20221013-C00166
  • The title compound was prepared in a manner analogous to Example 5 using 1-(6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Example 40) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C17H16F3N3O2, 351.1; m/z found, 352.2 [M+H]+. 1H NMR (500 MHz, CDCl3) 8.75 (d, J=1.9 Hz, 1H), 8.28 (d, J=1.0 Hz, 1H), 7.91 (dd, J=1.9, 1.0 Hz, 1H), 7.54 (dd, J=7.3, 2.2 Hz, 1H), 7.52-7.48 (m, 1H), 7.37-7.31 (dd, J=9.9, 8.5 Hz, 1H), 6.82-6.51 (t, J=73.2 Hz, 1H), 4.53-4.48 (m, 1H), 4.40-4.33 (dd, J=14.1, 7.9 Hz, 1H), 4.17-4.10 (m, 1H), 2.89-2.78 (br s, 1H), 1.70-1.60 (m, 2H), 1.12-1.06 (t, J=7.5 Hz, 3H).
    • Example 93: (RS)-1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol
  • Figure US20220324860A1-20221013-C00167
  • The title compound was prepared in a manner analogous to Example 5 using 1-[6-[4-chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one (Example 41) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C17H16ClF2N3O2, 367.8; m/z found, 368.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.72 (d, J=1.9 Hz, 1H), 8.24 (d, J=1.0 Hz, 1H), 7.93 (dd, J=1.9, 1.0 Hz, 1H), 7.62-7.58 (m, 1H), 7.54-7.52 (m, 1H), 7.50-7.46 (m, 1H), 6.65 (t, J=73.2 Hz, 1H), 4.53-4.48 (m, 1H), 4.36 (dd, J=14.2, 7.9 Hz, 1H), 4.17-4.10 (m, 1H), 3.01 (s, 1H), 1.71-1.57 (m, 2H), 1.10 (t, J=7.5 Hz, 3H).
    • Example 94: (RS)-1-[6-(3,4-Difluorophenyl)-3-fluoro-pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol
  • Figure US20220324860A1-20221013-C00168
  • The title compound was prepared in a manner analogous to Example 5 using 1-[6-(3,4-difluorophenyl)-3-fluoro-pyrazolo[4,3-b]pyridin-1-yl]butan-2-one (Example 35) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C16H14F3N3O, 321.1; m/z found, 322.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.64 (d, J=1.8 Hz, 1H), 7.87-7.85 (m, 1H), 7.48-7.42 (m, 1H), 7.39-7.30 (m, 2H), 4.34-4.28 (m, 1H), 4.25-4.18 (m, 1H), 4.14-4.07 (m, 1H), 2.94 (d, J=4.2 Hz, 1H), 1.71-1.56 (m, 2H), 1.10 (t, J=7.5 Hz, 3H).
    • Example 95: (RS)-1-[6-[3-(1,1-Difluoroethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol
  • Figure US20220324860A1-20221013-C00169
  • The title compound was prepared in a manner analogous to Example 5 using 1-[6-[3-(1,1-difluoroethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one (Example 31) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C18H19F2N3O, 331.1; m/z found, 332.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.76 (d, J=1.9 Hz, 1H), 8.21 (d, J=1.0 Hz, 1H), 7.97-7.95 (m, 1H), 7.80-7.77 (m, 1H), 7.73-7.69 (m, 1H), 7.61-7.56 (m, 2H), 4.53-4.47 (m, 1H), 4.36 (dd, J=14.1, 8.0 Hz, 1H), 4.18-4.11 (m, 1H), 3.25-3.20 (m, 1H), 2.01 (t, J=18.2 Hz, 3H), 1.69-1.59 (m, 2H), 1.10 (t, J=7.5 Hz, 3H).
    • Example 96: (RS)-3-Methyl-1-(6-phenylpyrazolo[4,3-b]pyridin-1-yl)butan-2-ol
  • Figure US20220324860A1-20221013-C00170
  • The title compound was prepared in a manner analogous to Example 3 using 3-methyl-1-(6-phenylpyrazolo[4,3-b]pyridin-1-yl)butan-2-one (Example 44) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C17H19N3O, 281.2; m/z found, 282.1 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.83 (d, J=1.9 Hz, 1H), 8.39-8.36 (m, 1H), 8.30-8.29 (m, 1H), 7.85-7.79 (m, 2H), 7.58-7.52 (m, 2H), 7.49-7.43 (m, 1H), 4.79 (d, J=5.9 Hz, 1H), 4.49-4.40 (m, 2H), 3.73-3.63 (m, 1H), 1.70-1.57 (m, 1H), 0.97 (d, J=6.8 Hz, 3H), 0.94 (d, J=6.8 Hz, 3H).
    • Example 97: (RS)-3-Methyl-1-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol
  • Figure US20220324860A1-20221013-C00171
  • The title compound was prepared in a manner analogous to Example 3 using 3-methyl-1-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one (Example 53) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C17H16F3N3O, 335.1; m/z found, 336.0 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.88 (d, J=2.0 Hz, 1H), 8.51-8.48 (m, 1H), 8.34-8.30 (m, 1H), 7.95-7.86 (m, 2H), 4.75 (d, J=6.0 Hz, 1H), 4.49-4.42 (m, 2H), 3.74-3.65 (m, 1H), 1.70-1.57 (m, 1H), 0.97 (d, J=6.8 Hz, 3H), 0.95 (d, J=6.8 Hz, 3H).
    • Example 98: 1-(2,2-Difluorobutyl)-6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00172
  • To 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one (Example 4) (64.0 mg, 0.19 mmol) stirring in DCM (2 mL) at 0° C. was added DAST (0.101 mL, 0.76 mmol). The reaction was slowly warmed to rt. After 23 h, the reaction was washed with a saturated solution of NaHCO3, then the organic layer was dried, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (hexanes\EtOAc 25 to 50%) afford the title compound as a yellow oil. MS (ESI): mass calcd. for C17H14F5N3, 355.1; m/z found, 356.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.91 (d, J=1.9 Hz, 1H), 8.59-8.49 (m, 1H), 8.44 (s, 1H), 8.13-8.00 (m, 2H), 7.64-7.53 (m, 1H), 7.31 (t, J=54.1 Hz, 1H), 5.08 (t, J=13.9 Hz, 2H), 2.06-1.82 (m, 2H), 1.01 (t, J=7.5 Hz, 3H).
    • Example 99: 1-(2,2-Difluorobutyl)-6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00173
  • The title compound was prepared in a manner analogous to Example 98 using 1-[6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one (Example 40) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C17H14F5N3O, 371.1; m/z found, 372.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.92-8.89 (m, 1H), 8.53-8.48 (m, 1H), 8.43 (s, 1H), 7.87-7.81 (m, 1H), 7.80-7.73 (m, 1H), 7.64-7.57 (m, 1H), 7.38 (t, J=73.2 Hz, 1H), 5.07 (t, J=13.8 Hz, 2H), 2.01-1.86 (m, 2H), 1.01 (t, J=7.5 Hz, 3H).
    • Example 100: (RS)-1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanol
  • Figure US20220324860A1-20221013-C00174
  • The title compound was prepared in a manner analogous to Example 3 using 1-cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone (Example 62) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C18H16F3N3O, 347.1; m/z found, 348.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J=1.9 Hz, 1H), 8.58-8.55 (m, 1H), 8.32 (d, J=0.9 Hz, 1H), 8.19-8.14 (m, 2H), 7.85-7.75 (m, 2H), 4.94 (d, J=5.2 Hz, 1H), 4.58-4.54 (m, 2H), 3.41-3.32 (m, 1H), 0.92-0.81 (m, 1H), 0.39-0.31 (m, 1H), 0.31-0.21 (m, 2H), 0.06-0.03 (m, 1H).
    • Example 101: (RS)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol
  • Figure US20220324860A1-20221013-C00175
  • The title compound was prepared in a manner analogous to Example 3 using 1-cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone (Example 69) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C18H18FN3O, 311.1; m/z found, 312.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.81 (d, J=1.9 Hz, 1H), 8.40-8.38 (m, 1H), 8.28 (d, J=0.9 Hz, 1H), 7.79-7.76 (m, 1H), 7.70-7.65 (m, 1H), 7.33-7.28 (m, 1H), 4.92 (d, J=5.2 Hz, 1H), 4.54-4.50 (m, 2H), 3.41-3.32 (m, 1H), 2.36-2.33 (m, 3H), 0.91-0.81 (m, 1H), 0.39-0.19 (m, 3H), 0.05-0.02 (m, 1H).
    • Example 102: (R)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol
  • Figure US20220324860A1-20221013-C00176
  • The title compound was prepared by the separation of Example 101 using chiral SFC (Stationary phase: CHIRALPAK IC 5 μm 250×20 mm, Mobile phase: 70% CO2, 30% iPrOH). MS (ESI): mass calcd. for C18H18FN3O, 311.1; m/z found, 312.1 [M+H]+.
    • Example 103: (S)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol
  • Figure US20220324860A1-20221013-C00177
  • The title compound was prepared by the separation of Example 101 using chiral SFC (Stationary phase: CHIRALPAK IC 5 μm 250×20 mm, Mobile phase: 70% CO2, 30% iPrOH). MS (ESI): mass calcd. for C18H18FN3O, 311.1; m/z found, 312.1 [M+H]+.
    • Example 104: (RS)-1-Cyclopropyl-2-(6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)ethan-1-ol
  • Figure US20220324860A1-20221013-C00178
  • The title compound was prepared in a manner analogous to Example 5 using 1-cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone (Example 76) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C18H16F3N3O, 347.1; m/z found, 348.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.84 (d, J=2.0 Hz, 1H), 8.51-8.44 (m, 1H), 8.31 (d, J=1.0 Hz, 1H), 8.11-8.04 (m, 2H), 7.60-7.53 (m, 1H), 7.29 (t, J=54.1 Hz, 1H), 4.92 (d, J=5.1 Hz, 1H), 4.58-4.50 (m, 2H), 3.40-3.33 (m, 1H), 0.91-0.83 (m, 1H), 0.40-0.31 (m, 1H), 0.30-0.21 (m, 2H), 0.05-0.03 (m, 1H).
    • Example 105: (E/Z)—N-Methoxy-3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-imine
  • Figure US20220324860A1-20221013-C00179
  • The title compound was prepared in a manner analogous to Example 6 using o-methylhydroxylamine hydrochloride instead of hydroxylamine hydrochloride, and EtOH as a solvent. (ESI): mass calcd. for C19H19F3N4O, 376.2; m/z found, 377.1 [M+H]+.
    • Example 106: (E/Z)-1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone oxime
  • Figure US20220324860A1-20221013-C00180
  • The title compound was prepared in a manner analogous to Example 6 using 1-cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone (Example 62) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C18H15F3N4O, 360.1; m/z found, 361.0 [M+H]+.
    • Example 107: (E/Z)-1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone oxime
  • Figure US20220324860A1-20221013-C00181
  • The title compound was prepared in a manner analogous to Example 6 using 1-cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethenone (Example 76) instead of 3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one, and triethylamine instead of Cs2CO3. MS (ESI): mass calcd. for C18H15F3N4O, 360.1; m/z found, 361.0 [M+H]+.
    • Example 108: 1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00182
  • The title compound was prepared in a manner analogous to Example 98 using 1-cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethenone (Example 76) instead of 1-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one. MS (ESI): mass calcd. for C18H14F5N3, 367.1; m/z found, 368.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.91 (d, J=1.9 Hz, 1H), 8.59-8.55 (m, 1H), 8.42 (d, J=0.9 Hz, 1H), 8.10-8.03 (m, 2H), 7.62-7.53 (m, 1H), 7.30 (t, J=54.1 Hz, 1H), 5.14 (t, J=13.3 Hz, 2H), 1.52-1.39 (m, 1H), 0.54-0.47 (m, 2H), 0.47-0.41 (m, 2H).
    • Example 109: 1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00183
  • A mixture of 1-cyclopropyl-2-[6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethenone (Example 77, 150 mg, 0.415 mmol) and Deoxo-Fluor® (50% in THF, 1.8 mL, 4.07 mmol, 2.26 M) was stirred at room temperature for 24 h, then at 80° C. for 2 h. The reaction was quenched with saturated sodium bicarbonate (11 mL) at 0° C. The layers were separated and the aqueous layer was extracted with EtOAc (3×5 mL). The combined organics were dried over MgSO4, filtered and evaporated. The residue was purified by preparative HPLC (METHOD G) to afford the title compound (38 mg, 0.099 mmol, 24%) as a brown oil. MS (ESI): mass calcd. for C18H14F5N3O, 383.1; m/z found, 384.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.91 (d, J=2.0 Hz, 1H), 8.56-8.52 (m, 1H), 8.42 (d, J=1.0 Hz, 1H), 7.84 (dd, J=7.6, 2.3 Hz, 1H), 7.80-7.73 (m, 1H), 7.61 (dd, J=10.5, 8.6 Hz, 1H), 7.38 (t, J=73.2 Hz, 1H), 5.13 (t, J=13.3 Hz, 2H), 1.52-1.38 (m, 1H), 0.54-0.46 (m, 2H), 0.47-0.40 (m, 2H).
    • Example 110: 6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[(3-methyloxetan-3-yl)methyl]pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00184
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine, and 3-(bromomethyl)-3-methyloxetane instead of (chloromethyl)(ethyl)sulfane, and THE instead of DMF. MS (ESI): mass calcd. for C18H16F3N3O, 347.1; m/z found, 348.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.80 (d, J=2.0 Hz, 1H), 8.21 (d, J=0.9 Hz, 1H), 8.14 (dd, J=2.1, 0.9 Hz, 1H), 7.89-7.85 (m, 1H), 7.77-7.72 (m, 1H), 7.32-7.25 (m, 1H), 6.97 (t, J=54.9 Hz, 1H), 4.83 (d, J=6.2 Hz, 2H), 4.70 (s, 2H), 4.47 (d, J=6.2 Hz, 2H), 1.29 (s, 3H).
    • Example 111: (RS)-1-(Tetrahydrofuran-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine hydrochloride salt
  • Figure US20220324860A1-20221013-C00185
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(trifluoromethyl)phenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 8) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and 2-(chloromethyl)tetrahydrofuran instead of chloromethyl)(ethyl)sulfane. Heating was not required, and the hydrochloride salt was obtained upon treatment from 3N HCl in MeOH after purification by reversed phase HPLC (METHOD H). MS (ESI): mass calcd. for C18H16F3N3O, 347.1; m/z found, 348.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.95 (d, J=1.85 Hz, 1H), 8.63 (dd, J=1.85, 0.92 Hz, 1H), 8.37 (d, J=0.92 Hz, 1H), 8.23-8.04 (m, 2H), 7.93-7.70 (m, 2H), 4.73-4.51 (m, 2H), 4.41-4.16 (m, 1H), 3.70-3.64 (m, 1H), 3.61-3.51 (m, 1H), 2.07-1.90 (m, 1H), 1.86-1.53 (m, 3H).
    • Example 112: (RS)-6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(tetrahydrofuran-2-ylmethyl)pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00186
  • The title compound was prepared in a manner analogous to Example 18 using 6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 4) instead of 6-[3-(difluoromethyl)-4-fluoro-phenyl]-1H-pyrazolo[4,3-b]pyridine. MS (ESI): mass calcd. for C18H16F3N3O2, 363.1; m/z found, 364.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.86 (d, J=2.0 Hz, 1H), 8.46 (dd, J=2.0, 1.0 Hz, 1H), 8.33 (d, J=0.9 Hz, 1H), 7.84 (dd, J=7.6, 2.3 Hz, 1H), 7.80-7.75 (m, 1H), 7.59 (dd, J=10.5, 8.6 Hz, 1H), 7.39 (t, J=73.2 Hz, 1H), 4.57 (d, J=5.6 Hz, 2H), 4.32-4.26 (m, 1H), 3.71-3.64 (m, 1H), 3.62-3.55 (m, 1H), 2.00-1.91 (m, 1H), 1.83-1.62 (m, 3H).
    • Example 113: (RS)-6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-(tetrahydrofuran-3-ylmethyl)pyrazolo[4,3-b]pyridine
  • Figure US20220324860A1-20221013-C00187
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and 3-(bromomethyl)tetrahydrofuran instead of (chloromethyl)(ethyl)sulfane. Purified by prep HPLC (METHOD D). MS (ESI): mass calcd. for C18H16F3N3O, 347.1; m/z found, 348.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.78 (d, J=1.9 Hz, 1H), 8.29 (d, J=1.0 Hz, 1H), 7.93-7.81 (m, 2H), 7.81-7.70 (m, 1H), 7.30 (ddt, J=9.7, 8.5, 1.1 Hz, 1H), 6.99 (t, J=54.8 Hz, 1H), 4.41 (d, J=7.7 Hz, 2H), 3.99 (td, J=8.3, 5.4 Hz, 1H), 3.84-3.73 (m, 2H), 3.65 (dd, J=9.0, 4.7 Hz, 1H), 3.01 (ddt, J=11.6, 7.9, 3.9 Hz, 1H), 2.07 (dtd, J=13.3, 8.1, 5.4 Hz, 1H), 1.82-1.68 (m, 1H).
    • Example 114: (RS)-5-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-1-methylpyrrolidin-2-one
  • Figure US20220324860A1-20221013-C00188
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 4) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and 5-(bromomethyl)-1-methylpyrrolidin-2-one instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C19H17F3N4O2, 390.1; m/z found, 391.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.89 (d, J=1.9 Hz, 1H), 8.60-8.50 (m, 1H), 8.44-8.33 (m, 1H), 7.91-7.83 (m, 1H), 7.82-7.75 (m, 1H), 7.65-7.57 (m, 1H), 7.38 (t, J=73.2 Hz, 1H), 4.75 (dd, J=14.6, 4.6 Hz, 1H), 4.68 (dd, J=14.6, 5.2 Hz, 1H), 4.14-4.02 (m, 1H), 2.71 (s, 3H), 2.08-1.92 (m, 2H), 1.83-1.67 (m, 2H).
    • Example 115: (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one
  • Figure US20220324860A1-20221013-C00189
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and 5-(bromomethyl)-1-methylpyrrolidin-2-one instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C19H17F3N4O, 374.1; m/z found, 375.1 [M+H]+. 1H NMR (500 MHz, MeOD) δ 8.80 (d, J=1.8 Hz, 1H), 8.39 (dd, J=1.9, 1.0 Hz, 1H), 8.27 (d, J=1.0 Hz, 1H), 8.00 (ddd, J=7.5, 2.2, 1.1 Hz, 1H), 7.95 (dddd, J=8.3, 3.4, 2.2, 0.9 Hz, 1H), 7.41 (dd, J=9.9, 8.7 Hz, 1H), 7.08 (t, J=54.6 Hz, 1H), 4.83-4.66 (m, 2H), 4.35-4.07 (m, 1H), 2.85 (s, 3H), 2.34-2.05 (m, 2H), 1.95 (ddt, J=12.1, 8.9, 2.9 Hz, 1H), 1.86-1.68 (m, 1H).
    • Example 116: (RS)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one
  • Figure US20220324860A1-20221013-C00190
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and 3-(bromomethyl)-1-methylpyrrolidin-2-one instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C19H17F3N4O, 374.1; m/z found, 375.1 [M+H]+. 1H NMR (500 MHz, MeOD) δ 8.81 (d, J=1.9 Hz, 1H), 8.44 (dd, J=1.9, 1.0 Hz, 1H), 8.26 (d, J=1.0 Hz, 1H), 8.07-7.94 (m, 2H), 7.50-7.40 (m, 1H), 7.11 (t, J=54.6 Hz, 1H), 4.82-4.76 (m, 2H), 3.39-3.28 (m, 1H), 3.20-3.04 (m, 2H), 2.75 (d, J=0.8 Hz, 3H), 2.20 (dddd, J=13.2, 9.3, 8.2, 4.0 Hz, 1H), 2.02 (dddd, J=13.1, 8.9, 7.9, 7.0 Hz, 1H).
    • Example 117: (S)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one
  • Figure US20220324860A1-20221013-C00191
  • The title compound was prepared by the separation of Example 116 using chiral SFC (Stationary phase: Chiralpak IC, 5 um 250×21 mm, Mobile phase: 30% methanol, 70% CO2). MS (ESI): mass calcd. for C19H17F3N4O, 374.1; m/z found, 375.1 [M+H]+.
    • Example 118: (R)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one
  • Figure US20220324860A1-20221013-C00192
  • The title compound was prepared by the separation of Example 116 using chiral SFC (Stationary phase: Chiralpak IC, 5 μM 250×21 mm, Mobile phase: 30% methanol, 70% CO2). MS (ESI): mass calcd. for C19H17F3N4O, 374.1; m/z found, 375.1 [M+H]+.
    • Example 119: (RS) 3-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-1-methylpyrrolidin-2-one
  • Figure US20220324860A1-20221013-C00193
  • The title compound was prepared in a manner analogous to Example 19 using 3-(bromomethyl)-1-methylpyrrolidin-2-one instead of 4-(chloromethyl)-1-methyl-pyrrolidin-2-one. MS (ESI): mass calcd. for C19H17F3N4O2, 390.4; m/z found, 391.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.87 (d, J=2.0 Hz, 1H), 8.52-8.49 (m, 1H), 8.35 (d, J=1.0 Hz, 1H), 7.86 (dd, J=7.6, 2.3 Hz, 1H), 7.82-7.75 (m, 1H), 7.60 (dd, J=10.5, 8.6 Hz, 1H), 7.38 (t, J=73.2 Hz, 1H), 4.74-4.65 (m, 2H), 3.23-3.16 (m, 1H), 3.07-2.99 (m, 2H), 2.66 (s, 3H), 1.98-1.90 (m, 1H), 1.81-1.71 (m, 1H).
    • Example 120: (RS)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one
  • Figure US20220324860A1-20221013-C00194
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and 4-(bromomethyl)-1-methyl-2-pyrrolidinone instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C19H17F3N4O, 374.1; m/z found, 375.1 [M+H]+. 1H NMR (500 MHz, MeOD) δ 8.81 (d, J=1.9 Hz, 1H), 8.44 (dd, J=1.8, 1.0 Hz, 1H), 8.25 (d, J=1.0 Hz, 1H), 8.08-7.93 (m, 2H), 7.42 (tt, J=9.7, 1.0 Hz, 1H), 7.08 (t, J=54.6 Hz, 1H), 4.68-4.51 (m, 2H), 3.52 (dd, J=10.3, 8.1 Hz, 1H), 3.38 (dd, J=10.3, 5.4 Hz, 1H), 3.19-3.06 (m, 1H), 2.84-2.73 (m, 3H), 2.53 (dd, J=17.0, 8.9 Hz, 1H), 2.31 (dd, J=17.0, 6.3 Hz, 1H).
    • Example 121: (S)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one
  • Figure US20220324860A1-20221013-C00195
  • The title compound was prepared by the separation of Example 120 using chiral SFC (Stationary phase: CHIRALPAK AD-H 5 μm 250*30 mm, Mobile phase: 75% CO2, 25% MeOH). MS (ESI): mass calcd. for C19H17F3N4O, 374.1; m/z found, 375.0 [M+H]+.
    • Example 122: (R)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one
  • Figure US20220324860A1-20221013-C00196
  • The title compound was prepared by the separation of Example 120 using chiral SFC (Stationary phase: CHIRALPAK AD-H 5 μm 250*30 mm, Mobile phase: 75% CO2, 25% MeOH). MS (ESI): mass calcd. for C19H17F3N4O, 374.1; m/z found, 375.0 [M+H]+.
    • Example 123: (R,S)-4-((6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-3-methyloxazolidin-2-one
  • Figure US20220324860A1-20221013-C00197
  • The title compound was prepared in a manner analogous to Example 18 using 6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 4) instead of 6-[3-(difluoromethyl)-4-fluoro-phenyl]-1H-pyrazolo[4,3-b]pyridine, and (RS)-4-(chloromethyl)-3-methyloxazolidin-2-one (Intermediate 20) instead of 2-(chloromethyl)oxolane. MS (ESI): mass calcd. for C18H15F3N4O3, 392.1; m/z found, 393.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.90 (d, J=1.9 Hz, 1H), 8.62-8.58 (m, 1H), 8.42-8.39 (m, 1H), 7.87 (dd, J=7.6, 2.3 Hz, 1H), 7.82-7.77 (m, 1H), 7.61 (dd, J=10.5, 8.6 Hz, 1H), 7.38 (t, J=73.2 Hz, 1H), 4.83 (dd, J=14.8, 4.1 Hz, 1H), 4.73 (dd, J=14.7, 4.6 Hz, 1H), 4.39-4.28 (m, 2H), 4.13 (dd, J=8.0, 4.0 Hz, 1H), 2.75 (s, 3H).
    • Example 124: (RS)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00198
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and (RS)-4-(chloromethyl)-3-methyloxazolidin-2-one (Intermediate 20) instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C18H15F3N4O2, 376.1; m/z found, 377.1 [M+H]+. 1H NMR (500 MHz, MeOD) δ 8.82 (d, J=1.9 Hz, 1H), 8.44 (dd, J=1.9, 1.0 Hz, 1H), 8.28 (d, J=1.0 Hz, 1H), 8.07-7.99 (m, 1H), 7.99-7.93 (m, 1H), 7.42 (dd, J=9.9, 8.7 Hz, 1H), 7.08 (t, J=54.6 Hz, 1H), 4.86-4.80 (m, 1H), 4.77-4.69 (m, 1H), 4.47-4.33 (m, 2H), 4.33-4.23 (m, 1H), 2.87 (s, 3H).
    • Example 125: (RS)-5-[[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00199
  • The title compound was prepared in a manner analogous to Example 20, using 6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 4) instead of 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine. MS (ESI): mass calcd. for C17H13F3N4O3, 378.1; m/z found, 379.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J=1.9 Hz, 1H), 8.52-8.48 (m, 1H), 8.39 (d, J=0.9 Hz, 1H), 7.85 (dd, J=7.6, 2.3 Hz, 1H), 7.80-7.75 (m, 1H), 7.61 (dd, J=10.5, 8.6 Hz, 1H), 7.52-7.48 (m, 1H), 7.38 (t, J=73.2 Hz, 1H), 5.08-5.00 (m, 1H), 4.83 (dd, J=15.0, 6.2 Hz, 1H), 4.77 (dd, J=14.9, 4.6 Hz, 1H), 3.66-3.60 (m, 1H), 3.38-3.33 (m, 1H).
    • Example 126: (RS)-5-[[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00200
  • The title compound was prepared in a manner analogous to Example 20, using 6-(4-chloro-3-(difluoromethoxy)phenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 5) instead of 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine. MS (ESI): mass calcd. for C17H13ClF2N4O3, 394.1; m/z found, 395.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.91 (d, J=1.9 Hz, 1H), 8.58-8.49 (m, 1H), 8.43-8.36 (m, 1H), 7.87-7.72 (m, 3H), 7.55-7.47 (m, 1H), 7.44 (t, J=73.2 Hz, 1H), 5.12-4.97 (m, 1H), 4.90-4.73 (m, 2H), 3.63 (t, J=9.0 Hz, 1H), 3.42-3.30 (m, 1H).
    • Example 127: (RS)-5-[[6-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00201
  • The title compound was prepared in a manner analogous to Example 20, using 6-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 6) instead of 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine. MS (ESI): mass calcd. for C18H15F3N4O2, 376.1; m/z found, 377.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J=1.9 Hz, 1H), 8.53-8.50 (m, 1H), 8.39 (d, J=1.0 Hz, 1H), 8.05-7.99 (m, 1H), 7.99-7.95 (m, 1H), 7.56 (dd, J=11.0, 8.6 Hz, 1H), 7.52-7.47 (m, 1H), 5.08-5.00 (m, 1H), 4.84 (dd, J=14.9, 6.2 Hz, 1H), 4.79 (dd, J=14.9, 4.4 Hz, 1H), 3.66-3.60 (m, 1H), 3.38-3.33 (m, 1H), 2.10 (t, J=19.1 Hz, 3H).
    • Example 128: (RS)-5-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-3-methyloxazolidin-2-one
  • Figure US20220324860A1-20221013-C00202
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 4) instead of 6-bromo-1H-pyrazolo[4,3-B]pyridine, and 5-(chloromethyl)-3-methyloxazolidin-2-one instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C18H15F3N4O3, 392.1; m/z found, 393.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.89 (d, J=1.9 Hz, 1H), 8.55-8.46 (m, 1H), 8.43-8.35 (m, 1H), 7.90-7.82 (m, 1H), 7.81-7.72 (m, 1H), 7.61 (dd, J=10.4, 8.7 Hz, 1H), 7.37 (t, J=73.1 Hz, 1H), 5.03-4.92 (m, 1H), 4.90-4.73 (m, 2H), 3.76-3.65 (m, 1H), 3.43 (dd, J=9.0, 5.9 Hz, 1H), 2.67 (s, 3H).
    • Example 129: (5R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00203
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and (R)-5-(chloromethyl)-3-methyloxazolidin-2-one (Intermediate 18) instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C18H15F3N4O2, 376.1; m/z found, 377.1 [M+H]+. 1H NMR (500 MHz, MeOD) δ 8.79 (d, J=1.9 Hz, 1H), 8.38 (dd, J=1.9, 1.0 Hz, 1H), 8.27 (d, J=1.0 Hz, 1H), 8.06-7.93 (m, 2H), 7.41 (dd, J=9.9, 8.7 Hz, 1H), 7.07 (t, J=54.6 Hz, 1H), 5.04 (dtd, J=9.1, 5.6, 3.4 Hz, 1H), 4.92-4.75 (m, 2H), 3.78 (t, J=9.1 Hz, 1H), 3.61 (dd, J=9.2, 5.6 Hz, 1H), 2.70 (s, 3H).
    • Example 130: (5S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00204
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and (S)-5-(chloromethyl)-3-methyloxazolidin-2-one (Intermediate 19) instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C18H15F3N4O2, 376.1; m/z found, 377.1 [M+H]+. 1H NMR (500 MHz, MeOD) δ 8.76 (dd, J=1.7, 0.9 Hz, 1H), 8.35 (dt, J=1.8, 0.8 Hz, 1H), 8.29-8.22 (m, 1H), 7.97 (dd, J=7.0, 2.1 Hz, 1H), 7.92 (d, J=6.3 Hz, 1H), 7.37 (t, J=9.5 Hz, 1H), 7.06 (t, J=54.6 Hz, 1H), 5.02 (dtd, J=9.2, 5.7, 3.5 Hz, 1H), 4.87-4.74 (m, 2H), 3.77 (t, J=9.1 Hz, 1H), 3.59 (dd, J=9.2, 5.7 Hz, 1H), 2.70 (s, 3H).
    • Example 131: (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-ethyl-oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00205
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and 5-(bromomethyl)-3-ethyl-1,3-oxazolidin-2-one instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C19H17F3N4O2, 390.1; m/z found, 391.2 [M+H]+. 1H NMR (500 MHz, MeOD) δ 8.79 (d, J=1.9 Hz, 1H), 8.38 (dd, J=1.9, 1.0 Hz, 1H), 8.27 (d, J=1.0 Hz, 1H), 8.05-7.93 (m, 2H), 7.41 (dd, J=10.0, 8.7 Hz, 1H), 7.07 (t, J=54.6 Hz, 1H), 5.06 (dtd, J=9.0, 5.2, 3.1 Hz, 1H), 4.94-4.87 (m, 1H), 4.82-4.74 (m, 1H), 3.77 (t, J=9.2 Hz, 1H), 3.63 (dd, J=9.2, 5.3 Hz, 1H), 3.17-3.00 (m, 2H), 0.90 (t, J=7.3 Hz, 3H).
    • Example 132: (S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-ethyl-oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00206
  • The title compound was prepared by the separation of Example 131 using chiral SFC (Stationary phase: Chiralpak IA, Sum 250×21 mm, Mobile phase: 35% methanol with 0.2% triethylamine, 65% CO2). MS (ESI): mass calcd. for C19H17F3N4O2, 390.1; m/z found, 391.2 [M+H]+.
    • Example 133: (R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-ethyl-oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00207
  • The title compound was prepared by the separation of Example 131 using chiral SFC (Stationary phase: Chiralpak IA, Sum 250×21 mm, Mobile phase: 35% methanol with 0.2% triethylamine, 65% CO2). MS (ESI): mass calcd. for C19H17F3N4O2, 390.1; m/z found, 391.2 [M+H]+.
    • Example 134: (RS)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00208
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine, and 5-(bromomethyl)-3-cyclopropyl-1,3-oxazolidin-2-one instead of (chloromethyl)(ethyl)sulfane. MS (ESI): mass calcd. for C20H17F3N4O2, 402.1; m/z found, 403.2 [M+H]+. 1H NMR (500 MHz, MeOD) δ 8.79 (d, J=1.9 Hz, 1H), 8.35 (dd, J=1.9, 1.0 Hz, 1H), 8.27 (d, J=1.0 Hz, 1H), 8.05-7.94 (m, 2H), 7.45-7.37 (m, 1H), 7.07 (t, J=54.6 Hz, 1H), 5.01 (dtd, J=9.2, 4.7, 3.0 Hz, 1H), 4.93-4.86 (m, 1H), 4.80-4.63 (m, 1H), 3.78 (t, J=9.1 Hz, 1H), 3.58 (dd, J=9.2, 4.7 Hz, 1H), 2.29 (tt, J=7.0, 3.6 Hz, 1H), 0.66-0.51 (m, 2H), 0.35 (dtd, J=11.1, 3.7, 2.1 Hz, 1H), 0.16 (dtd, J=10.2, 3.6, 2.0 Hz, 1H).
    • Example 135: (S)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00209
  • The title compound was prepared by the separation of Example 134 using chiral SFC (Stationary phase: Chiralpak AS, Sum 250×21 mm, Mobile phase: 15% methanol:isopropanol (1:1) with 0.2% isopropylamine, 85% CO2). MS (ESI): mass calcd. for C20H17F3N4O2, 402.1; m/z found, 403.2 [M+H]+.
    • Example 136: (R)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one
  • Figure US20220324860A1-20221013-C00210
  • The title compound was prepared by the separation of Example 134 using chiral SFC (Stationary phase: Chiralpak AS, 5 um 250×21 mm, Mobile phase: 15% methanol:isopropanol (1:1) with 0.2% isopropylamine, 85% CO2). MS (ESI): mass calcd. for C20H17F3N4O2, 402.1; m/z found, 403.2 [M+H]+.
    • Example 137: 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(2-thienyl)ethanone
  • Figure US20220324860A1-20221013-C00211
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 2-chloro-1-(thiophen-2-yl)ethan-1-one instead of (chloromethyl)(ethyl)sulfane, and 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine. MS (ESI): mass calcd. for C19H12F3N3OS, 387.1; m/z found, 388.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.92 (d, J=1.9 Hz, 1H), 8.59-8.52 (m, 1H), 8.46-8.37 (m, 1H), 8.30-8.22 (m, 1H), 8.18-8.12 (m, 1H), 8.10-8.01 (m, 2H), 7.61-7.50 (m, 1H), 7.41-7.35 (m, 1H), 7.28 (t, J=54.2 Hz, 1H), 6.20 (s, 2H).
    • Example 138: 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(3-thienyl)ethanone
  • Figure US20220324860A1-20221013-C00212
  • The title compound was prepared in a manner analogous to Intermediate 16, Step A, using 2-chloro-1-(thiophen-3-yl)ethan-1-one instead of (chloromethyl)(ethyl)sulfane, and 6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (Intermediate 3) instead of 6-bromo-1H-pyrazolo[4,3-b]pyridine. MS (ESI): mass calcd. for C19H12F3N3OS, 387.1; m/z found, 388.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.91 (d, J=1.9 Hz, 1H), 8.76 (dd, J=2.9, 1.3 Hz, 1H), 8.56-8.52 (m, 1H), 8.41 (d, J=1.0 Hz, 1H), 8.09-8.01 (m, 2H), 7.74 (dd, J=5.0, 2.8 Hz, 1H), 7.60 (dd, J=5.1, 1.3 Hz, 1H), 7.58-7.51 (m, 1H), 7.28 (t, J=54.1 Hz, 1H), 6.15 (s, 2H).
    • Example 139: 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(4-pyridyl)ethanone
  • Figure US20220324860A1-20221013-C00213
  • The title compound was prepared in a manner analogous to Example 14 using 2-bromo-1-(pyridin-4-yl)ethan-1-one (Intermediate 22) instead of 2-bromo-1-(2-pyridyl)ethanone hydrobromide. MS (ESI): mass calcd. for C20H13F3N4O, 382.1; m/z found, 383.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.97-8.85 (m, 3H), 8.57-8.51 (m, 1H), 8.46-8.40 (m, 1H), 8.09-8.00 (m, 2H), 7.99-7.94 (m, 2H), 7.59-7.51 (m, 1H), 7.28 (t, J=54.1 Hz, 1H), 6.32 (s, 2H).
    • Example 140: 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(3-fluoropyridin-2-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00214
  • The title compound was prepared in a manner analogous to Example 15 using 2-bromo-1-(3-fluoropyridin-2-yl)ethan-1-one (Intermediate 24) instead of 2-bromo-1-(5-fluoropyridin-2-yl)ethan-1-one. MS (ESI): mass calcd. for C20H12F4N4O, 400.1; m/z found, 401.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.99-8.86 (m, 1H), 8.74-8.65 (m, 1H), 8.61-8.53 (m, 1H), 8.46-8.38 (m, 1H), 8.05 (d, J=6.2 Hz, 2H), 8.02-7.94 (m, 1H), 7.92-7.83 (m, 1H), 7.60-7.49 (m, 1H), 7.28 (t, J=54.1 Hz, 1H), 6.25 (s, 2H).
    • Example 141: 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(3,5-difluoropyridin-2-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00215
  • The title compound was prepared in a manner analogous to Example 15 using 2-bromo-1-(3,5-difluoropyridin-2-yl)ethan-1-one (Intermediate 23) instead of 2-bromo-1-(5-fluoropyridin-2-yl)ethan-1-one. MS (ESI): mass calcd. for C20H11F5N4O, 418.1; m/z found, 419.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.91 (d, J=2.0 Hz, 1H), 8.80 (d, J=2.3 Hz, 1H), 8.56-8.51 (m, 1H), 8.43-8.41 (m, 1H), 8.24-8.18 (m, 1H), 8.08-8.02 (m, 2H), 7.60-7.52 (m, 1H), 7.28 (t, J=54.2 Hz, 1H), 6.22 (s, 2H).
    • Example 142: 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(pyrazin-2-yl)ethan-1-one
  • Figure US20220324860A1-20221013-C00216
  • The title compound was prepared in a manner analogous to Example 15 using 2-bromo-1-(pyrazin-2-yl)ethan-1-one (Intermediate 25) instead of 2-bromo-1-(5-fluoropyridin-2-yl)ethan-1-one. MS (ESI): mass calcd. for C20H11F5N4O, 383.1; m/z found, 384.1 [M+H]+. 1H NMR (500 MHz, Methanol-d4) δ 9.20 (d, J=1.5 Hz, 1H), 8.91-8.89 (m, 1H), 8.85 (d, J=1.9 Hz, 1H), 8.84-8.82 (m, 1H), 8.38-8.36 (m, 1H), 8.34-8.31 (m, 1H), 7.97-7.91 (m, 2H), 7.42-7.37 (m, 1H), 7.06 (t, J=54.6 Hz, 1H), 6.31 (s, 2H). NMR in MeOH results in mixture of ketone and methanol hemiacetal
    • BIOLOGICAL ASSAYS
  • Effects of Test Articles on Cloned Human NR1/GluN2B Ion Channels Expressed in Mammalian Cells
  • NMDA receptors are ion channels that are highly permeable to Ca2+ ions, rendering it possible to monitor NMDA receptor function using cell-based calcium flux assay. In this assay, co-agonists glutamate and glycine are added to cells heterologously expressing human GluN1/GluN2B NMDA receptors to initiate cellular Ca2+ influx. The time course of the changes in intracellular calcium is measured using a fluorescent dye and a FLIPR (Fluorometric Imaging Plate Reader) device.
  • Twenty four hours before measurements, the expression of the NMDA receptors in the stable cell line is induced with Tet-On inducible system in the presence of a non-selective NMDA receptor blocker. On the day of the experiment, cell culture media is carefully washed and the cells are loaded with Calcium 5 Dye Kit (Molecular Devices) in dye loading buffer containing 137 mM NaCl, 4 mM KCl, 2 mM CaCl2), 0.5 mM MgCl2 (standard assay) or 1.5 mM MgCl2 (HTS assay), 10 mM HEPES and 5 mM D-glucose; pH 7.4. After 1 h incubation at the room temperature, the dye is washed away with the assay buffer (137 mM NaCl (standard assay) or 150 mM (HTS assay), 4 mM KCl (standard assay) or 3 mM (HTS assay), 2 mM CaCl2), 0.01 mM EDTA, 10 mM HEPES and 5 mM D-glucose; pH 7.4) In the FLIPR TETRA reader, various concentrations of the test compounds are added to the cells for 5 min while fluorescence is monitored to detect potential agonist activity. Next, co-agonists, glutamate and glycine are added for another 5 minutes. The concentration of glutamate corresponding to ˜EC40 (standard assay) or EC40 (HTS assay) is used to maximize the assay's signal window and ability to detect NMDA receptor antagonists and negative allosteric modulators. A saturating concentration (10 μM) of glycine is also present in the assay. A non-selective NMDA receptor antagonist, (+)MK-801 is used as a positive control for antagonist activity. The fluorescent signal in the presence of test compounds is quantified and normalized to the signal defined by the appropriate control wells.
  • TABLE 3
    GluN2B
    Standard Assay
    Ex # Compound Name IC50 (μM)
    1 1-[6-(3,5-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan- 0.019
    2-one;
    2 3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3- 0.061
    b]pyridin-1-yl]butan-2-one;
    3 (RS)-3-Methyl-1-[6-[3- 0.567
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-
    2-ol;
    4 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.010
    b]pyridin-1-yl]butan-2-one;
    5 (RS)-1-[6-[3-(Difluoromethyl)-4-fluoro- 0.048
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    6 (E/Z)-3-Methyl-1-[6-[3- 2.480
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-
    2-one oxime;
    7 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1- 0.021
    yl]-3-methyl-butan-2-one;
    8 (RS)-1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3- 0.222
    b]pyridin-1-yl]-3-methyl-butan-2-ol;
    9 1-Cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3- 0.030
    b]pyridin-1-yl]ethanone;
    10 (RS)-1-Cyclopropyl-2-[6-(3,4,5- 0.696
    trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
    11 (RS)-1-(2-Cyclopropyl-2-methoxy-ethyl)-6-(3,4,5- 1.780
    trifluorophenyl)pyrazolo[4,3-b]pyridine;
    12 (RS)-6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1- 0.146
    (ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine;
    13 6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1- 1.800
    (ethylsulfonylmethyl)pyrazolo[4,3-b]pyridine;
    14 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.112
    b]pyridin-1-yl]-1-(2-pyridyl)ethanone;
    15 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3- 0.160
    b]pyridin-1-yl)-1-(5-fluoropyridin-2-yl)ethan-1-one;
    16 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3- 0.090
    b]pyridin-1-yl)-1-(pyridin-3-yl)ethan-1-one;
    17 (RS)-1-(Oxetan-2-ylmethyl)-6-[3- 0.085
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
    18 (RS)-6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1- 0.035
    (tetrahydrofuran-2-ylmethyl)pyrazolo[4,3-b]pyridine;
    19 (RS)-4-[[6-[3-(Difluoromethoxy)-4-fluoro- 0.992
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-
    pyrrolidin-2-one;
    20 (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro- 0.197
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-
    one;
    21 (S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 1.840
    b]pyridin-1-yl]methyl]oxazolidin-2-one;
    22 (R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.187
    b]pyridin-1-yl]methyl]oxazolidin-2-one;
    23 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.014
    b]pyridin-1-yl]propan-2-one;
    24 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1- 0.015
    yl]propan-2-one;
    25 1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3- 0.034
    b]pyridin-1-yl]propan-2-one;
    26 1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3- 0.036
    b]pyridin-1-yl]propan-2-one;
    27 1-[6-(5-Chloro-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]butan- 0.013
    2-one;
    28 1-[6-(4-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2- 0.032
    one;
    29 1-[6-(3-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2- 0.028
    one;
    30 1-[6-[3-(Difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1- 0.027
    yl]butan-2-one;
    31 1-[6-[3-(1,1-Difluoroethyl)phenyl]pyrazolo[4,3-b]pyridin-1- 0.035
    yl]butan-2-one;
    32 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1- 0.012
    yl]butan-2-one;
    33 1-[6-(2,3-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan- 0.046
    2-one;
    34 1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan- 0.017
    2-one;
    35 1-[6-(3,4-Difluorophenyl)-3-fluoro-pyrazolo[4,3-b]pyridin- 0.005
    1-yl]butan-2-one;
    36 1-(6-(3-(Difluoromethyl)-4-fluorophenyl)-3-methyl-1H- 0.027
    pyrazolo[4,3-b]pyridin-1-yl)butan-2-one;
    37 1-[6-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.041
    b]pyridin-1-yl]butan-2-one;
    38 1-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3- 0.030
    b]pyridin-1-yl]butan-2-one;
    39 1-[6-[4-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3- 0.075
    b]pyridin-1-yl]butan-2-one;
    40 1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3- 0.011
    b]pyridin-1-yl]butan-2-one;
    41 1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3- 0.021
    b]pyridin-1-yl]butan-2-one;
    42 1-[6-(3,4,5-Trifluorophenyl)pyrazolo[4,3-b]pyridin-1- 0.027
    yl]butan-2-one;
    43 1-[6-(2,3,4-Trifluorophenyl)pyrazolo[4,3-b]pyridin-1- 0.028
    yl]butan-2-one;
    44 3-Methyl-1-(6-phenylpyrazolo[4,3-b]pyridin-1-yl)butan-2- 0.089
    one;
    45 1-[6-(4-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl- 0.036
    butan-2-one;
    46 1-[6-(3-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl- 0.030
    butan-2-one;
    47 1-[6-[3-(Difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1- 0.023
    yl]-3-methyl-butan-2-one;
    48 1-[6-(2,3-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3- 0.172
    methyl-butan-2-one;
    49 1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3- 0.025
    methyl-butan-2-one;
    50 1-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3- 0.076
    b]pyridin-1-yl]-3-methyl-butan-2-one;
    51 1-[6-[4-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3- 0.296
    b]pyridin-1-yl]-3-methyl-butan-2-one;
    52 1-[6-(4-Fluoro-2-methyl-phenyl)pyrazolo[4,3-b]pyridin-1- 0.090
    yl]-3-methyl-butan-2-one;
    53 3-Methyl-1-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin- 0.041
    1-yl]butan-2-one;
    54 3-Methyl-1-[6-(2,3,4-trifluorophenyl)pyrazolo[4,3-b]pyridin- 0.205
    1-yl]butan-2-one;
    55 2-[6-(5-Chloro-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]-1- 0.008
    cyclopropyl-ethanone;
    56 1-Cyclopropyl-2-[6-(5-methyl-2-thienyl)pyrazolo[4,3- 0.015
    b]pyridin-1-yl]ethanone;
    57 1-Cyclopropyl-2-[6-(3-fluorophenyl)pyrazolo[4,3-b]pyridin- 0.026
    1-yl]ethanone;
    58 1-Cyclopropyl-2-[6-(2-fluorophenyl)pyrazolo[4,3-b]pyridin- 0.148
    1-yl]ethanone;
    59 1-Cyclopropyl-2-[6-(4-fluorophenyl)pyrazolo[4,3-b]pyridin- 0.013
    1-yl]ethanone;
    60 1-Cyclopropyl-2-[6-(m-tolyl)pyrazolo[4,3-b]pyridin-1- 0.008
    yl]ethanone;
    61 1-Cyclopropyl-2-[6-[3-(difluoromethyl)phenyl]pyrazolo[4,3- 0.012
    b]pyridin-1-yl]ethanone;
    62 1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3- 0.046
    b]pyridin-1-yl]ethanone;
    63 1-Cyclopropyl-2-[6-[3- 0.031
    (trifluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    64 1-Cyclopropyl-2-[6-(2,3-difluorophenyl)pyrazolo[4,3- 0.037
    b]pyridin-1-yl]ethanone;
    65 1-Cyclopropyl-2-[6-(3,4-difluorophenyl)pyrazolo[4,3- 0.013
    b]pyridin-1-yl]ethanone;
    66 1-Cyclopropyl-2-[6-(3,5-difluorophenyl)pyrazolo[4,3- 0.019
    b]pyridin-1-yl]ethanone;
    67 2-[6-(3-Chloro-2-fluoro-phenyl)pyrazolo[4,3-b]pyridin-1- 0.016
    yl]-1-cyclopropyl-ethanone;
    68 2-[6-(3-Chloro-4-fluoro-phenyl)pyrazolo[4,3-b]pyridin-1- 0.007
    yl]-1-cyclopropyl-ethanone;
    69 1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3- 0.019
    b]pyridin-1-yl]ethanone;
    70 1-Cyclobutyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3- 0.063
    b]pyridin-1-yl]ethanone;
    71 1-Cyclopropyl-2-[6-(2-fluoro-3-methyl-phenyl)pyrazolo[4,3- 0.007
    b]pyridin-1-yl]ethanone;
    72 1-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)pyrazolo[4,3- 0.199
    b]pyridin-1-yl]ethanone;
    73 1-Cyclopropyl-2-[6-[2-fluoro-3- 0.043
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    74 1-Cyclopropyl-2-[6-[4-fluoro-3- 0.036
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]ethanone;
    75 2-[6-[4-Chloro-3-(trifluoromethyl)phenyl]pyrazolo[4,3- 0.076
    b]pyridin-1-yl]-1-cyclopropyl-ethanone;
    76 1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro- 0.018
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    77 1-Cyclopropyl-2-[6-[3-(difluoromethoxy)-4-fluoro- 0.014
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    78 1-Cyclopropyl-2-[6-(4-fluoro-2,3-dimethyl- 0.085
    phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    79 1-Cyclopropyl-2-[6-(2,3,4-trifluorophenyl)pyrazolo[4,3- 0.030
    b]pyridin-1-yl]ethanone;
    80 (RS)-1-(Ethylsulfinylmethyl)-6-(3- 0.823
    fluorophenyl)pyrazolo[4,3-b]pyridine;
    81 (RS)-1-(Ethylsulfinylmethyl)-6-[3- 0.128
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
    82 (RS)6-(3,4-Difluorophenyl)-1- 0.893
    (ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine;
    83 (RS)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1- 0.034
    ((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
    84 (S*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1- 0.029
    ((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
    85 (R*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1- 0.066
    ((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
    86 (RS)-1-(Ethylsulfinylmethyl)-6-[2-fluoro-3- 0.080
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
    87 (RS)-6-[4-Chloro-3-(difluoromethoxy)phenyl]-1- 0.109
    (ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine;
    88 (RS)-1-(Ethylsulfinylmethyl)-6-(3,4,5- 0.736
    trifluorophenyl)pyrazolo[4,3-b]pyridine;
    89 6-(4-Fluoro-3-methyl-phenyl)-1-(2- 0.754
    methoxyethyl)pyrazolo[4,3-b]pyridine;
    90 (RS)-4-Methoxy-1-[6-[3- 1.420
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-
    2-ol;
    91 (RS)-1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1- 0.526
    yl]butan-2-ol;
    92 (RS)-1-[6-[3-(Difluoromethoxy)-4-fluoro- 0.282
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    93 (RS)-1-[6-[4-Chloro-3- 0.415
    (difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-
    2-ol;
    94 (RS)-1-[6-(3,4-Difluorophenyl)-3-fluoro-pyrazolo[4,3- 0.965
    b]pyridin-1-yl]butan-2-ol;
    95 (RS)-1-[6-[3-(1,1-Difluoroethyl)phenyl]pyrazolo[4,3- 0.272
    b]pyridin-1-yl]butan-2-ol;
    96 (RS)-3-Methyl-1-(6-phenylpyrazolo[4,3-b]pyridin-1- 1.530
    yl)butan-2-ol;
    97 (RS)-3-Methyl-1-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3- 0.591
    b]pyridin-1-yl]butan-2-ol;
    98 1-(2,2-Difluorobutyl)-6-[3-(difluoromethyl)-4-fluoro- 0.089
    phenyl]pyrazolo[4,3-b]pyridine;
    99 1-(2,2-Difluorobutyl)-6-[3-(difluoromethoxy)-4-fluoro- 0.213
    phenyl]pyrazolo[4,3-b]pyridine;
    100 (RS)-1-Cyclopropyl-2-[6-[3- 0.290
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanol;
    101 (RS)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl- 0.167
    phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
    102 (R)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl- 0.109
    phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
    103 (S)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl- 0.272
    phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
    104 (RS)-1-Cyclopropyl-2-(6-(3-(difluoromethyl)-4- 0.165
    fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)ethan-1-ol;
    105 (E/Z)-N-Methoxy-3-methyl-1-[6-[3- 5.250
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-
    2-imine;
    106 (E/Z)-1-Cyclopropyl-2-[6-[3- 1.490
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]ethanone oxime;
    107 (E/Z)-1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro- 0.065
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone oxime;
    108 1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3-(difluoromethyl)- 0.045
    4-fluoro-phenyl]pyrazolo[4,3-b]pyridine;
    109 1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3- 0.069
    (difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine;
    110 6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[(3-methyloxetan- 2.060
    3-yl)methyl]pyrazolo[4,3-b]pyridine;
    111 (RS)-1-(Tetrahydrofuran-2-ylmethyl)-6-[3- 0.093
    (trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
    112 (RS)-6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1- 0.113
    (tetrahydrofuran-2-ylmethyl)pyrazolo[4,3-b]pyridine;
    113 (RS)-6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1- 0.023
    (tetrahydrofuran-3-ylmethyl)pyrazolo[4,3-b]pyridine;
    114 (RS)-5-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H- >2.99985
    pyrazolo[4,3-b]pyridin-1-yl)methyl)-1-methylpyrrolidin-2-
    one;
    115 (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro- >2.99985
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-
    pyrrolidin-2-one;
    116 (RS)-3-[[6-[3-(Difluoromethyl)-4-fluoro- 0.303
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-
    pyrrolidin-2-one;
    117 (S)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 1.210
    b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    118 (R)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.125
    b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    119 (RS)-3-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H- 0.352
    pyrazolo[4,3-b]pyridin-1-yl)methyl)-1-methylpyrrolidin-2-
    one;
    120 (RS)-4-[[6-[3-(Difluoromethyl)-4-fluoro- 0.089
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-
    pyrrolidin-2-one;
    121 (S)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.685
    b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    122 (R)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.120
    b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    123 (RS)-4-((6-(3-(difluoromethoxy)-4-fluorophenyl)-1H- 2.830
    pyrazolo[4,3-b]pyridin-1-yl)methyl)-3-methyloxazolidin-2-
    one;
    124 (RS)-4-[[6-[3-(Difluoromethyl)-4-fluoro- 1.890
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-
    oxazolidin-2-one;
    125 (RS)-5-[[6-[3-(Difluoromethoxy)-4-fluoro- 0.498
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-
    one;
    126 (RS)-5-[[6-[4-Chloro-3- 0.306
    (difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-
    yl]methyl]oxazolidin-2-one;
    127 (RS)-5-[[6-[3-(1,1-Difluoroethyl)-4-fluoro- 0.973
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-
    one;
    128 (RS)-5-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H- 0.165
    pyrazolo[4,3-b]pyridin-1-yl)methyl)-3-methyloxazolidin-2-
    one;
    129 (5R)-5-[[6-[3-(Difluoromethyl)-4-fluoro- 0.030
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-
    oxazolidin-2-one;
    130 (5S)-5-[[6-[3-(Difluoromethyl)-4-fluoro- 0.478
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-
    oxazolidin-2-one;
    131 (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro- 0.193
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-ethyl-
    oxazolidin-2-one;
    132 (S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 1.430
    b]pyridin-1-yl]methyl]-3-ethyl-oxazolidin-2-one;
    133 (R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.204
    b]pyridin-1-yl]methyl]-3-ethyl-oxazolidin-2-one;
    134 (RS)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro- 1.630
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-
    one;
    135 (S)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro- >2.99985
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-
    one;
    136 (R)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro- 0.997
    phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-
    one;
    137 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.036
    b]pyridin-1-yl]-1-(2-thienyl)ethanone;
    138 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.100
    b]pyridin-1-yl]-1-(3-thienyl)ethanone;
    139 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3- 0.118
    b]pyridin-1-yl]-1-(4-pyridyl)ethanone;
    140 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3- 0.191
    b]pyridin-1-yl)-1-(3-fluoropyridin-2-yl)ethan-1-one;
    141 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3- 0.409
    b]pyridin-1-yl)-1-(3,5-difluoropyridin-2-yl)ethan-1-one; and
    142 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3- 0.074
    b]pyridin-1-yl)-1-(pyrazin-2-yl)ethan-1-one.
  • Protocol for Liver Microsomal Stability (Extraction Ratio)
  • Liver Microsomal Stability. Microsomal stability studies (Chrovian et al, “1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators”. ACS Med Chem Lett. 2019 Jan. 10; 10(3):261-266) were conducted on a Biomek® FX Robotic Liquid Handling Workstation (Beckman Coulter, Brea, Calif.), which consists of a 96-channel pipette head, a 12-position workstation deck, and a plate incubator. Test compounds (1 μM) were spiked in a reaction mix consisting of 100 mM potassium phosphate buffer (pH 7.4), 3 mM MgCl2, and 0.5 mg/mL liver microsomes from mouse, rat, and human (BD Gentest). The reaction was brought to 37° C. and initiated by adding NADPH to a final concentration of 1 mM. After mixing on the plate deck, 50 μL aliquots were excised from the reaction plate at 0, 5, 10, 20, 40, and 60 min and quenched with four volumes of acetonitrile spiked with 500 μg/nL of the internal standard phenytoin. Quenched plates were centrifuged at 5700 rpm for 10 min at 4° C., and supernatant was diluted 1:3 in water before LC/MS/MS analysis. The compound half-lives were derived from plots of the ln of percent remaining compound over time to determine the intrinsic clearance. The predicted hepatic clearance was derived from the intrinsic clearance value using equations from the well-stirred model (Current Drug Metabolism, 2008, 9, 940-951), where no correction was made plasma protein binding and the blood to plasma concentration ratio was assumed to be one. The extraction ratio (ER) was calculated by dividing the predicted hepatic clearance by species blood flow (Q), where Q is 90, 55, and 21.7 mL/min/kg for mouse, rat and human, respectively.
  • Results of the assay performed on the compounds of Examples are shown in Table 4.
  • Example # Extraction Ratio @ 1 μM
    4 0.66
    25 0.64
    36 0.72
    38 0.61
    42 0.63
    61 0.43
    78 0.52
    85 0.46
    86 0.50
    131 0.58
    • SPECIFIC EMBODIMENTS
  • The present disclosure is exemplified by specific embodiments 1 to 27 below.
    • 1. A compound having the structure of Formula (I):
  • Figure US20220324860A1-20221013-C00217
      • wherein
      • R1 is H, halo, or CH3;
      • Ar1 is selected from the group consisting of:
        • (a) phenyl;
        • (b) phenyl substituted with one member selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl;
        • (c) phenyl substituted with two or three members each independently selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl; and
        • (d) thienyl substituted with one member selected from the group consisting of: halo, and C1-6alkyl;
      • R2 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00218
      •  wherein Ra is selected from the group consisting of: C1-6alkyl; C3-6cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
  • Figure US20220324860A1-20221013-C00219
      •  wherein Rb is C1-6alkyl;
        • (f) C1-6alkyl substituted with one, two, or three members each independently selected from the group consisting of: OH, halo, OC1-6alkyl, (═N—OH), (═N—OCH3), and cyclopropyl; and
        • (g) oxetanyl; oxetanyl substituted with C1-6alkyl; tetrahydrofuranyl; oxazolidinone; oxazolidinone substituted with C1-4alkyl, or cyclopropyl; and pyrrolidinone substituted with C1-4alkyl;
        • and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides thereof.
      • 2. The compound of embodiment 1, wherein R1 is H.
      • 3. The compound of embodiment 1, wherein R1 is F.
      • 4. The compound of embodiment 1, wherein R1 is CH3.
      • 5. The compound of embodiment 1, wherein Ar1 is phenyl.
      • 6. The compound of embodiment 1, wherein Ar1 is phenyl substituted with one member selected from the group consisting of: F, CH3, CF2H, CF2CH3, CF3, and OCF3.
      • 7. The compound of embodiment 1, wherein Ar1 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00220
      • 8. The compound of embodiment 1, wherein Ar1 is phenyl substituted with two members each independently selected from the group consisting of: F, Cl, CH3, CF2H, CF3, CF2CH3, and OCF2H.
      • 9. The compound of embodiment 1, wherein Ar1 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00221
      • 10. The compound of embodiment 1, wherein Ar1 is phenyl substituted with three members each independently selected from the group consisting of: F and CH3.
      • 11. The compound of embodiment 1, wherein Ar1 is
  • Figure US20220324860A1-20221013-C00222
      • 12. The compound of embodiment 1, wherein Ar1 is thienyl is substituted with Cl or CH3.
      • 13. The compound of embodiment 1, wherein Ar1 is or
  • Figure US20220324860A1-20221013-C00223
      • 14. The compound of embodiment 1, wherein R2 is
  • Figure US20220324860A1-20221013-C00224
      • 15. The compound of embodiment 1, wherein R2 is
  • Figure US20220324860A1-20221013-C00225
      • 16. The compound of embodiment 1, wherein R2 is
  • Figure US20220324860A1-20221013-C00226
      • 17. The compound of embodiment 1, wherein R2 is
  • Figure US20220324860A1-20221013-C00227
      • 18. The compound of embodiment 1, having the structure of Formula (IA):
  • Figure US20220324860A1-20221013-C00228
        • wherein
        • HAL is F or Cl;
        • R1 is H, F, or CH3;
        • R2 is selected from the group consisting of:
        • (a) (S═O)CH2CH3; (SO2)CH2CH3; or
  • Figure US20220324860A1-20221013-C00229
        •  wherein Ra is selected from the group consisting of: CH3, CH2CH3, CH(CH3)2, cyclopropyl, cyclobutyl,
  • Figure US20220324860A1-20221013-C00230
        • (b) CH2OCH3, CH(OH)(CH2CH3), CH(OH)CH(CH3)2, CF2CH2CH3, CF2(cyclopropyl), CH(OCH3)(cyclopropyl), CH(OH)(cyclopropyl), or
  • Figure US20220324860A1-20221013-C00231
        •  and
  • Figure US20220324860A1-20221013-C00232
        • Rc is H, F or CH3;
        • Rd is selected from the group consisting of: H, F, Cl, CH3, CF2H, CF2CH3, CF3, and OCF2H; and
        • Re is H or F; wherein when Re is F, Rc is H;
        • and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides thereof.
      • 19. The compound of embodiment 18, where HAL is F; R1 is H; Rc is H; and Re is H.
      • 20. The compound of embodiment 1, having the structure of Formula (IB):
  • Figure US20220324860A1-20221013-C00233
        • wherein
        • Ar1 is selected from the group consisting of:
          • (a) phenyl, 3-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 3-(difluoromethyl)phenyl, 3-(1,1-difluoroethyl)phenyl, 3-(trifluoromethyl)phenyl, 3-(trifluoromethoxy)phenyl, 5-methyl-2-thienyl, or 5-chloro-2-thienyl; and
          • (b) 2-fluoro-3-methyl-phenyl, 2,3-difluorophenyl, 3,5-difluorophenyl, 3-chloro-2-fluoro-phenyl, 2-fluoro-3-(trifluoromethyl)phenyl, 4-chloro-3-(difluoromethoxy)phenyl, or 4-chloro-3-(trifluoromethyl)phenyl; and
        • R2 is selected from the group consisting of: (S═O)CH2CH3, (C═O)CH2CH3, (C═O)CH(CH3)2, and (C═O)cyclopropyl;
        • and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides thereof.
      • 21. A compound selected from the group consisting of:
    • 1-[6-(3,5-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • (RS)-3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    • 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • (RS)-1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    • (E/Z)-3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one oxime;
    • 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
    • (RS)-1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-ol;
    • 1-Cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • (RS)-1-Cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
    • (RS)-1-(2-Cyclopropyl-2-methoxy-ethyl)-6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridine;
    • (RS)-6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine;
    • 6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(ethylsulfonylmethyl)pyrazolo[4,3-b]pyridine;
    • 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(2-pyridyl)ethanone;
    • 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(5-fluoropyridin-2-yl)ethan-1-one;
    • 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(pyridin-3-yl)ethan-1-one;
    • (RS)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
    • (RS)-6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-(tetrahydrofuran-2-ylmethyl)pyrazolo[4,3-b]pyridine;
    • (RS)-4-[[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    • (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
    • (S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
    • (R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
    • 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
    • 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
    • 1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
    • 1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
    • 1-[6-(5-Chloro-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-(4-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-(3-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-[3-(Difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-[3-(1,1-Difluoroethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-(2,3-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-(3,4-Difluorophenyl)-3-fluoro-pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-(6-(3-(Difluoromethyl)-4-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one;
    • 1-[6-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-[4-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-(3,4,5-Trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-(2,3,4-Trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 3-Methyl-1-(6-phenylpyrazolo[4,3-b]pyridin-1-yl)butan-2-one;
    • 1-[6-(4-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
    • 1-[6-(3-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
    • 1-[6-[3-(Difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
    • 1-[6-(2,3-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
    • 1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
    • 1-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
    • 1-[6-[4-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
    • 1-[6-(4-Fluoro-2-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
    • 3-Methyl-1-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 3-Methyl-1-[6-(2,3,4-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 2-[6-(5-Chloro-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone;
    • 1-Cyclopropyl-2-[6-(5-methyl-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-(3-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-(2-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-(4-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-(m-tolyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-[3-(difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-[3-(trifluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-(2,3-difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-(3,4-difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-(3, 5-difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 2-[6-(3-Chloro-2-fluoro-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone;
    • 2-[6-(3-Chloro-4-fluoro-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone;
    • 1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclobutyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-(2-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-[2-fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-[4-fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 2-[6-[4-Chloro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone;
    • 1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-(4-fluoro-2,3-dimethyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-(2,3,4-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • (RS)-1-(Ethylsulfinylmethyl)-6-(3-fluorophenyl)pyrazolo[4,3-b]pyridine;
    • (RS)-1-(Ethylsulfinylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
    • (RS) 6-(3,4-Difluorophenyl)-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine;
    • (RS)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
    • (S*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
    • (R*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
    • (RS)-1-(Ethylsulfinylmethyl)-6-[2-fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
    • (RS)-6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine;
    • (RS)-1-(Ethylsulfinylmethyl)-6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridine;
    • 6-(4-Fluoro-3-methyl-phenyl)-1-(2-methoxyethyl)pyrazolo[4,3-b]pyridine;
    • (RS)-4-Methoxy-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    • (RS)-1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    • (RS)-1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    • (RS)-1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    • (RS)-1-[6-(3,4-Difluorophenyl)-3-fluoro-pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    • (RS)-1-[6-[3-(1,1-Difluoroethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    • (RS)-3-Methyl-1-(6-phenylpyrazolo[4,3-b]pyridin-1-yl)butan-2-ol;
    • (RS)-3-Methyl-1-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
    • 1-(2,2-Difluorobutyl)-6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine;
    • 1-(2,2-Difluorobutyl)-6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine;
    • (RS)-1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanol;
    • (RS)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
    • (R)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
    • (S)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
    • (RS)-1-Cyclopropyl-2-(6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)ethan-1-ol;
    • (E/Z)—N-Methoxy-3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-imine;
    • (E/Z)-1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone oxime;
    • (E/Z)-1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone oxime;
    • 1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine;
    • 1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine;
    • 6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[(3-methyloxetan-3-yl)methyl]pyrazolo[4,3-b]pyridine;
    • (RS)-1-(Tetrahydrofuran-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
    • (RS)-6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(tetrahydrofuran-2-ylmethyl)pyrazolo[4,3-b]pyridine;
    • (RS)-6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-(tetrahydrofuran-3-ylmethyl)pyrazolo[4,3-b]pyridine;
    • (RS)-5-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-1-methylpyrrolidin-2-one;
    • (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    • (RS)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    • (S)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    • (R)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    • (RS)-3-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-1-methylpyrrolidin-2-one;
    • (RS)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    • (S)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    • (R)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
    • (RS)-4-((6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-3-methyloxazolidin-2-one;
    • (RS)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one;
    • (RS)-5-[[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
    • (RS)-5-[[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
    • (RS)-5-[[6-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
    • (RS)-5-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-3-methyloxazolidin-2-one;
    • (5R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one;
    • (5S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one;
    • (RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-ethyl-oxazolidin-2-one;
    • (S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-ethyl-oxazolidin-2-one;
    • (R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-ethyl-oxazolidin-2-one;
    • (RS)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
    • (S)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
    • (R)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
    • 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(2-thienyl)ethanone;
    • 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(3-thienyl)ethanone;
    • 2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(4-pyridyl)ethanone;
    • 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(3-fluoropyridin-2-yl)ethan-1-one;
    • 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(3,5-difluoropyridin-2-yl)ethan-1-one;
    • 2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(pyrazin-2-yl)ethan-1-one;
    • and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides thereof.
      • 22. A compound selected from the group consisting of:
    • 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
    • 1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-(6-(3-(Difluoromethyl)-4-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one;
    • 1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
    • 1-Cyclopropyl-2-[6-(4-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • 1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
    • (RS)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
    • (S*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine; and
    • (5R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one;
    • and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, or N-oxides thereof.
      • 23. A pharmaceutical composition comprising: (A) an effective amount of at least one compound selected from compounds of Formula (I):
  • Figure US20220324860A1-20221013-C00234
        • wherein
        • R1 is H, halo, or CH3;
        • Ar1 is selected from the group consisting of:
          • (a) phenyl;
          • (b) phenyl substituted with one member selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl;
          • (c) phenyl substituted with two or three members each independently selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl; and
          • (d) thienyl substituted with one member selected from the group consisting of: halo, and C1-6alkyl;
        • R2 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00235
        •  wherein Ra is selected from the group consisting of: C1-6alkyl; C3-6cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
  • Figure US20220324860A1-20221013-C00236
        •  wherein Rb is C1-6alkyl;
        • (f) C1-6alkyl substituted with one, two, or three members each independently selected from the group consisting of: OH, halo, OC1-6alkyl, (═N—OH), (═N—OCH3), and cyclopropyl; and
        • (g) oxetanyl; oxetanyl substituted with C1-6alkyl; tetrahydrofuranyl; oxazolidinone; oxazolidinone substituted with C1-4alkyl, or cyclopropyl; and pyrrolidinone substituted with C1-4alkyl;
        • and pharmaceutically acceptable salts, stereoisomers, isotopic variants, N-oxides, or solvates of compounds of Formula (I);
        • (B) at least one pharmaceutically acceptable excipient.
      • 24. A pharmaceutical composition comprising an effective amount of at least one compound of embodiment 21 and at least one pharmaceutically acceptable excipient.
      • 25. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I):
  • Figure US20220324860A1-20221013-C00237
        • wherein
        • R1 is H, halo, or CH3;
        • Ar1 is selected from the group consisting of:
          • (a) phenyl;
          • (b) phenyl substituted with one member selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl;
          • (c) phenyl substituted with two or three members each independently selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl; and
          • (d) thienyl substituted with one member selected from the group consisting of: halo, and C1-6alkyl;
        • R2 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00238
        •  wherein Ra is selected from the group consisting of: C1-6alkyl; C3-6cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
  • Figure US20220324860A1-20221013-C00239
        •  wherein Rb is C1-6alkyl;
      • (f) C1-6alkyl substituted with one, two, or three members each independently selected from the group consisting of: OH, halo, OC1-6alkyl, (═N—OH), (═N—OCH3), and cyclopropyl; and
      • (g) oxetanyl; oxetanyl substituted with C1-6alkyl; tetrahydrofuranyl; oxazolidinone; oxazolidinone substituted with C1-4alkyl, or cyclopropyl; and pyrrolidinone substituted with C1-4alkyl;
      • and pharmaceutically acceptable salts, stereoisomers, isotopic variants, N-oxides, or solvates of compounds of Formula (I).
      • 26. The method of embodiment 25, wherein the disorder, disease or condition mediated by the GluN2B receptor is selected from the group consisting of: bipolar disorder, major depressive disorder, treatment-resistant depression, post-partum depression, seasonal affective disorder, Alzheimer's disease, Parkinson's disease, Huntington's chorea, multiple sclerosis, cognitive impairment, head injury, spinal cord injury, stroke, epilepsy, dyskinesias, amyotrophic lateral sclerosis, neurodegeneration associated with bacterial or chronic infections, pain, diabetic neuropathy, migraine, cerebral ischemia, schizophrenia, encephalitis, autism and autism spectrum disorders, memory and learning disorders, obsessive compulsive disorder, attention deficit hyperactivity disorder (ADHD) and addictive illnesses.
      • 27. The method of embodiment 25 wherein the disorder, disease or condition is selected from the group consisting of treatment-resistant depression, major depressive disorder and bipolar disorder.
  • The present disclosure is further exemplified by specific embodiments 1 to 45 below.
      • 1. A compound having the structure of Formula (I):
  • Figure US20220324860A1-20221013-C00240
      • or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof,
      • wherein
      • R1 is H, halo, or CH3;
      • Ar1 is selected from the group consisting of:
        • (a) phenyl;
        • (b) phenyl substituted with one member selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl;
        • (c) phenyl substituted with two or three members each independently selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl; and
        • (d) thienyl substituted with one member selected from the group consisting of: halo, and C1-6alkyl;
      • R2 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00241
      •  wherein Ra is selected from the group consisting of: C1-6alkyl; C3-6cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
  • Figure US20220324860A1-20221013-C00242
      •  wherein Rb is C1-6alkyl;
        • (f) C1-6alkyl substituted with one, two, or three members each independently selected from the group consisting of: OH, halo, OC1-6alkyl, (═N—OH), (═N—OCH3), and cyclopropyl; and
        • (g) oxetanyl; oxetanyl substituted with C1-6alkyl; tetrahydrofuranyl; oxazolidinone; oxazolidinone substituted with C1-4alkyl, or cyclopropyl; and pyrrolidinone substituted with C1-4alkyl.
      • 2. The compound of embodiment 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R1 is H.
      • 3. The compound of embodiment 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R1 is F.
      • 4. The compound of embodiment 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R1 is CH3.
      • 5. The compound of any one of embodiments 1 to 4, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is phenyl.
      • 6. The compound of any one of embodiments 1 to 4, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is phenyl substituted with one member selected from the group consisting of: F, CH3, CF2H, CF2CH3, CF3, and OCF3.
      • 7. The compound of any one of embodiments 1 to 4, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00243
      • 8. The compound of any one of embodiments 1 to 4, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is phenyl substituted with two members each independently selected from the group consisting of: F, Cl, CH3, CF2H, CF3, CF2CH3, and OCF2H.
      • 9. The compound of any one of embodiments 1 to 4, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is selected from the group consisting of:
  • Figure US20220324860A1-20221013-C00244
      • 10. The compound of any one of embodiments 1 to 4, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is phenyl substituted with three members each independently selected from the group consisting of: F and CH3.
      • 11. The compound of any one of embodiments 1 to 4, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is
  • Figure US20220324860A1-20221013-C00245
      • 12. The compound of any one of embodiments 1 to 4, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is thienyl is substituted with Cl or CH3.
      • 13. The compound of any one of embodiments 1 to 4, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is
  • Figure US20220324860A1-20221013-C00246
      • 14. The compound of any one of embodiments 1 to 13, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R2 is
  • Figure US20220324860A1-20221013-C00247
      • 15. The compound of any one of embodiments 1 to 13, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R2 is
  • Figure US20220324860A1-20221013-C00248
      • 16. The compound of any one of embodiments 1 to 13, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R2 is
  • Figure US20220324860A1-20221013-C00249
      • 17. The compound of any one of embodiments 1 to 13, or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R2 is
  • Figure US20220324860A1-20221013-C00250
      • 18. The compound of embodiment 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, having the structure of Formula (IA):
  • Figure US20220324860A1-20221013-C00251
        • wherein
        • HAL is F or Cl;
        • R1 is H, F, or CH3;
        • R2 is selected from the group consisting of:
          • (a) (S═O)CH2CH3; (SO2)CH2CH3; or
  • Figure US20220324860A1-20221013-C00252
          •  wherein Ra is selected from the group consisting of: CH3, CH2CH3, CH(CH3)2, cyclopropyl, cyclobutyl,
  • Figure US20220324860A1-20221013-C00253
          • (b) CH2OCH3, CH(OH)(CH2CH3), CH(OH)CH(CH3)2, CF2CH2CH3, CF2(cyclopropyl), CH(OCH3)(cyclopropyl), CH(OH)(cyclopropyl), or
  • Figure US20220324860A1-20221013-C00254
          •  and
  • Figure US20220324860A1-20221013-C00255
        • Rc is H, F or CH3;
        • Rd is selected from the group consisting of: H, F, Cl, CH3, CF2H, CF2CH3, CF3, and OCF2H; and
        • Re is H or F; wherein when Re is F, Rc is H.
      • 19. The compound of embodiment 18 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, where HAL is F; R1 is H; Rc is H; and Re is H.
      • 20. The compound of embodiment 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, having the structure of Formula (IB):
  • Figure US20220324860A1-20221013-C00256
        • wherein
        • Ar1 is selected from the group consisting of:
          • (a) phenyl, 3-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 3-(difluoromethyl)phenyl, 3-(1,1-difluoroethyl)phenyl, 3-(trifluoromethyl)phenyl, 3-(trifluoromethoxy)phenyl, 5-methyl-2-thienyl, or 5-chloro-2-thienyl; and
          • (b) 2-fluoro-3-methyl-phenyl, 2,3-difluorophenyl, 3,5-difluorophenyl, 3-chloro-2-fluoro-phenyl, 2-fluoro-3-(trifluoromethyl)phenyl, 4-chloro-3-(difluoromethoxy)phenyl, or 4-chloro-3-(trifluoromethyl)phenyl; and
        • R2 is selected from the group consisting of: (S═O)CH2CH3, (C═O)CH2CH3, (C═O)CH(CH3)2, and (C═O)cyclopropyl.
      • 21. A compound selected from the compounds in Table 1 and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, and N-oxides thereof.
      • 22. The compound of any one of embodiments 1 to 21, or a pharmaceutically acceptable salt or solvate thereof.
      • 23. The compound of any one of embodiments 1 to 21, or a pharmaceutically acceptable salt or N-oxide thereof.
      • 24. The compound of any one of embodiments 1 to 21, or a pharmaceutically acceptable salt thereof.
      • 25. The compound of any one of embodiments 1 to 21.
      • 26. A pharmaceutically acceptable salt of the compound of any one of embodiments 1 to 21.
      • 27. A pharmaceutical composition comprising the compound of any one of embodiments 1 to 21, or a pharmaceutically acceptable salt, solvate, isotopic variant, or N-oxide thereof, and a pharmaceutically acceptable excipient.
      • 28. A pharmaceutical composition comprising the compound of any one of embodiments 1 to 21, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
      • 29. A pharmaceutical composition comprising the compound of any one of embodiments 1 to 21, or a pharmaceutically acceptable salt or N-oxide thereof, and a pharmaceutically acceptable excipient.
      • 30. A pharmaceutical composition comprising the compound of any one of embodiments 1 to 21, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
      • 31. A pharmaceutical composition comprising the compound of any one of embodiments 1 to 21 and a pharmaceutically acceptable excipient.
      • 32. A pharmaceutical composition comprising a pharmaceutically acceptable salt of the compound of any one of embodiments 1 to 21, and a pharmaceutically acceptable excipient.
      • 33. A unit dosage form comprising a therapeutically effective amount of the pharmaceutical composition of any one of embodiments 27 to 32.
      • 34. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to the subject a therapeutically effective amount of the compound of any one of embodiments 1 to 21, or a pharmaceutically acceptable salt, solvate, isotopic variant, or N-oxide thereof.
      • 35. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to the subject a therapeutically effective amount of the compound of any one of embodiments 1 to 21, or a pharmaceutically acceptable salt, or solvate thereof.
      • 36. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to the subject a therapeutically effective amount of the compound of any one of embodiments 1 to 21, or a pharmaceutically acceptable salt or N-oxide thereof.
      • 37. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to the subject a therapeutically effective amount of the compound of any one of embodiments 1 to 21, or a pharmaceutically acceptable salt thereof.
      • 38. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of any one of embodiments 27 to 32 or the unit dosage form of embodiment 33.
      • 39. The method of any one of embodiments 34 to 38, wherein the disease, disorder or medical condition mediated by GluN2B receptor activity comprises bipolar disorder, major depressive disorder, treatment-resistant depression, a mood disorder, post-partum depression, seasonal affective disorder, Alzheimer's disease, Parkinson's disease, Huntington's chorea, multiple sclerosis, cognitive impairment, head injury, spinal cord injury, stroke, epilepsy, dyskinesias, amyotrophic lateral sclerosis, neurodegeneration associated with a bacterial or chronic infection, pain, diabetic neuropathy, migraine, cerebral ischemia, schizophrenia, encephalitis, autism or an autism spectrum disorder, a memory disorder, a learning disorder, obsessive compulsive disorder, attention deficit hyperactivity disorder (ADHD) or an addictive illness.
      • 40. The method of embodiment 39, wherein the disease, disorder or medical condition mediated by GluN2B receptor activity comprises bipolar disorder, a mood disorder, treatment resistant depression, major depressive disorder, or epilepsy.
      • 41. The method of embodiment 39, wherein the disease, disorder or medical condition mediated by GluN2B receptor activity comprises bipolar disorder.
      • 42. The method of embodiment 39, wherein the disease, disorder or medical condition mediated by GluN2B receptor activity comprises a mood disorder.
      • 43. The method of embodiment 39, wherein the disease, disorder or medical condition mediated by GluN2B receptor activity comprises treatment resistant depression.
      • 44. The method of embodiment 39, wherein the disease, disorder or medical condition mediated by GluN2B receptor activity comprises major depressive disorder.
      • 45. The method of embodiment 39, wherein the disease, disorder or medical condition mediated by GluN2B receptor activity comprises epilepsy.

Claims (27)

What is claimed is:
1. A compound having the structure of Formula (I):
Figure US20220324860A1-20221013-C00257
or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof,
wherein
R1 is H, halo, or CH3;
Ar1 is selected from the group consisting of:
(a) phenyl;
(b) phenyl substituted with one member selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl;
(c) phenyl substituted with two or three members each independently selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl; and
(d) thienyl substituted with one member selected from the group consisting of: halo, and C1-6alkyl;
R2 is selected from the group consisting of:
Figure US20220324860A1-20221013-C00258
 wherein Ra is selected from the group consisting of: C1-6alkyl; C3-6cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
Figure US20220324860A1-20221013-C00259
 wherein Rb is C1-6alkyl;
(f) C1-6alkyl substituted with one, two, or three members each independently selected from the group consisting of: OH, halo, OC1-6alkyl, (═N—OH), (═N—OCH3), and cyclopropyl; and
(g) oxetanyl; oxetanyl substituted with C1-6alkyl; tetrahydrofuranyl; oxazolidinone; oxazolidinone substituted with C1-4alkyl, or cyclopropyl; and pyrrolidinone substituted with C1-4alkyl.
2. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R1 is H.
3. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R1 is F.
4. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R1 is CH3.
5. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is phenyl.
6. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is phenyl substituted with one member selected from the group consisting of: F, CH3, CF2H, CF2CH3, CF3, and OCF3.
7. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is selected from the group consisting of:
Figure US20220324860A1-20221013-C00260
8. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is phenyl substituted with two members each independently selected from the group consisting of: F, Cl, CH3, CF2H, CF3, CF2CH3, and OCF2H.
9. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is selected from the group consisting of:
Figure US20220324860A1-20221013-C00261
10. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is phenyl substituted with three members each independently selected from the group consisting of: F and CH3.
11. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is
Figure US20220324860A1-20221013-C00262
12. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is thienyl is substituted with Cl or CH3.
13. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein Ar1 is
Figure US20220324860A1-20221013-C00263
14. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R2 is
Figure US20220324860A1-20221013-C00264
15. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R2 is
Figure US20220324860A1-20221013-C00265
16. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R2 is
Figure US20220324860A1-20221013-C00266
17. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, wherein R2 is
Figure US20220324860A1-20221013-C00267
18. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, having the structure of Formula (IA):
Figure US20220324860A1-20221013-C00268
wherein
HAL is F or Cl;
R1 is H, F, or CH3;
R2 is selected from the group consisting of:
(a) (S═O)CH2CH3; (SO2)CH2CH3; or
Figure US20220324860A1-20221013-C00269
wherein Ra is selected from the group consisting of: CH3, CH2CH3, CH(CH3)2, cyclopropyl, cyclobutyl,
Figure US20220324860A1-20221013-C00270
(b) CH2OCH3, CH(OH)(CH2CH3), CH(OH)CH(CH3)2, CF2CH2CH3, CF2(cyclopropyl), CH(OCH3)(cyclopropyl), CH(OH)(cyclopropyl), or
Figure US20220324860A1-20221013-C00271
and
Figure US20220324860A1-20221013-C00272
Rc is H, F or CH3;
Rd is selected from the group consisting of: H, F, Cl, CH3, CF2H, CF2CH3, CF3, and OCF2H; and
Re is H or F; wherein when Re is F, Rc is H.
19. The compound of claim 18 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, where HAL is F; R1 is H; Rc is H; and Rc is H.
20. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, having the structure of Formula (IB):
Figure US20220324860A1-20221013-C00273
wherein
Ar1 is selected from the group consisting of:
(a) phenyl, 3-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 3-(difluoromethyl)phenyl, 3-(1,1-difluoroethyl)phenyl, 3-(trifluoromethyl)phenyl, 3-(trifluoromethoxy)phenyl, 5-methyl-2-thienyl, or 5-chloro-2-thienyl; and
(b) 2-fluoro-3-methyl-phenyl, 2,3-difluorophenyl, 3,5-difluorophenyl, 3-chloro-2-fluoro-phenyl, 2-fluoro-3-(trifluoromethyl)phenyl, 4-chloro-3-(difluoromethoxy)phenyl, or 4-chloro-3-(trifluoromethyl)phenyl; and
R2 is selected from the group consisting of: (S═O)CH2CH3, (C═O)CH2CH3, (C═O)CH(CH3)2, and (C═O)cyclopropyl.
21. A compound selected from the group consisting of:
1-[6-(3,5-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
(RS)-3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
(RS)-1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
(E/Z)-3-Methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one oxime;
1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
(RS)-1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-ol;
1-Cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
(RS)-1-Cyclopropyl-2-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
(RS)-1-(2-Cyclopropyl-2-methoxy-ethyl)-6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridine;
(RS)-6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine;
6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(ethylsulfonylmethyl)pyrazolo[4,3-b]pyridine;
2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(2-pyridyl)ethanone;
2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(5-fluoropyridin-2-yl)ethan-1-one;
2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(pyridin-3-yl)ethan-1-one;
(RS)-1-(Oxetan-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
(RS)-6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-(tetrahydrofuran-2-ylmethyl)pyrazolo[4,3-b]pyridine;
(RS)-4-[[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
(RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
(S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
(R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
1-[6-(5-Chloro-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-(4-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-(3-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-[3-(Difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-[3-(1,1-Difluoroethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-(4-Fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-(2,3-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-(3,4-Difluorophenyl)-3-fluoro-pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-(6-(3-(Difluoromethyl)-4-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one;
1-[6-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-[4-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-(3,4,5-Trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-(2,3,4-Trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
3-Methyl-1-(6-phenylpyrazolo[4,3-b]pyridin-1-yl)butan-2-one;
1-[6-(4-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
1-[6-(3-Fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
1-[6-[3-(Difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
1-[6-(2,3-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
1-[6-[2-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
1-[6-[4-Fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
1-[6-(4-Fluoro-2-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-3-methyl-butan-2-one;
3-Methyl-1-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
3-Methyl-1-[6-(2,3,4-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
2-[6-(5-Chloro-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone;
1-Cyclopropyl-2-[6-(5-methyl-2-thienyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-(3-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-(2-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-(4-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-(m-tolyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-[3-(difluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-[3-(trifluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-(2,3-difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-(3,4-difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-(3, 5-difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
2-[6-(3-Chloro-2-fluoro-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone;
2-[6-(3-Chloro-4-fluoro-phenyl)pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone;
1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclobutyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-(2-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-(4-fluoro-2-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-[2-fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-[4-fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
2-[6-[4-Chloro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-cyclopropyl-ethanone;
1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-(4-fluoro-2,3-dimethyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-(2,3,4-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
(RS)-1-(Ethylsulfinylmethyl)-6-(3-fluorophenyl)pyrazolo[4,3-b]pyridine;
(RS)-1-(Ethylsulfinylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
(RS) 6-(3,4-Difluorophenyl)-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine;
(RS)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
(S*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
(R*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
(RS)-1-(Ethylsulfinylmethyl)-6-[2-fluoro-3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
(RS)-6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-(ethylsulfinylmethyl)pyrazolo[4,3-b]pyridine;
(RS)-1-(Ethylsulfinylmethyl)-6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridine;
6-(4-Fluoro-3-methyl-phenyl)-1-(2-methoxyethyl)pyrazolo[4,3-b]pyridine;
(RS)-4-Methoxy-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
(RS)-1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
(RS)-1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
(RS)-1-[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
(RS)-1-[6-(3,4-Difluorophenyl)-3-fluoro-pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
(RS)-1-[6-[3-(1,1-Difluoroethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
(RS)-3-Methyl-1-(6-phenylpyrazolo[4,3-b]pyridin-1-yl)butan-2-ol;
(RS)-3-Methyl-1-[6-(3,4,5-trifluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-ol;
1-(2,2-Difluorobutyl)-6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine;
1-(2,2-Difluorobutyl)-6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine;
(RS)-1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanol;
(RS)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
(R)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
(S)-1-Cyclopropyl-2-[6-(4-fluoro-3-methyl-phenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanol;
(RS)-1-Cyclopropyl-2-(6-(3-(difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)ethan-1-ol;
(E/Z)—N-Methoxy-3-methyl-1-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-imine;
(E/Z)-1-Cyclopropyl-2-[6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone oxime;
(E/Z)-1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone oxime;
1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine;
1-(2-Cyclopropyl-2,2-difluoro-ethyl)-6-[3-(difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridine;
6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-[(3-methyloxetan-3-yl)methyl]pyrazolo[4,3-b]pyridine;
(RS)-1-(Tetrahydrofuran-2-ylmethyl)-6-[3-(trifluoromethyl)phenyl]pyrazolo[4,3-b]pyridine;
(RS)-6-[3-(Difluoromethoxy)-4-fluoro-phenyl]-1-(tetrahydrofuran-2-ylmethyl)pyrazolo[4,3-b]pyridine;
(RS)-6-[3-(Difluoromethyl)-4-fluoro-phenyl]-1-(tetrahydrofuran-3-ylmethyl)pyrazolo[4,3-b]pyridine;
(RS)-5-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-1-methylpyrrolidin-2-one;
(RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
(RS)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
(S)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
(R)-3-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
(RS)-3-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-1-methylpyrrolidin-2-one;
(RS)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
(S)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
(R)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-1-methyl-pyrrolidin-2-one;
(RS)-4-((6-(3-(difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-3-methyloxazolidin-2-one;
(RS)-4-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one;
(RS)-5-[[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
(RS)-5-[[6-[4-Chloro-3-(difluoromethoxy)phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
(RS)-5-[[6-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
(RS)-5-((6-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methyl)-3-methyloxazolidin-2-one;
(5R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one;
(5S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one;
(RS)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-ethyl-oxazolidin-2-one;
(S)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-ethyl-oxazolidin-2-one;
(R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-ethyl-oxazolidin-2-one;
(RS)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
(S)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
(R)-3-Cyclopropyl-5-[[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]oxazolidin-2-one;
2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(2-thienyl)ethanone;
2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(3-thienyl)ethanone;
2-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]-1-(4-pyridyl)ethanone;
2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(3-fluoropyridin-2-yl)ethan-1-one;
2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(3,5-difluoropyridin-2-yl)ethan-1-one;
2-(6-(3-(Difluoromethyl)-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)-1-(pyrazin-2-yl)ethan-1-one;
and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, and N-oxides thereof.
22. A compound selected from the group consisting of:
1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]propan-2-one;
1-[6-(3,4-Difluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-(6-(3-(Difluoromethyl)-4-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-b]pyridin-1-yl)butan-2-one;
1-[6-[3-(Difluoromethoxy)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]butan-2-one;
1-Cyclopropyl-2-[6-(4-fluorophenyl)pyrazolo[4,3-b]pyridin-1-yl]ethanone;
1-Cyclopropyl-2-[6-[3-(difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]ethanone;
(RS)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
(S*)-6-(3-(Difluoromethyl)-4-fluorophenyl)-1-((ethylsulfinyl)methyl)-1H-pyrazolo[4,3-b]pyridine;
(5R)-5-[[6-[3-(Difluoromethyl)-4-fluoro-phenyl]pyrazolo[4,3-b]pyridin-1-yl]methyl]-3-methyl-oxazolidin-2-one;
and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, and N-oxides thereof.
23. A pharmaceutical composition comprising: (A) an effective amount of at least one compound selected from compounds of Formula (I):
Figure US20220324860A1-20221013-C00274
and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, and N-oxides of compounds of Formula (I),
wherein
R1 is H, halo, or CH3;
Ar1 is selected from the group consisting of:
(a) phenyl;
(b) phenyl substituted with one member selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl;
(c) phenyl substituted with two or three members each independently selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl; and
(d) thienyl substituted with one member selected from the group consisting of: halo, and C1-6alkyl;
R2 is selected from the group consisting of:
Figure US20220324860A1-20221013-C00275
 wherein Ra is selected from the group consisting of: C1-6alkyl; C3-6cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
Figure US20220324860A1-20221013-C00276
 wherein Rb is C1-6alkyl;
(f) C1-6alkyl substituted with one, two, or three members each independently selected from the group consisting of: OH, halo, OC1-6alkyl, (═N—OH), (═N—OCH3), and cyclopropyl; and
(g) oxetanyl; oxetanyl substituted with C1-6alkyl; tetrahydrofuranyl; oxazolidinone; oxazolidinone substituted with C1-4alkyl, or cyclopropyl; and pyrrolidinone substituted with C1-4alkyl;
and
(B) at least one pharmaceutically acceptable excipient.
24. A pharmaceutical composition comprising an effective amount of at least one compound of claim 21 or a pharmaceutically acceptable salt, solvate, stereoisomer, isotopic variant, or N-oxide thereof, and at least one pharmaceutically acceptable excipient.
25. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by GluN2B receptor activity, comprising administering to a subject in need of such treatment an effective amount of at least one compound selected from compounds of Formula (I):
Figure US20220324860A1-20221013-C00277
and pharmaceutically acceptable salts, solvates, stereoisomers, isotopic variants, and N-oxides of compounds of Formula (I),
wherein
R1 is H, halo, or CH3;
Ar1 is selected from the group consisting of:
(e) phenyl;
(f) phenyl substituted with one member selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl;
(g) phenyl substituted with two or three members each independently selected from the group consisting of: halo, C1-6alkyl, C1-6perhaloalkyl, and OC1-6perhaloalkyl; and
(h) thienyl substituted with one member selected from the group consisting of: halo, and C1-6alkyl;
R2 is selected from the group consisting of:
Figure US20220324860A1-20221013-C00278
 wherein Ra is selected from the group consisting of: C1-6alkyl; C3-6cycloalkyl; thienyl; pyridyl; pyridyl substituted with one or two F members; pyrazinyl;
Figure US20220324860A1-20221013-C00279
 wherein Rb is C1-6alkyl;
(f) C1-6alkyl substituted with one, two, or three members each independently selected from the group consisting of: OH, halo, OC1-6alkyl, (═N—OH), (═N—OCH3), and cyclopropyl; and
(g) oxetanyl; oxetanyl substituted with C1-6alkyl; tetrahydrofuranyl; oxazolidinone; oxazolidinone substituted with C1-4alkyl, or cyclopropyl; and pyrrolidinone substituted with C1-4alkyl.
26. The method of claim 25, wherein the disorder, disease or condition mediated by the GluN2B receptor is selected from the group consisting of: bipolar disorder, major depressive disorder, treatment-resistant depression, post-partum depression, seasonal affective disorder, Alzheimer's disease, Parkinson's disease, Huntington's chorea, multiple sclerosis, cognitive impairment, head injury, spinal cord injury, stroke, epilepsy, dyskinesias, amyotrophic lateral sclerosis, neurodegeneration associated with bacterial or chronic infections, pain, diabetic neuropathy, migraine, cerebral ischemia, schizophrenia, encephalitis, autism and autism spectrum disorders, memory and learning disorders, obsessive compulsive disorder, attention deficit hyperactivity disorder (ADHD) and addictive illnesses.
27. The method of claim 25 wherein the disorder, disease or condition is selected from the group consisting of treatment-resistant depression, major depressive disorder and bipolar disorder.
US17/618,066 2019-06-14 2020-06-12 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Pending US20220324860A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/618,066 US20220324860A1 (en) 2019-06-14 2020-06-12 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861674P 2019-06-14 2019-06-14
PCT/EP2020/066391 WO2020249791A1 (en) 2019-06-14 2020-06-12 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
US17/618,066 US20220324860A1 (en) 2019-06-14 2020-06-12 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Publications (1)

Publication Number Publication Date
US20220324860A1 true US20220324860A1 (en) 2022-10-13

Family

ID=71120146

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/618,066 Pending US20220324860A1 (en) 2019-06-14 2020-06-12 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
US16/899,836 Active US11161846B2 (en) 2019-06-14 2020-06-12 Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/899,836 Active US11161846B2 (en) 2019-06-14 2020-06-12 Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators

Country Status (10)

Country Link
US (2) US20220324860A1 (en)
EP (1) EP3983073A1 (en)
JP (1) JP2022536174A (en)
KR (1) KR20220020917A (en)
CN (1) CN113993583A (en)
AU (1) AU2020293642A1 (en)
BR (1) BR112021025136A2 (en)
CA (1) CA3143102A1 (en)
MX (1) MX2021015510A (en)
WO (1) WO2020249791A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11993587B2 (en) 2019-06-14 2024-05-28 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (en) 2016-10-06 2018-06-01 比利時商健生藥品公司 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
KR20220024511A (en) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
JP2022538774A (en) 2019-06-14 2022-09-06 ヤンセン ファーマシューティカ エヌ．ベー． Pyridine carbamates and their use as GLUN2B receptor modulators
WO2024178219A1 (en) * 2023-02-23 2024-08-29 Brian Shoichet 1-acyl-3-aminoindazoles for treating cystic fibrosis

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
JP3192662B2 (en) 1996-07-31 2001-07-30 日研化学株式会社 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical compositions containing the same
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
US7534800B2 (en) 2002-03-28 2009-05-19 Eisai R & D Development Co., Ltd. 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EA200601266A1 (en) 2004-02-18 2007-02-27 Астразенека Аб TRIAZOLE COMPOUNDS AND THEIR APPLICATION AS ANTAGONISTS OF GLUTAMAT METABOTROPIC RECEPTOR
AU2005286592A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
CA2686651C (en) 2007-05-25 2015-11-24 Abbott Gmbh & Co. Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
CN101842357A (en) 2007-08-30 2010-09-22 武田药品工业株式会社 Substituted pyrazole derivative
US20100249164A1 (en) 2007-10-31 2010-09-30 Renger John J Modulation of sleep with nr2b receptor antagonists
RU2499598C2 (en) 2008-03-27 2013-11-27 Евотек Интернациональ Гмбх Method of treating disorders using selective nr2b subtype nmda receptor antagonist
US20110130384A1 (en) 2008-06-25 2011-06-02 Takeda Pharmaceutical Company Limited Amide compound
MX2011001019A (en) 2008-08-05 2011-03-25 Daiichi Sankyo Co Ltd Imidazopyridin-2-on derivative.
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
RU2517181C2 (en) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Indole and benzomorpholine derivatives as modulator of metabotropic glutamate receptors
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
US8969342B2 (en) 2009-03-20 2015-03-03 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
US8765784B2 (en) 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
JP2012188363A (en) 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd Azabenzoimidazolone derivative
WO2013060029A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp Allosteric modulators of metabotropic glutamate receptors
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
MA37975B2 (en) 2012-09-11 2021-03-31 Genzyme Corp Glucosylceramide synthase inhibitors
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
JP2016516710A (en) 2013-03-13 2016-06-09 アッヴィ・インコーポレイテッド Pyridine CDK9 kinase inhibitor
AU2014233437B2 (en) 2013-03-15 2018-07-26 Opna Immuno Oncology, SA Heterocyclic compounds and uses thereof
KR102307566B1 (en) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 Novel bicyclic bromodomain inhibitors
AU2014296261B2 (en) 2013-07-31 2018-11-15 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
WO2016025918A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Pyrazoles
PL3180329T3 (en) 2014-08-15 2020-08-24 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
US12006328B2 (en) 2014-11-18 2024-06-11 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto
MA41803A (en) 2015-03-24 2018-01-30 Almirall Sa AMINO-INDAZOLES USED AS SODIUM CHANNEL INHIBITORS
MD3319963T2 (en) * 2015-07-09 2020-05-31 Janssen Pharmaceutica Nv Substituted 4-azaindoles and their use as GluN2B receptor modulators
WO2017139428A1 (en) 2016-02-10 2017-08-17 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
TW201819376A (en) * 2016-10-06 2018-06-01 比利時商健生藥品公司 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
AU2018282747B2 (en) 2017-06-14 2024-01-18 Trevena, Inc. Compounds for modulating S1P1 activity and methods of using the same
MA52244A (en) 2018-04-04 2021-02-17 Janssen Pharmaceutica Nv PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS MODULATORS OF THE GLUN2B RECEPTOR
CN110294756A (en) 2019-06-04 2019-10-01 广州市原子高科同位素医药有限公司 GluN2B subunit targeting type central nervous system positive electron tracer and its preparation
KR20220024511A (en) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
WO2020249802A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
JP2022538774A (en) 2019-06-14 2022-09-06 ヤンセン ファーマシューティカ エヌ．ベー． Pyridine carbamates and their use as GLUN2B receptor modulators
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11993587B2 (en) 2019-06-14 2024-05-28 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators

Also Published As

Publication number Publication date
AU2020293642A1 (en) 2022-01-20
CN113993583A (en) 2022-01-28
KR20220020917A (en) 2022-02-21
US20200392130A1 (en) 2020-12-17
WO2020249791A1 (en) 2020-12-17
MX2021015510A (en) 2022-04-11
US11161846B2 (en) 2021-11-02
CA3143102A1 (en) 2020-12-17
BR112021025136A2 (en) 2022-01-25
JP2022536174A (en) 2022-08-12
EP3983073A1 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
US11161846B2 (en) Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
US11759455B2 (en) Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
US10377753B2 (en) Substituted 4-azaindoles and their use as GluN2B receptor modulators
US11447503B2 (en) Pyridine carbamates and their use as GLUN2B receptor modulators
US11214563B2 (en) Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators
US11530210B2 (en) Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators
US11618750B2 (en) Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators
US10087185B2 (en) Fused bicylic pyridine compounds and their use as AMPA receptor modulators
US20220274984A1 (en) Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
EA046270B1 (en) SUBSTITUTED HETEROAROMATIC PYRAZOLOPYRIDINES AND THEIR APPLICATION AS GluN2B RECEPTOR MODULATORS

Legal Events

Date Code Title Description
AS Assignment

Owner name: JANSSEN PHARMACEUTICA NV, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HISCOX, AFTON;STENNE, BRICE;GELIN, CHRISTINE;AND OTHERS;SIGNING DATES FROM 20200803 TO 20200810;REEL/FRAME:059909/0894

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: JANSSEN PHARMACEUTICA NV, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HISCOX, AFTON;STENNE, BRICE;GELIN, CHRISTINE;AND OTHERS;SIGNING DATES FROM 20190626 TO 20190725;REEL/FRAME:065682/0286